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 i 
Abstract 
 
Betaglycan, also known as TGFβRIII, is a component of the TGFβ receptor, being thought to 
act as a co-factor in signal transduction. It has proven roles in TGFβ-mediated embryogenesis 
and carcinogenesis, and facilitates signalling by activins and inhibins within the endocrine 
system. Despite the recognised importance of TGFβ in immunity, little is known about 
betaglycan in immune regulation.  
 
In mice, absolute deficiency of any of the three isoforms of TGFβ, or any of the individual 
TGFβ receptor components results in embryonic or perinatal lethality, limiting the ability to 
study peripheral immune responses in these models. We developed a chimeric model in which 
betaglycan-deficient stem cells were transferred to immunodeficient hosts, allowing study of 
mature animals with betaglycan deletion restricted to T and B lymphocytes. We were thus 
able to investigate peripheral immune responses in vivo, and assess TGFβ signalling to T 
lymphocytes in vitro, in the presence and absence of betaglycan. 
 
Betaglycan deficiency resulted in upregulated CD4+ and CD8+ T lymphocyte activation, with 
increased Th1 polarisation in peripheral lymphocyte compartments in both naïve and antigen-
experienced animals. These observations confirm the involvement of betaglycan in T 
lymphocyte biology, providing the first evidence for its role in regulation of peripheral 
immune responses. 
  
 ii 
Dedication  
 
To those who ask “why?” 
 
If you should find yourself sat before me in an outpatient clinic with potentially blinding 
ocular inflammatory disease, I promise that I will manage your inflammation to the absolute 
best of my ability. I have access to the most advanced diagnostic aids and therapeutic 
interventions, can call on world-renowned experts for help and advice, and can provide the 
best available treatment to control your disease. I will do everything within my power to help 
you. 
 
As a patient in my clinic, I know that your only concern is protecting your eyesight. I know 
that your livelihood and family are dependent on you maintaining good vision. I know that 
you will listen to what I say, and use the treatment I suggest, even if that treatment makes you 
unwell, because your eyes are important to you. 
 
What you probably don’t realise, is that despite trying to act calm, confident and reassuring, I 
don’t know why you are sat before me. I don’t know why you are suffering this condition 
when others will live a lifetime without it. I don’t know why some of the treatment that I use 
will work for you whilst other treatments won’t. Ultimately, I don’t know if I am going to be 
able to completely prevent you from going blind, or just postpone an inevitable loss of your 
visual function.  
 
I realise that these are the exact questions to which you need answers, but you will be too 
polite to ask because you think it will take up more of my time, and because you assume that I 
must know what I’m doing. 
 
Please allow me to reassure you that I ask these questions too. These are the questions that 
motivate me. I hope that through this thesis, I have taken the first steps towards giving us both 
the answers that we need. Whilst there is still much to learn, I promise to build on my 
experience so far, and will continue to ask “why?” until we are both satisfied with the 
answers. 
 
Robert Barry, Birmingham, 2015 
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1 GENERAL INTRODUCTION 
 
1.1 Key concepts in immunity 
 
1.1.1 Innate and adaptive immunity 
 
Broadly speaking, the human immune system is divided into two components comprising an 
innate and adaptive response. The activity of these components is intrinsically linked, such 
that neither in isolation is sufficient to provide comprehensive immunological protection to 
the host.  
 
The innate immune response provides a first line of defence through the action of 
macrophages and neutrophils. These cells are important in quickly recognising and destroying 
pathogens, however their activity is restricted by the limited range of non-varying receptors 
through which they are able to recognise invading microorganisms. The innate response exists 
primarily to limit damage whilst activating a more targeted adaptive immune response. 
 
The adaptive immune response has evolved to eradicate a broad range of pathogens, and is 
activated on recognition of foreign, or ‘non-self’ antigens. Lymphocytes are the effector cells 
of the adaptive immune system, and are broadly divided into two groups, each with distinct 
functions, named according to the circumstances of their discovery. T lymphocytes are 
involved in cellular immunity, and were named following their discovery in the human 
thymus (Miller 1961; Miller 1962). B lymphocytes are involved in antibody production, and 
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whilst they are commonly considered to be named after their main site of production in 
humans in the bone marrow, the name is actually derived from their initial discovery in the 
bursa of Fabricius in birds (Glick et al. 1956).  The innate immune system utilizes antigen-
presenting cells (APC) such as dendritic cells (DC) to present pathogens to the adaptive 
immune system (specifically T lymphocytes), providing an essential bridge between the two 
systems and allowing recruitment of antigen-specific effector cells to the site of infection. 
 
1.1.2 T lymphocytes and MHC restriction 
 
T lymphocytes are the main effector cells of the adaptive immune response. T lymphocytes 
have evolved to react to invading pathogens through a very tightly regulated mechanism 
involving the T cell receptor (TCR), and its interaction with foreign antigen displayed on the 
surface of cells of the host organism. The T lymphocyte is able to detect this foreign antigen 
because infected cells display peptide fragments derived from the invading pathogen in 
specialized cell-surface glycoproteins known as major histocompatibility complex (MHC) 
molecules. This interaction between the TCR and MHC molecule is referred to as “MHC 
restriction” (Zinkernagel & Doherty 1974; Unanue 1984; Townsend & Bodmer 1989).  
 
A diverse array of TCR is produced through rearrangement of germ line-encoded gene 
segments in developing T lymphocytes in the thymus. Two types of TCR have been 
described, each with distinct functions and distribution. TCR which engage the MHC / 
peptide complex are heterodimers comprising an α and β chain (α:β-T lymphocytes); in mice, 
each α chain is constructed from one of 50-100 Vα, and one of 50 Jα, and each β chain from 
one of 20-50 Vβ, one of 12 Jβ, and one of two Dβ. The exact number of gene segments varies 
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between different species (Huseby et al. 2005). Random rearrangement of these genes allows 
generation of a diverse array of different TCR, able to recognise a multitude of MHC / 
peptide combinations. Whilst such random gene rearrangement generates a useful repertoire 
of TCR against foreign peptides, it also allows development of TCR recognising host 
peptides. This process thus necessitates strict regulation to protect against uncontrolled self-
reactivity.  
 
T lymphocytes develop from haemopoietic stem cell precursors which migrate to the thymus, 
initially entering at the cortico-medullary junction and migrating through the thymic cortex. 
During T lymphocyte maturation, a variety of self-peptides are initially presented in MHC by 
cortical thymic epithelial cells (cTEC); low affinity interactions result in positive selection of 
T lymphocytes enabling further maturation, whilst cells unable to recognise self-peptide / 
MHC present on cTEC die by apoptosis. Positively selected T lymphocytes next migrate to 
the cortico-medullary junction, where a process of negative selection results in removal of 
those T lymphocytes displaying high affinity interaction between self-peptide / MHC and 
TCR, thereby eliminating potentially harmful self-reactive T lymphocytes. Negative selection 
is mediated by bone-marrow derived dendritic cells, macrophages and medullary thymic 
epithelial cells (mTEC) expressing tissue-specific self-antigens under the control of the 
autoimmune regulator (AIRE) protein (Anderson et al. 2002; Guerau-de-Arellano et al. 2009). 
Selection of T lymphocytes is therefore determined by their relative affinity for self-peptide / 
MHC in the thymus (Starr et al. 2003; Kyewski & Klein 2006). 
 
 T lymphocytes which fail to react to appropriate MHC stimulation, or those which react to 
host-derived peptides are deleted to ensure that the population of peripheral T lymphocytes is 
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sensitive to invading pathogen, without being damaging to host tissue. Failure of this 
selection process is thought to be at least partially responsible for autoimmune disease and 
loss of self tolerance (Marrack et al. 2011; Parham 2013) (discussed further in section 1.1.8).  
 
A second subset of T lymphocytes exists with a receptor comprising a γ chains and a δ chain 
(γ:δ-T lymphocytes). These cells are mainly distributed in mucosal and epithelial tissues and 
comprise less than 5% of the total T lymphocyte population in peripheral blood. They are 
thought to be able to act as antigen presenting cells, and have both pro-inflammatory and 
regulatory functions in different disease states (Su et al. 2013). They do not require antigen 
presentation by the MHC molecule, and their exact role remains a topic of investigation 
(Janeway et al. 2001). They will not be discussed further in this review, and the term ‘T 
lymphocyte’ will refer to α:β-T lymphocytes unless otherwise specified. 
 
There are two classes of MHC molecule; class I molecules can be expressed by any nucleated 
cell, and predominantly present peptide fragments of intracellular pathogens (most commonly 
viruses) to cytotoxic CD8+ T lymphocytes, which respond by killing a cell they recognise. 
Class II molecules are expressed only by APC which participate in the immune response, 
such as CD4+ T lymphocytes, B lymphocytes, DC and macrophages (discussed further in 
section 1.1.3). Cells expressing class II molecules are involved in activation of other effector 
cells of the immune system, and have thus generally been considered to have a “helper” 
function. Direct class II-dependent cell lysis has however also been observed both in vivo and 
in vitro, with some CD4+ T lymphocytes demonstrating cytotoxicity against influenza virus 
in the mouse, and measles virus, human immunodeficiency virus (HIV) and Epstein-Barr 
virus (EBV) in humans (Jellison et al. 2005).   
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In the mouse, MHC molecules are encoded by clusters of genes on chromosome 17. These are 
referred to as H2 genes; there are three main MHC class I H2 genes called H2-K, -D and -L, 
and two main MHC class II genes called H2-A and -E. In humans, a similar arrangement of 
Human Leukocyte Antigen (HLA) genes exists on chromosome 6 referred to as HLA-A, -B, 
and -C corresponding to MHC class I molecules, and HLA-DP, -DQ and –DR corresponding 
to MHC class II. The polygenic nature of the MHC results in generation of a set of MHC 
molecules with different ranges of peptide affinities, each able to bind a different range of 
peptides, thus allowing host cells to present peptide from a wide range of potential pathogens. 
The MHC repertoire is further increased by the polymorphic nature and co-dominant 
expression of MHC genes, which generates a greater range of specificities than would be 
permitted simply by different gene combinations alone (Janeway et al. 2001). 
 
The diversity of both the TCR and MHC ensures the host is able to respond to a vast range of 
invading pathogens, whilst thymic selection restricts TCR stimulation to foreign peptide / 
MHC-only activation and in theory, prevents the initiation of an immune response against 
host tissues. 
 
1.1.3 T lymphocyte subsets 
 
As inferred above, T lymphocytes can be broadly classified as being either directly 
“cytotoxic”, acting to kill cells infected with invading bacteria or viruses, or have a “helper” 
function, signalling to other cells to assist in the immune response. These subsets are 
determined by the expression of cell-surface co-receptors, which are crucial to the function of 
the TCR: Cytotoxic T lymphocytes express the cell-surface protein CD8, which binds to the 
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class I MHC molecule, whereas helper T lymphocytes express CD4, which binds to the class 
II MHC molecule. Although this cytotoxic / helper distinction is often referenced, it should be 
acknowledged that this categorisation is an over-simplified version of the true situation, as 
highlighted by the presence of cytotoxic MHC class II-expressing CD4+ T lymphocytes as 
previously discussed.  
 
There is step-wise expression of TCR components during intra-thymic development; initially, 
T lymphocytes express neither CD4 nor CD8 and are referred to as “double negative” (dn). 
These cells give rise to both γ:δ and α:β-T lymphocytes; γ:δ-T lymphocytes express neither 
CD4 nor CD8 even as mature cells. Conversely, α:β-T lymphocytes first express both CD4 
and CD8 becoming “double positive” (dp), initially expressing the pre-TCR (pTα:β), at which 
point cells enlarge and divide. They next become smaller resting double positive cells 
expressing the α:β TCR, at which point most cells undergo apoptosis. Only cells with the 
ability to recognise self MHC molecules survive, down-regulating either CD4 or CD8 to 
become “single positive” cells with a mature TCR (Janeway et al. 2001) (Figure 1.1). 
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Figure 1.1 T lymphocyte development in the thymus. Mature γ:δ and α:β-T lymphocytes 
develop from a common precursor which does not express CD3, CD4 or CD8. Mature γ:δ-T 
lymphocytes express only CD3 and remain both CD4 and CD8 negative. α:β-T lymphocytes 
follow a sequence of upregulation of CD3, CD4 and CD8, before down regulating either CD4 
or CD8 to become mature CD4+ or CD8+ α:β-T lymphocytes.  
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CD4+ T-helper (Th) lymphocytes can be divided into at least four main lineages; Th1, Th2, 
Th17 and regulatory (Treg) T cells (Valerie Dardalhon et al. 2008). More recently, additional 
subsets have been identified (Th9, Th22), and this classification has been further complicated 
by the discovery of overlap or ‘plasticity’ between different T lymphocyte subsets; whereas T 
helper lymphocytes were once considered terminally differentiated, it is now recognised that 
the mature T lymphocyte phenotype can change (Nakayamada et al. 2012).  
 
Subsets of CD4+ T lymphocytes can be identified by the particular combination of cytokines 
required for differentiation from naïve precursors, expression of nuclear transcription factors, 
expression of surface receptors and cytokines secreted. This is illustrated in figure 1.2, and 
discussed over the forthcoming pages. 
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Figure 1.2 T lymphocyte differentiation from naïve progenitor cells. Diagram illustrating 
cytokines required for murine T lymphocyte lineage differentiation, transcription factors 
(italic), surface markers and cytokines secreted.  
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Th1 lymphocytes are important in supporting cellular immunity and are involved in clearance 
of intra-cellular pathogens (Fietta & Delsante 2009). They differentiate from naïve T 
lymphocytes in the presence of interleukin-12 (IL-12) and express the transcription factor T-
Bet, which in turn induces IFNγ and defines the prototypical Th1 response (Szabo et al. 
2000). IFNγ activates macrophages and promotes IL-12 secretion by DC, acting as a feed-
forward mechanism to potentiate the Th1 response. T-Bet also induces CXCR3, allowing Th1 
lymphocytes to enter peripheral tissues (Lord et al. 2005). 
 
Th2 lymphocytes are critical for clearance of extra-cellular parasites and are involved in 
allergic responses (Romagnani 1994). They differentiate from naïve T lymphocytes in the 
presence of IL-4 and express the transcription factor GATA-3, which in turn induces the Th2 
cytokines IL-4, IL-5 and IL-13 (Zheng & Flavell 1997; Lantelme et al. 2001). It also induces 
the chemokine receptor CCR4 and the prostaglandin D2 receptor CRTh2 in humans (De Fanis 
et al. 2007). The Th2 cytokines potentiate the allergic response; IL-4 inhibits Th1 and Th17 
lymphocyte responses and promotes IgE production by B lymphocytes, whilst IL-5 activates 
eosinophils.  
 
Th17 lymphocytes are critical for immune responses against extracellular bacteria and fungi, 
and are thought to give rise to pathogenic cells that drive chronic inflammation in organ-
specific autoimmune disease (Korn, Oukka, et al. 2007). They express the transcription factor 
RORC, which drives IL-17 production and expression of the IL-23 receptor (Acosta-
Rodriguez et al. 2007; Annunziato et al. 2007; Wilson et al. 2007). In turn, IL-17 acts via 
epithelial cells to attract neutrophils, and CCR6 is important in recruiting Th17 lymphocytes 
to inflamed gut or skin (Schutyser et al. 2003). Th17 cells are induced in murine models by 
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TGFβ and IL-6 (Veldhoen et al. 2006), with IL-1β, IL-21 and IL-23 also contributing to their 
development (Shainheit et al. 2008; Korn, Bettelli, et al. 2007; Zhou et al. 2007; Nurieva et al. 
2007). 
 
Th9 lymphocytes are defined by IL-9 secretion, and express the transcription factors PU1 
(Ramming et al. 2012; Chang et al. 2010) and IRF4 (Staudt et al. 2010). They are generated in 
response to IL-4 and TGFβ (Putheti et al. 2010; Veldhoen et al. 2008) and are involved in 
allergic asthma and autoimmunity (Valérie Dardalhon et al. 2008). 
 
Th22 lymphocytes are involved in immune responses in the skin, and are identified by 
secretion of IL-22 and expression of the transcription factor AHR (Geginat et al. 2013). IL-22 
induces proliferation of epithelial cells and is involved in psoriasis (Ma et al. 2008; Zheng et 
al. 2007).  
 
Treg are a subset which suppress otherwise pathogenic immunity and can also induce self-
tolerance (Corthay 2009). Treg can be produced in the thymus (“naturally occurring” nTreg) 
or induced in the periphery (“induced” iTreg) and are characterised by expression of the 
Forkhead Box P3 (FoxP3) gene, IL-2 receptor α chain (CD25) and low expression of CD127 
(Vignali et al. 2009). Treg suppress pathogenic T lymphocyte function through a range of 
mechanisms including the production of immunosuppressive cytokines such as IL-10 and 
TGFβ, release of protease enzymes causing destruction of effector cells, and prevention of 
antigen-presenting cell maturation (Vignali et al. 2009; Corthay 2009). Treg are also known 
to constitutively express Cytotoxic T Lymphocyte Associated Antigen 4 (CTLA-4), which is 
considered important in immune homeostasis. CTLA-4 binds CD80 and CD86; these ligands 
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are mainly expressed by APC, and are also bound by CD28 on T lymphocytes in the process 
of activation. CTLA-4 binds these ligands with higher affinity than CD28 and is thus able to 
act as an antagonist of CD28-ligand binding, inhibiting T lymphocyte-mediated immune 
responses (Walker & Sansom 2011).  
 
1.1.4 T lymphocyte activation and memory subsets 
 
All T lymphocyte subsets originate from naïve cells that have not yet encountered specific 
antigen. On exposure to antigen, naïve cells undergo clonal expansion targeted towards 
eradicating the invading pathogen, followed by contraction of the effector cell population. 
The eventual effector phenotype is determined by the nature of co-stimulation from the innate 
immune system as described above. A small population of ‘memory’ cells specific to the 
invading pathogen persists after cessation of the immune response. This population of 
already-differentiated memory cells retain their effector function, and are able to proliferate 
on repeat exposure to the same pathogen, thus enabling a more rapid adaptive immune 
response to future infection (Mitchell & Williams 2010). 
 
Naïve T lymphocytes circulate in peripheral blood, entering lymph nodes via high endothelial 
venules (HEV), where they encounter antigen and undergo differentiation to an effector 
phenotype (Geginat et al. 2013). To be able to enter HEV, naïve cells require L-selectin 
(CD62L) and the chemokine receptor CCR7 (Bradley et al. 1994; Förster et al. 1999); CD62L 
binds to vascular addressins present on HEV and is responsible for the initial binding of 
blood-borne T lymphocytes (Berg et al. 1991), whilst CCR7 regulates responsiveness to 
chemokines present within the HEV (Gunn et al. 1998). In humans, these naïve cells are 
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identified by expression of both CD62L and the longest isoform of the common lymphocyte 
antigen CD45 (CD45RA) in the absence of the short isoform (CD45RO) (Clement 1992). 
CD45 is a tyrosine phosphatase which regulates the activation threshold of T lymphocytes 
(Hermiston et al. 2003). On activation, naïve T lymphocytes lose CD62L and express 
CD45RO in the absence of CD45RA.  
 
On contraction of the effector lymphocyte population, two distinct subsets of memory 
lymphocytes are retained. ‘Effector Memory’ lymphocytes (Tem) circulate in the blood and 
are able to rapidly proliferate in response to repeat antigenic challenge, retaining their effector 
function without the requirement for trafficking to the lymph node. ‘Central Memory’ 
lymphocytes (Tcm) similarly retain their antigen-specificity, but on repeat antigenic challenge 
retain the ability to migrate to lymph nodes and mount secondary proliferative responses. In 
humans, memory populations retain CD45RO, and are distinguished by their relative 
expression of CCR7; Tcm retain CCR7 whilst Tem lose CCR7 (Sallusto et al. 1999). 
 
An analogous situation exists in mice, where the surface marker CD44 is widely used to 
identify both activated and memory T lymphocyte populations; CD44 is an adhesion molecule 
expressed by most cells which mediates binding to the extracellular matrix (ECM) via 
hyaluronic acid. It is up-regulated on active T lymphocytes, and high expression is maintained 
indefinitely on memory cells (Baaten et al. 2010). Naïve cells are characterised by high 
expression of CD62L and low expression of CD44, In this state, naïve cells retain the ability 
to enter HEV (CD62L+) but remain undifferentiated (CD44 low). As described above, 
memory cells are identified by high expression of CD44, but can be further sub-divided into 
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Tem and Tcm populations by the presence of low or high CD62L expression respectively 
(Pepper & Jenkins 2011). 
 
A third population of memory T lymphocyte has been described; tissue-resident T 
lymphocytes (Trm) are a subset of Tem which remain positioned within non-lymphoid tissues 
following resolution of antigenic challenge without recirculating through blood. Similar to 
Tem, Trm are defined by absent CD62L expression, however they also express a number of 
markers not shared by other memory T lymphocytes, including CD69 and CD103. Whilst the 
precise functional significance of these markers remains unknown, CD69 is thought to 
antagonise sphingosine-1 phosphate receptor 1 (S1PR1), which is an important mediator of T 
lymphocyte egress from lymph nodes, and CD103 is thought to be important in maintaining 
survival of CD8+ cells and may promote adherence to epithelial cells. Trm are thus thought to 
reside at epithelial surfaces and provide a first response to invading pathogens (Schenkel & 
Masopust 2014).  
 
1.1.5 T lymphocyte recruitment to tissue 
 
Once activated, T lymphocytes must enter the circulation and travel to their target site, where 
they must then localize to tissue. Tissue recruitment is a complex process dependent on 
integrin binding, adhesion molecule expression and cytokine secretion. These mechanisms are 
known to be both site and cell-specific (Lukacs 2000).  
 
Leukocytes must first adhere to the vascular endothelium. Contact is initially mediated by 
tethering and rolling of leukocytes on the endothelial cell surface, dependent on the binding of 
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P- or E-selectin on the endothelial cell surface to glycoprotein ligands on the leukocyte (Ley 
et al. 2007; McEver & Zhu 2010). This interaction slows the velocity of the rolling leucocyte, 
allowing firm adhesion to the endothelium, mediated by leukocyte integrins, such as very late 
antigen (VLA)-4 , lymphocyte function-associated antigen (LFA)-1 or macrophage-1 antigen 
(Mac-1). These interact with endothelial ligands, including vascular cell adhesion molecule 
(VCAM)-1, intercellular adhesion molecule (ICAM)-1, ICAM-2, or receptor for advanced 
glycation end products (RAGE) (Chavakis 2012; Vestweber 2007; Ley et al. 2007). Finally, 
transmigration of leukocytes through the endothelium generally occurs by passing through 
endothelial junctions and involves several adhesion receptors, such as integrins, junctional 
adhesion molecules (JAM), platelet endothelial cell adhesion molecule-1 (PECAM-1) or 
CD99 (Chavakis 2012; Vestweber 2007; Ley et al. 2007; Woodfin et al. 2011).  
 
This process can be modulated by cytokines or chemokines; tissue-derived cytokines can 
upregulate endothelial adhesion molecule expression, whilst tissue-derived chemokines can 
induce conformational changes on leukocyte integrins, leading to their activation (Vestweber 
2007; Ley et al. 2007; Shamri et al. 2005).  
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1.1.6 B lymphocytes and immunoglobulin 
 
B lymphocytes develop in the bone marrow from haemopoietic precursors. The antigen 
recognition molecules of B lymphocytes are immunoglobulins (Ig), which when bound to the 
cell membrane form the B cell receptor (BCR). Similar to the TCR, Ig are produced with a 
wide range of specificities, with each B lymphocyte producing Ig of a single specificity. 
Antibodies are the secreted form of the BCR, produced by terminally differentiated B 
lymphocytes, which are known as plasma cells. Antibody is able to bind pathogens or their 
toxic products in extra-cellular spaces; this is the main effector function of B lymphocytes in 
immunity (Janeway et al. 2001). 
 
Antibody molecules are approximately Y-shaped consisting of three portions, loosely 
connected by a flexible tether. All antibodies consist of two heavy (‘H’) chains and two light 
(‘L’) chains; in any antibody the two H chains and two L chains are identical, giving the 
antibody two identical antigen-binding sites. Two types of L chain, termed lambda (λ) and 
kappa (κ) are found in antibodies; a given antibody has either lambda or kappa chains but 
never both. Five classes of antibody exist, termed IgM, IgD, IgG, IgA and IgE; the class, and 
therefore effector function of antibodies is determined by the H chain structure, conferred by 
the carboxyl-terminal part of the H chain (C region). H chains of each class are denoted by the 
corresponding lower-case Greek letter µ, δ, γ, α, or ε. Antibody is identical to the BCR of the 
cell that secretes it with the exception of a small portion of the C-terminus of the heavy chain 
constant region (Janeway et al. 2001). 
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Generation of Ig begins with functional rearrangement of Ig gene segments. V, D and J 
segments in the heavy (‘H’) chain locus, and V and J segments in the light (‘L’) chain locus 
combine to generate a repertoire of antibodies recognising greater than 5 x 1013 distinct 
antigens. Three developmental stages are described; pro-B lymphocytes lack functional Ig, 
and are generated by rearrangement of D and J segments of the H chain, followed by a second 
rearrangement joining a V region to the DJ segment. Pro-B lymphocytes undergo cell division 
and further rearrangement of L chain segments to become pre-B lymphocytes, and finally an 
IgM molecule is formed by functional rearrangement of the µ-H chain gene segments to 
define the immature B lymphocyte. IgM is expressed at the cell surface. These cells leave the 
bone marrow and migrate to B cell zones in secondary lymphoid organs, where they 
differentiate to an effector phenotype, undergoing Ig class-switching on interaction with 
antigen (Pieper et al. 2013). 
 
1.1.7 B lymphocyte function 
 
The importance of the B lymphocyte in immune responses was initially attributed to the 
ability to produce antibody. Antibodies provide protection against antigens by several 
mechanisms, including ‘neutralisation’ whereby they bind to pathogens or their toxic products 
and block their access to target cells, ‘opsonisation’ whereby they bind to pathogens and 
foreign particles enabling phagocytosis by other immune cells, and finally by activation of the 
compliment cascade (Janeway et al. 2001).   
 
It is now known that the ability to eradicate invading pathogens is dependent on the interplay 
between both the T and B lymphocyte response. B lymphocytes are able to internalise 
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antigens bound by their cell-surface BCR, and present these as peptide:MHC class II 
complexes. B lymphocytes thus play a crucial role in antigen presentation to CD4+ T 
lymphocytes, enabling activation and clonal proliferation of antigen-specific T lymphocytes 
(Lebien & Tedder 2008).  
 
Furthermore, B lymphocytes have been shown to secrete a range of cytokines which modulate 
the local immune response, including regulation of local T lymphocytes. For example, B 
lymphocytes secreting IL-10 have an immunosuppressive function and have been termed 
‘regulatory B lymphocytes’ (Breg), (Mauri & Bosma 2012).  ‘Effector’ B lymphocytes have 
also been identified which are able to regulate differentiation of naïve CD4+ T lymphocytes 
through secretion of IL-4 and IFNγ (Harris et al. 2000). 
 
1.1.8 Immunological tolerance 
 
The human immune system must achieve a balance between effective elimination of 
pathogens, whilst maintaining tolerance to self-antigens and achieving homeostasis. 
Immunological tolerance refers to the reduction or inhibition of the ability to mount an 
immune response on exposure to antigen. Tolerance can be naturally acquired against host 
antigens, or induced against exogenous antigens. 
 
There are many determinants of the immune response, including the antigen itself, its dose 
and route of administration, and the genetic background of the host. In turn, there are many 
points at which this response is regulated, being further influenced by the effects of 
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responding immune cells, the nature of associated cytokine stimulation, and the activity of 
other biological systems in the host. 
 
1.1.8.1 Factors determining the extent, induction and duration of tolerance 
 
The size of a potentially antigenic molecule can determine the level of immune response 
against that antigen; molecules which exist as aggregates are often more antigenic than those 
which exist as monomers (Ratanji et al. 2014). For example, serum proteins such as γ-
globulin and albumin are strongly antigenic when present as aggregates, but induce tolerance 
when present as monomers (Ellis & Henney 1969). This is attributed to the rapid ingestion of 
larger, aggregated molecules by professional APC resulting in efficient presentation to T 
lymphocytes and potentiation of an immune response, whereas monomers may escape 
ingestion by APC, remaining in the circulation for prolonged periods and being processed 
more slowly (Zouali 2014). 
 
Initial induction of an immune response depends on the availability of antigen in secondary 
lymphoid organs in a dose and time-dependent manner; if antigen is present at very low 
concentration or does not reach secondary lymphoid tissues, it may be ignored by immune 
cells and no immune response will be mounted. Conversely, if present at excessively high 
concentrations in multiple sites, antigen is likely to induce a state of high activity, and may 
even deplete the immune system of all antigen-specific cells resulting in a state of tolerance or 
immune deficiency (Zinkernagel et al. 1997). 
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Route of administration is thought to determine relative availability of an antigen to APC. In 
general, subcutaneous administration of antigen is thought to result in uptake by Langerhans 
cells and induction of an immune response, whereas intra-venous immunisation results in 
presentation by resting B lymphocytes and induction of tolerance. Oral administration is also 
thought to promote antigenic tolerance (Cuppari et al. 2014). 
 
Genetic influences have been demonstrated between strains of laboratory mouse, with some 
strains being relatively resistant to tolerance induction. For example BALB/c mice are 
relatively resistant to tolerance induction by xenogeneic γ-globulin, and this resistance 
segregates amongst offspring (Lukić et al. 1975). In humans, genetic variation in MHC genes 
has been shown to influence the level of response to antigen, susceptibility to infection and 
autoimmune disease. This is thought to be explained by alteration of reporter gene activity 
and allele-specific expression, and variation in DNA binding-sites for regulatory factors 
(Handunnetthi et al. 2010). 
 
Interaction between components of the immune system and antigen involves several clones 
specific for different epitopes, each with different affinities for the invading antigen. The 
affinity of this interaction with antigen determines whether a clone may be tolerised, with the 
completeness of resulting tolerance dependent on the proportion of tolerant and non-tolerant 
clones (Zouali 2014). 
 
Tolerance may be induced by a lack of appropriate co-stimulation of T and B lymphocytes. T 
lymphocyte activation is dependent on two signals: in addition to the interaction with the 
processed peptide on APC, co-stimulation by accessory molecules expressed on APC is also 
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necessary. Well-characterised molecules include CD80 and CD86 ligands on APC interacting 
with CD28 and CTLA-4 receptors on T lymphocytes, and the CD40 molecule on 
macrophages, dendritic cells and B lymphocytes interacting with the CD40L receptor on 
activated T lymphocytes. In the absence of appropriate co-stimulation, T lymphocytes may 
become apoptotic or unresponsive, abrogating initiation of an adaptive immune response 
against the antigen (Chen & Flies 2013). Similar co-stimulation is necessary for activation of 
B lymphocytes following BCR / antigen interaction, with interaction between CD40 and 
CD40L being necessary to induce germinal center (GC) formation, Ig isotype switching, Ig 
somatic hypermutation and formation of long-lived plasma cells and memory B lymphocytes. 
(Clark & Ledbetter 1986; Elgueta et al. 2009; Mauri & Bosma 2012). 
 
1.1.8.2 Mechanisms of central tolerance 
 
Central tolerance describes the multitude of processes which exist to remove immature 
lymphocytes with the potential to mount immune responses against host tissues from primary 
lymphoid organs. 
 
As previously discussed, potentially auto-reactive T and B lymphocytes are generated in the 
thymus and bone marrow respectively, which must be identified and eliminated. T 
lymphocytes must first undergo a process of positive selection, during which only those 
recognising peptide in self-MHC molecules are permitted to continue development; T 
lymphocytes failing to recognise self-MHC undergo apoptosis in the thymus. Positively 
selected T lymphocytes with high affinity for self-peptide bound to MHC molecules are then 
eliminated by clonal deletion, in a process termed negative selection (Starr et al. 2003; 
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Kyewski & Klein 2006; Anderson et al. 2007) (see section 1.1.2). Similarly, auto-reactive B 
lymphocytes are induced to die by apoptosis at the transition between pre-BCR to mature-
BCR in the bone marrow. These process ensure that T and B lymphocytes with the potential 
to recognise and mount immune responses against self-peptides are deleted before entering 
the circulation, serving as a mechanism of central tolerance induction (Nemazee & Buerki 
1989; Chen et al. 1995).  
 
Whilst tolerance was initially considered to result only from deletion of auto-reactive 
lymphocytes in primary lymphoid organs, it was later demonstrated that populations of 
inactive lymphocytes exhibiting poor responsiveness to strong antigenic challenge can be 
detected in tolerant animals. The term anergy was first used to describe this functionally silent 
state observed in B lymphocytes (Nossal & Pike 1980). In vitro, B lymphocyte stimulation in 
the absence of T lymphocyte help results in a state of anergy, thus preventing aberrant 
activation of B lymphocytes (Healy et al. 1997). Similarly, in vitro activation of T 
lymphocytes in the absence of appropriate co-stimulation results in development of a 
functionally inactive state in the activated T lymphocyte. Such inactive T lymphocytes are 
incapable of producing IL2, and are unable to proliferate if later exposed to antigen and 
appropriate co-stimulatory ligands (Fields et al. 1996; L. Li et al. 2006).  
 
B lymphocytes have also been shown to undergo a process of receptor editing, in which 
variable region genes expressed by B lymphocytes are altered resulting in changes to the 
specificity of the BCR (Gay et al. 1993; Tiegs et al. 1993; Radic & Zouali 1996). In contrast 
to the process of clonal deletion, where autoreactive B lymphocytes are eliminated, receptor 
editing induces gene rearrangement in autoreactive lymphocytes. This has the dual benefit of 
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neutralising potentially auto-reactive B lymphocytes, whilst expanding the primary B 
lymphocyte repertoire (Zouali 2008). 
 
1.1.8.3 Peripheral tolerance 
 
Central tolerance enables elimination of lymphocytes sensitive to self antigens present in 
primary lymphoid organs. Antigens produced in peripheral non-lymphoid tissues do not 
circulate in sufficient amounts in primary lymphoid organs, and mechanisms of peripheral 
tolerance are thus necessary to restrict auto-reactive lymphocytes that have not been silenced 
in primary organs.  
 
There is significant regulation of the immune response by activated T lymphocytes, with the 
type of response determined by the nature of cytokines secreted. For example, Th1 cells 
secrete IFNγ, which stimulates macrophages and increases Th1 cell numbers by positive 
feedback (Szabo et al. 2000), whereas Treg secrete cytokines such as IL-10 and TGFβ, 
suppressing immune responses and promoting tolerance (Corthay 2009). Peripheral tolerance 
can thus be induced through preferential activation of specific T lymphocyte subsets. 
 
Activation-induced cell death (AICD) is a process whereby repeated stimulation of T 
lymphocytes via the TCR results in programmed cell death by apoptosis, and is thus a 
mechanism of negative regulation of activated T lymphocytes which helps maintain 
peripheral immune tolerance (Green et al. 2003). Apoptosis is induced through interaction of 
Fas receptors (CD95) on lymphocytes with Fas receptor ligand (CD95L) expressed by a wide 
range of effector cells (Nguyen & Russell 2001). Interestingly, CD95L is expressed on 
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activated T lymphocytes, and can be secreted in a soluble form, thereby enabling autocrine T 
lymphocyte ‘suicide’. This is thought to be an important mechanism through which the 
pathogenic potential of activated T lymphocytes can be limited (Dhein et al. 1995). 
 
As previously discussed, two distinct groups of Treg exist, including nTreg which are 
generated in the thymus, and iTreg which develop from naïve T lymphocytes in the periphery 
(see section 1.1.3). During the process of negative selection of T lymphocytes in the thymus, 
relatively higher-affinity interactions between self-peptide / MHC and the developing TCR 
which remain below the threshold for initiating death by apoptosis result in FoxP3 induction 
and development of nTreg (Ohkura et al. 2013). Development of peripheral iTreg occurs in 
response to interaction between TCR on naïve T lymphocytes and foreign peptide / MHC in 
the absence of pro-inflammatory co-stimulation (Li & Zheng 2015). TGFβ is implicated in 
both processes, by exerting an anti-apoptotic effect on nTreg (Ouyang et al. 2010), and by 
inducing Smad binding to the FoxP3 locus and directly promoting FoxP3 expression in iTreg 
(Schlenner et al. 2012) (discussed further in section 1.2.4). Treg induce immunological 
tolerance through a variety of mechanisms, including secretion of immunosuppressive 
cytokines such as IL-10 and TGFβ, killing or functional modulation of APC or T lymphocytes 
by release of perforin, granzymes, or by a CTLA- 4–dependent mechanism (see section 1.1.3) 
(Walker & Sansom 2011), deprivation of cytokines such as IL- 2, and degradation of ATP 
through ectonucleotidases (Shevach 2009).  
 
Similarly, Breg are able to negatively regulate inflammation and autoimmune disease through 
production of IL-10 (Mauri & Bosma 2012). Furthermore, immunoglobulins secreted by B 
lymphocytes are able both to positively regulate immune responses through processes 
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including immune complex formation and increased B lymphocyte activation, or negatively 
regulate antigen presentation through feedback inhibition of B lymphocyte function by 
mechanisms including reduction of antibody avidity following Ig class switching (Hjelm et al. 
2006). 
 
Certain sites appear to be almost exempt from localised immune responses, including the 
brain, eye and testis. Whilst immune responses are observed in these locations, they appear to 
be more tightly regulated than those at other sites, usually displaying a far higher threshold for 
immune activation. Such tissues are considered sites of ‘immune privilege’, and this 
characteristic was initially attributed to the lack of lymphatic drainage and natural blood-
tissue barriers observed in these areas. It was thought that physical barriers prevented access 
of effector immune cells to these tissues (Forrester et al. 2008). It is however now accepted 
that immune privilege is a consequence of interactions between the immune system and 
specialized tissues (Van Parijs & Abbas 1998). For example, CD95L, the ligand for the Fas 
receptor CD95, is expressed constitutively in the eye and testis, and activated CD95+ T 
lymphocytes entering these sites are thus induced to undergo apoptosis by AICD (Griffith & 
Ferguson 2011).  
 
Finally, there is interaction between the neuro-endocrine and immune system via the 
hypothalamo-pituitary-adrenal axis, with secretion of endogenous corticosteroids observed to 
negatively regulate peripheral immune activation (Haddad et al. 2002). The immune response 
is thus regulated at many points by a wide variety of intrinsic and extrinsic mechanisms.  
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1.2 Transforming Growth Factor β (TGFβ)  
 
1.2.1 Function 
 
The Transforming Growth Factor Beta (TGFβ) superfamily includes the isoforms of TGFβ, 
activins and inhibins, mullerian inhibitory substance, growth and differentiation factors 
(GDF) and bone morphogenic peptides (BMP). These proteins have a wide range of roles 
including proliferation, differentiation, apoptosis, chemotaxis, tumour suppression and 
immune regulation (Dallas et al. 2008).  TGFβ is also important in embryogenesis, and 
alterations in TGFβ signalling have been implicated in many human disease states 
(Santibañez et al. 2011). 
 
1.2.2 Isoforms 
 
Three TGFβ isoforms have been identified in mammals, encoded by different genes 
(Massagué & Chen 2000). Significant sequence homology is observed between isoforms with 
71% similarity between TGFβ1 and TGFβ2, and 76% similarity between TGFβ2 and TGFβ3 
(Kondaiah et al. 1990). Interestingly, there is greater than 76% sequence homology between 
all isoforms of mature TGFβ between most mammalian and avian species, suggesting 
significant evolutionary conservation of TGFβ molecules (Massagué 1990).  
There is differential expression of the isoforms during embryogenesis (Pelton et al. 1989; 
Schmid et al. 1991; Millan et al. 1991), which is thought to explain why mice with targeted 
deletions of each isoform show different phenotypes: 
 
 27 
TGFβ1 deletions result in two distinct phenotypes; approximately 50% of embryos die around 
mid-gestation due to defects in yolk sac vasculogenesis and haematopoiesis (Dickson et al. 
1995), whilst the remainder survive beyond birth, possibly due to transfer of maternal TGFβ1 
across the placenta. Mice surviving to birth proceed to experience spontaneous activation of a 
self targeted immune responses leading to death between three and four weeks of age 
(Kulkarni et al. 1993; Shull et al. 1992).  
 
TGFβ2 deletions also result in perinatal death, although this is due to extensive 
developmental defects in the cardiac, pulmonary, musculoskeletal, craniofacial and urogenital 
systems (Sanford et al. 1997). Loss of TGFβ3 results in cleft palate and abnormal pulmonary 
development with death within a few hours of birth (Kaartinen et al. 1995; Proetzel et al. 
1995). 
 
These observations suggest that each isoform must have a distinct function during 
embryogenesis, and thus differential responses to each isoform may persist in mature tissues. 
Indeed, there is significant variation in the predominant TGFβ isoform at different sites in the 
human body. TGFβ1 is thought to be the predominant isoform acting in the immune system 
(Wan & Flavell 2007), and accounts for 80-90% of the TGFβ found in bone (Bonewald 1999; 
Dallas et al. 2008). TGFβ1 also appears to prevail in the intra-ocular environment during 
active uveitis, whilst TGFβ2 is the predominant isoform in the un-inflamed eye (Denniston et 
al. 2011; Stein-Streilein 2008). TGFβ2 is the predominant isoform in the prostate gland 
(Dallas et al. 2005) and kidney mesangial cells (Marra et al. 1996). TGFβ3 is the only isoform 
constitutively expressed in the intact epidermis and as a result is specifically implicated in 
wound healing (Schmid et al. 1993). 
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1.2.3 Structure 
 
TGFβ molecules encoded as large precursor proteins of 390-412 amino acids, which undergo 
proteolytic cleavage by endopeptidase furin to yield two products which assemble into 
homodimers. The 65-75kDa dimer from the N-terminal region is known as the latency-
associated peptide (LAP), whilst the 25kDa dimer from the C-terminal portion is the mature 
TGFβ molecule (Khalil 1999). 
 
Each mature TGFβ monomer comprises nine cysteine residues, of which eight form 
disulphide bonds comprising the ‘cysteine knot’ which is common to all TGFβ superfamily 
members. The ninth cysteine residue forms a bond with the ninth residue of another monomer 
to form the dimeric structure. The area between the fifth and sixth cysteine residues is 
exposed at the surface of the molecule and is thought to be involved in receptor binding 
(Daopin et al. 1992) (Figure 1.3). 
 
All TGFβ molecules are described as having a common structure described as a ‘TGFβ-fold’, 
comprising a cysteine knot with two pairs of β-strands extending from an α-helix (Lin et al. 
2006) (Figure 1.3). The monomers are arranged such that the central helix of one monomer is 
oriented in the concave surface formed by the β-strands of the other, with stabilising inter-
chain disulphide bonds present in most examples (Hinck 2012).  
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Figure 1.3 Schematic representation of TGFβ monomer structure. Each monomer 
consists of nine cysteine residues (red circles), of which eight form disulphide bonds (dashed 
lines) to create a ‘cysteine knot’, and the ninth forms a bond with the ninth residue of another 
TGFβ monomer (dashed arrow). The monomeric structure is described as a TGFβ fold, 
comprising an α-helix (green) with two pairs of β-strands (one pair of strands illustrated by 
purple line, one pair of strands illustrated by blue line). 
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1.2.4 TGFβ in immune regulation 
 
In the context of immune regulation, TGFβ has traditionally been considered a potent 
suppressor of immune activation (Yoshimura et al. 2010).  In-vitro assays have demonstrated 
TGFβ to act as a negative regulator of cell proliferation and induce iTreg differentiation of 
naïve T lymphocytes. TGFβ was first shown to suppress T lymphocyte proliferation through 
inhibition of IL-2 receptor expression (Kehrl et al. 1986), and later to induce differentiation of 
naïve T lymphocytes to a regulatory FoxP3+ phenotype (iTreg) (Li & Flavell 2008; Wan & 
Flavell 2007; Ming O Li et al. 2006; Chen et al. 2003), seemingly justifying its label as an 
immunosuppressive molecule. More recently, it has been suggested that TGFβ dampens the 
effect of CD28 signalling to T lymphocytes, inhibiting growth and proliferation of CD4+ T 
lymphocytes (Delisle et al. 2013).  
 
Such in-vitro assays have however demonstrated that the response to TGFβ is highly context-
dependent. Paradoxically, some groups demonstrated the ability to induce proliferation of 
effector T lymphocytes in response to TGFβ (Bode et al. 2004), and others suggested TGFβ to 
confer protection against T lymphocyte apoptosis in some situations (Chen et al. 2001; 
Sanjabi et al. 2009) thus providing evidence of a pro-inflammatory effect. In addition, TGFβ 
has also emerged as an important cytokine in the generation of a pathogenic effector Th17 
lymphocyte response. When present at lower levels than those necessary for FoxP3 induction, 
and with co-stimulation by IL-6, TGFβ will induce differentiation of naïve T lymphocytes to 
a potentially destructive Th17 phenotype (Korn, Oukka, et al. 2007; Rubtsov & Rudensky 
2007; Mangan et al. 2006; Bettelli et al. 2006; Veldhoen et al. 2006) (Figure 1.4). 
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Figure 1.4 The dual role of TGFβ. TGFβ is able to induce differentiation of naïve T 
lymphocytes to either an immunosuppressive iTreg phenotype or pro-inflammatory Th17 
phenotype; TGFβ-dependent immune responses are thus dependent on the co-stimulatory 
cytokines present at the time of signal transduction.  
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Perhaps most interestingly, there is evidence that TGFβ3 is able to differentiate naïve CD4+ T 
lymphocytes to a more pathogenic phenotype than TGFβ1; Lee et al differentiated Th17 cells 
from naïve CD4+ T lymphocytes using either TGFβ1 or TGFβ3, using the resulting cells to 
induce a murine model of experimental autoimmune encephalomyelitis (EAE) (Lee et al. 
2012).  Th17 lymphocytes differentiated with TGFβ3 and IL-6 resulted in EAE induction, 
whereas lymphocytes induced by TGFβ1 and IL-6 did not readily induce autoimmune disease 
without further exposure to IL-23. This suggests that not only can TGFβ have a pro-
inflammatory function, but that there may also be a differential response between different 
isoforms. 
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In-vivo studies of TGFβ in immune regulation have been limited partly by the embryonic 
lethality of murine knock-out models, and also due to the widespread expression of both 
TGFβ and its receptors. It is thus difficult to separate the effects of TGFβ on T lymphocytes 
from its effects on antigen presenting cells or non-lymphoid cells. 
 
To overcome some of these difficulties, Gorelik and Flavell adopted a transgenic approach, 
whereby they were able to breed mice expressing a dominant negative form of the type-II 
TGFβ receptor (dnTGFβRII) under the control of a T lymphocyte specific promoter (Gorelik 
& Flavell 2000). Whilst dnTGFβRII retains the ability to bind all isoforms of TGFβ, it is 
unable to phosphorylate TGFβRI and mediate signal transduction (Wieser et al. 1993; Wrana 
et al. 1994). This allowed for specific blockade of TGFβ signalling to T lymphocytes, 
allowing targeted investigation of TGFβ-dependent T lymphocyte responses in-vivo. 
 
Mice expressing dnTGFβRII on T lymphocytes developed autoimmune disease characterised 
by inflammatory infiltration in multiple organ systems and presence of circulating 
autoantibodies. In addition, most T lymphocytes appeared to differentiate to an effector 
phenotype with increased IFNγ and IL-4 secretion. The immunosuppressive activity of TGFβ 
thus appears to dominate in vivo. 
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1.2.5 TGFβ in disease 
 
1.2.5.1 Uveitis and EAU 
 
An example of the contrasting effects of TGFβ can be found in the eye when considering the 
disease state of uveitis – a condition characterised by inflammation involving the structures of 
the uveal tract (the iris, ciliary body and choroid). Visual impairment is common (Darrell et 
al. 1962; Suttorp-Schulten & Rothova 1996; Goldstein 1980), and may result from direct 
damage to uveal tract structures, or from involvement of adjacent tissues such as the retina 
and optic nerve (Forrester 1991). Whilst uveitis can have an infectious aetiology, most disease 
in the West is non-infectious (Barry et al. 2014); such non-infectious disease is believed to 
result from influx of effector cells and inappropriate activation of the intra-ocular immune 
system: 
 
Changes in the ocular microenvironment are thought to result in a switch between an un-
inflamed regulatory state, and an inflamed pathogenic state; studies in humans have 
demonstrated high levels of TGFβ (particularly TGFβ2) in the aqueous humour of un-
inflamed eyes (Denniston et al. 2011), whereas TGFβ levels have been shown to decrease in 
active uveitis (Curnow et al. 2005).  
 
Experimental models also support the role of TGFβ in T lymphocyte driven ocular 
inflammation; experimental autoimmune uveoretinitis (EAU) is perhaps the most commonly 
used model of autoimmune ocular inflammation. It is a T lymphocyte mediated disease that 
targets the neural retina and related tissues, and is thought to be a useful model of posterior 
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segment uveitis (inflammation of the choroid and retina) in humans (Caspi 2003). It is 
induced by the subcutaneous injection of a soluble retinal antigen – usually s-antigen or 
interphotoreceptor retinoid binding protein (IRBP) – in a complete Freund’s adjuvant (CFA) 
vehicle, and results in a predominantly CD4+ T lymphocyte mediated response in the retina 
(Gasparin et al. 2012). Using EAU as a model for investigation, it has been shown that lower 
levels of TGFβ, in the presence of other pro-inflammatory cytokines such as IL-6 and IL-23 
actually promote a pathogenic Th17-driven uveitis (Zhou et al. 2012; Zhou et al. 2011; 
Bettelli et al. 2006).  
 
Based on these observations, it thus appears TGFβ is implicated in both the un-inflamed and 
inflamed ocular microenvironment, and therefore has a crucial function in ocular immune 
regulation. 
 
1.2.5.2 Multiple sclerosis and EAE 
 
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) 
involving demyelination and neuronal injury (Hauser & Oksenberg 2006; Steinman & Zamvil 
2006). The aetiology of MS is currently unknown, although environmental and genetic factors 
are thought to be involved in disease pathogenesis. Th17 cells have been detected in the CNS 
of patients with MS and are thought to be the main pathogenic effector cell in this condition 
(Axtell et al. 2010). 
 
Experimental autoimmune encephalomyelitis (EAE) is a murine model of MS. It is classically 
induced through the subcutaneous immunisation of susceptible mice with encephalitogenic 
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antigens derived from CNS proteins, such as myelin basic protein (MBP) and myelin 
oligodendrocyte glycoprotein (MOG). This results in the induction of autoreactive T 
lymphocytes in the CNS and is considered a useful tool for modelling human disease 
(Rangachari & Kuchroo 2013).  
 
TGFβ has been found at elevated levels in the CNS of mice in the recovery phase of EAE 
(Issazadeh et al. 1996), which appears to correlate with an expansion of resident FoxP3+ Treg 
populations (O’Connor et al. 2007; Zorzella-Pezavento et al. 2013). Activated TGFβ has also 
been shown to be necessary for differentiation of naïve T lymphocytes to pathogenic Th17 
cells in the active phase of EAE, again demonstrating TGFβ to be both an activator and 
suppressor of localised immune responses (Yoshida et al. 2014). 
 
1.2.5.3 Inflammatory bowel disease and experimental colitis 
 
TGFβ is also known to be a mediator of intestinal epithelial restitution and defence (Dignass 
& Podolsky 1993), and is strongly implicated in the pathogenesis of inflammatory bowel 
disease in humans. It is found at elevated levels in active lesions of Crohn’s disease and 
ulcerative colitis, and normalises in quiescent disease (Babyatsky et al. 1996). Whilst 
traditionally considered to be Th1 /Th2-mediated, Th17 cells have more recently been 
identified in active disease (Kobayashi et al. 2008; Olsen et al. 2011; Siakavellas & Bamias 
2012). 
 
Several models of experimental murine colitis have been developed; the earliest and perhaps 
best characterised of these involves transfer of either CD4+CD62L+ (central memory) or 
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CD4+CD25- (non-regulatory) T lymphocytes to a severe combined immunodeficiency 
(SCID) mouse host (Powrie et al. 1994; Blumberg et al. 1999). Th17 cells have been 
identified and observed to correlate with disease progression in these mice, with IL-17 
blockade shown to prevent development of inflammation (Wedebye Schmidt et al. 2013). 
Likewise, transfer of TGFβ-induced Treg cells have been demonstrated to suppress active 
experimental colitis in this model (Mottet et al. 2003; Fantini et al. 2006). 
 
In each of these examples, both active inflammation and resolution of inflammation appear 
dependent on TGFβ. Differential signalling by TGFβ thus appears important in immune 
regulation. 
 
1.3 TGFβ signalling 
 
1.3.1 Ligand activation 
 
TGFβ is synthesized as a precursor and secreted in a latent form by most cell types; the 
mature 25kDa homodimer is released by post-translational processing at the site of activity 
(Dallas et al. 2008).   
 
Briefly, the pre region of TGFβ precursor contains a signal peptide, and pro-TGFβ is 
processed in the Golgi apparatus, removing the N terminus of the immature protein. This new 
protein forms a homodimer known as the latency-associated peptide (LAP), which forms a 
non-covalent bond to a homodimer of mature TGFβ. In order to bind to, and signal through its 
receptor, TGFβ must be released from the LAP by the action of a TGFβ activator, either by 
 38 
proteolysis or a conformational change. Several molecules have been described as latent 
TGFβ activators, including proteases such as plasmin, matrix meyalloproteinase-1 and 2 
(MMP-1 and MMP-2), thrombospondin-1, integrins and reactive oxygen species. Cells 
producing these TGFβ activators may differ from those secreting TGFβ. This is thought to be 
an important early regulator of TGFβ signalling (Annes et al. 2003). 
 
1.3.2 Receptor structure 
 
TGFβ (and members of the TGFβ superfamily) signal through a complex of cell surface 
receptors consisting of two type I (TGFβRI) and two type II (TGFβRII) transmembrane 
receptors. Both TGFβRI and TGFβRII are serine / threonine kinases, of approximately 55kDa 
and 75kDa respectively (Chang 2002). Both have short extra-cellular domains with a long 
cytoplasmic region containing the serine / threonine kinase (Dallas et al. 2008) (Figure 1.5). 
 
TGFβRI and TGFβRII have been shown to have higher affinity for TGFβ1 and TGFβ3 
isoforms than for TGFβ2 (Wrana et al. 1992) although subsets of receptors with higher 
affinity for TGFβ2 have been identified in some cell lines (Cheifetz et al. 1990), suggesting 
variation in the binding properties of receptors on different cell types at different sites, thus 
implicating other receptor isoforms in the signalling cascade. 
 
Absolute deficiency of any either of the two main TGFβ receptor subunits is embryonic 
lethal, resulting in death around mid-gestation. Murine models of TGFβRI or II gene knock-
out are characterised by severe defects in vascular development in the placenta and yolk sac 
(Larsson et al. 2001; Dickson et al. 1995; Oshima et al. 1996). 
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Figure 1.5 Schematic representation of TGFβ receptor and signalling pathway. TGFβ 
binds to TGFβRI, transphosphorylating TGFβRII, which in turn transphosphorylates 
intracellular Smad proteins. Phosphorylated Smad proteins are released from the receptor 
complex and migrate to the cell nucleus where they influence gene expression.    
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1.3.3 Signalling cascade 
 
All members of the TGFβ superfamily exert their function through binding the 
aforementioned cell-surface serine/threonine kinase receptors (TGFβRI and TGFβRII) 
(Santibañez et al. 2011; Massague 1992).  Ligand binding forms a stable complex consisting 
of two of each type of receptor (Feng & Derynck 2005). Ligand initially binds to the 
TGFβRII component allowing it to phosphorylate the kinase domain of the TGFβRI receptor 
(Souchelnytskyi et al. 1996; Kang et al. 2009). This in turn initiates the intracellular signalling 
cascade through the phosphorylation of Smad proteins (Santibañez et al. 2011); TGFβRI 
initially phosphorylates Smad 2 and Smad 3 which in turn form a complex with Smad 4 
(Massagué 1998). These phosphorylated Smad proteins dissociate from the receptor and 
translocate to the nucleus, acting as transcription factors controlling gene expression within 
the cell nucleus (Shi & Massagué 2003). 
 
Whilst full details of the signalling cascade are beyond the scope of this thesis, it is important 
to note that there is significant signalling versatility in TGFβ gene responses, determined by 
differential Smad-receptor interactions, Smad complex formation, interaction with accessory 
proteins and involvement of non-Smad signalling pathways. The outcome of TGFβ / receptor 
interaction is thus ultimately determined by the exact nature of the resulting signalling 
cascade, allowing TGFβ to induce cell-specific responses and have site-specific effects (Feng 
& Derynck 2005). 
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1.4 Betaglycan 
 
1.4.1 Structure 
 
There is a third component of the receptor for TGFβ; TGFβRIII, which is also known as 
betaglycan. Betaglycan is a membrane-anchored proteoglycan, which binds TGFβ via its core 
protein. It consists of 853 amino acids, with two large extra-cellular cysteine-containing 
domains separated by a short spacer region, a single pass transmembrane and short 42 amino-
acid cytoplasmic domain (Massague 1992; Bilandzic & Stenvers 2011). It can also exist in a 
soluble form through proteolytic cleavage of the extra-cellular domains close to the cell 
membrane (Velasco-Loyden et al. 2004) being found in serum and ECM (Andres et al. 1989).  
 
1.4.2 Current understanding of function 
 
Betaglycan is able to bind all three isoforms of TGFβ, and also binds inhibin A, inhibin B and 
certain BMP (Bilandzic & Stenvers 2011). Betaglycan is present on a wide range of cell 
types, including mesenchymal, neuronal, and epithelial cells, being most strongly expressed 
on CD4+ T lymphocytes (Figure 1.6) and in the placenta (Pakula et al. 2007). It is however 
absent from certain myoblasts, epithelial, endothelial, and haematopoietic cells which still 
respond to TGFβ (López-Casillas et al. 1991). This early observation led to the suggestion 
that betaglycan itself has no intrinsic enzyme activity, but acts as a co-factor in TGFβ 
signalling, concentrating ligand at the cell surface to potentiate signalling through the 
TGFβRI/RII complex (Wang et al. 1991). It is thus considered an accessory molecule in 
TGFβ signalling. 
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Figure 1.6 Betaglycan expression on T lymphocytes. Murine thymocytes and lymph node 
(LN) cells were stained with antibodies for CD4, CD8 and betaglycan (red line) or isotype 
control (green line). Highest expression was observed on CD4+ T lymphocytes. 
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Betaglycan is thought to have a dual role in regulation of TGFβ signalling: In the membrane 
bound form, betaglycan is thought to potentiate binding of ligand to the receptor complex, by 
binding TGFβ and presenting it to TGFβRII as an early regulatory step in initiation of the 
signalling cascade (Akhurst et al. 1990; López-Casillas et al. 1993; López-Casillas et al. 1994; 
Wang et al. 1991). Conversely, soluble betaglycan generated through proteolytic cleavage at 
the cell membrane is thought to have an opposite effect, by sequestering TGFβ away from the 
cell surface receptor complex (Bandyopadhyay et al. 1999; López-Casillas et al. 1994; Sun & 
Chen 1997). It therefore appears that betaglycan may have a dual role in regulation of TGFβ 
binding to the receptor complex.  
 
The effect of betaglycan on TGFβ-TGFβRI/II affinity and subsequent TGFβ potency is 
complicated by the wide variety of in vitro assays reported, and differences in cell lines on 
which results are based:  
 
Competition assays using tracer radioligands have previously shown that whilst all TGFβ 
isoforms have a similar affinity for betaglycan, TGFβ2 is of significantly lower affinity for 
TGFβRI and TGFβRII than TGFβ1 or TGFβ3. Furthermore, in cell lines lacking betaglycan, 
TGFβ2 has reduced potency in growth inhibition assays. The foetal bovine heart endothelial 
(FBHE) cell line is naturally betaglycan deficient; TGFβ2 is at least 50 times less potent as a 
growth inhibitor of FBHE cells than TGFβ1 or TGFβ3 (Cheifetz et al. 1990).  
 
It was subsequently shown that TGFβRII is of intrinsically low affinity for TGFβ; rat L6E9 
skeletal muscle myoblast cell lines express TGFβRI and TGFβRII, but lack betaglycan. 
Lopez-Casillas et al transfected these cells with betaglycan in order to characterise its effect 
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on TGFβ affinity and cell responsiveness (López-Casillas et al. 1993). In the absence of 
betaglycan up to 90% of TGFβ1 bound to TGFβRII with low affinity, and TGFβ2 binding 
was almost undetectable. Transfection with betaglycan resulted in a 50-fold increase in 
affinity for both TGFβ isoforms. This increased affinity for TGFβRII resulted in a similar 
increase in TGFβ2 binding to TGFβRI, whilst there was only a limited increase in TGFβ1 
binding to TGFβRI.  These observations correlated with the growth inhibitory response of 
both isoforms, with a 10-fold reduction in TGFβ2 potency observed in L6E9 cells when 
compared to assays using TGFβ1, and a corresponding 10-fold increase in TGFβ2 potency 
following transfection with betaglycan.   
 
Sankar et al later similarly transfected bovine aortic endothelial cells (BAEC - another 
betaglycan-deficient cell line) with betaglycan, demonstrating increased potency of TGFβ2 
assessed by a number of criteria including inhibition of migration and proliferation (Sankar et 
al. 1995). 
 
These experiments suggest that betaglycan promotes presentation of all isoforms of TGFβ to 
TGFβRII, increasing affinity of both TGFβ1 and TGFβ2 for the receptor complex. Whilst this 
has a limited effect on TGFβ1 signalling, it allows a 10-fold increase in the potency of TGFβ2 
signalling.  
 
To examine the function of betaglycan in vivo, several groups have developed betaglycan 
knock-out (TGFβRIII-/-) mice. Similar to other TGFβ receptor knock-out models, these mice 
display embryonic lethality (discussed later), however they permit investigation of 
embryonic-derived cell populations. Stenvers el al derived fibroblasts from mutant and wild-
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type embryos, and cultured them in the presence of either TGFβ1 or TGFβ2. Cellular 
proliferation was measured by thymidine incorporation. Whilst both isoforms resulted in 
dose-dependent inhibition of proliferation, significantly higher doses of TGFβ2 were needed 
to induce inhibition in cells derived from betaglycan deficient embryos compared to TGFβ1, 
with calculations of IC50 suggesting that TGFβ2 is 10-fold less potent than TGFβ1 in mutant 
than wild type cell lines (Stenvers et al. 2003). Interestingly, no significant differences in 
Smad 2 phosphorylation were observed when comparing the response to TGFβ1 or TGFβ2 
between mutant and wild type cells. TGFβ3-dependent responses were not investigated. 
Betaglycan has thus emerged as an important co-factor in TGFβ signalling, with particular 
significance for the TGFβ2 isoform (Figure 1.7).  
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Figure 1.7 Schematic representation of TGFβ receptor and signalling cascade 
illustrating role of membrane-bound betaglycan.  Membrane-bound betaglycan is a non-
signalling component of the TGFβ receptor which is thought to present TGFβ to the 
signalling components. It is also able to exist in a soluble form through cleavage close to the 
cell membrane; in this form it is believed to sequester TGFβ away from the signalling 
complex.   
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1.4.3 Role of betaglycan in embryogenesis 
 
Early observations of betaglycan showed higher expression in foetal than adult tissues, 
suggesting an important role in embryogenesis (Andres et al. 1989). This was confirmed in 
studies of betaglycan knock-out (TGFβRIII-/-) mice, which displayed embryonic-lethal 
cardiac and hepatic defects arising around mid-gestation, which were not observed in 
heterozygote (TGFβRIII+/-) or wild-type (TGFβRIII+/+) mice (Stenvers et al. 2003). 
Embryos generated through timed pregnancies between heterozygotes were obtained by 
caesarean delivery at time-points between E12.5 and E18.5. The resulting embryos followed 
Mendelian inheritance patterns, with a betaglycan knock-out genotype in 25%. In these 
knock-out embryos, development was largely unaffected at time points up to E15.5 with less 
than 10% dying. This death rate increased to over 55% by E18.5, with any remaining knock-
outs showing significant anatomical abnormalities incompatible with life. Knock-out embryos 
were observed to die due to a combination of severe haemorrhagic liver destruction, disrupted 
erythropoiesis, and defects in the walls of cardiac ventricles.  
 
It has since been shown that the cytoplasmic domain of betaglycan is necessary for TGFβ2-
induced transformation of epithelial cells to endocardial cells in heart valve development 
(Townsend et al. 2012), and betaglycan is also necessary for development of normal coronary 
vasculature (Compton et al. 2007).   
 
As well as these defects in cardiac development, betaglycan has been linked to other aspects 
of embryogenesis. Betaglycan deficient mice have been shown to display abnormal kidney 
development, with knock-out embryos demonstrating evidence of renal hypoplasia at E13.5, 
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and heterozygote adults exhibiting reduced nephron number when compared to wild-type 
adults (Walker et al. 2011).  Knock-out mice also show impaired seminiferous cord and 
leydig cell development in the mouse testis with abnormalities of embryogenesis occurring 
between E11.5 and E14.5 (Sarraj et al. 2013). 
 
1.4.4 Endocrine signalling 
 
Betaglycan also has a role in the activin / inhibin pathway through the ability to bind inhibin, 
and thereby antagonise activin signalling (Lewis et al. 2000; Looyenga et al. 2010); it is thus 
important in regulation of gonadal development and functioning at the level of the pituitary. 
Loss of the inhibin-binding site on betaglycan has been shown to inhibit inhibin-mediated 
antagonism of activin-induced follicle stimulating hormone (FSH) and gonadotrophin-
releasing hormone (GRH) production in animal studies (Wiater et al. 2006; Escalona et al. 
2009), which has been linked to a wide range of reproductive disorders in both animal and 
human investigations (Stenvers et al. 2003; Stenvers & Findlay 2010; Zhu et al. 2010).  
 
In addition to these effects on the reproductive axis at the level of the pituitary, betaglycan 
and inhibin are thought to have direct effects on somatic cell populations at the gonads 
(Stenvers & Findlay 2010). Inhibin has been shown to antagonise BMP-mediated down-
regulation of luteinising hormone (LH)-induced steroidogenesis on bovine thecal cells 
(Glister et al. 2010), and loss of betaglycan expression on follicular cells has been linked to 
several reproductive diseases in humans (Bilandzic et al. 2009; Zhu et al. 2010). 
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Activins and inhibins are also produced at the adrenal cortex, and perhaps unsurprisingly 
there is high expression of betaglycan at this site (Vänttinen et al. 2003). Again, reduced 
betaglycan expression is thought to disrupt inhibin-mediated antagonism of activin signalling, 
resulting in significant derangements of steroidogenesis and apoptosis. This has been 
implicated in many diseases of the renal cortex, most notably cancer (Looyenga et al. 2010). 
 
1.4.5 Carcinogenesis 
 
Most of the research on betaglycan function to date has been in the context of carcinogenesis. 
Betaglycan deletions have been associated with haematological (Lambert et al. 2011), colonic 
(Gatza, Holtzhausen, et al. 2011), ovarian (Bilandzic et al. 2009), pancreatic (Gordon et al. 
2008), prostate (Sharifi et al. 2007), renal (Bilandzic et al. 2013; Cooper et al. 2010), adrenal 
(Vänttinen et al. 2003), lung (Finger et al. 2008), and breast cancers (Pal et al. 2012; Lee et al. 
2010).  
 
TGFβ has a paradoxical role in carcinogenesis; early in disease it is generally considered a 
tumour suppressor through the ability to inhibit cell growth and promote apoptosis or 
differentiation, yet it is thought to have tumour-promoting effects later in the disease process 
by inhibiting the tumour-eradicating effects of the local immune system (Massagué 2008). 
Betaglycan deletions are thought to display a similar dichotomy, being tumour-promoting if 
occurring early in the course of disease, but tumour-suppressive if occurring later in the 
disease (Gatza, Oh, et al. 2011). 
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This has recently been demonstrated using the example of bladder urothelial cancer; samples 
either of fresh tumour or metastatic paracarcinoma tissue specimens were retrieved from 56 
patients and betaglycan expression determined by western blotting (Liu et al. 2013). 
Expression was reduced compared to corresponding normal tissue in 18/30 fresh tumour 
specimens, and increased in 19/26 metastatic samples. These findings correlated with analysis 
of cell lines; the superficial urothelial bladder cancer cell line 5637 displayed decreased 
betaglycan expression, whereas the invasive cancer line T24 displayed increased expression 
when compared with the SV-HUC-1 normal urothelial cell line. Furthermore, knock-down of 
betaglycan gene expression in the T24 cell line resulted in reduced cell growth, motility and 
invasion. The authors conclude that loss of betaglycan correlates with initial tumour 
development, whereas upregulation of betaglycan enhances metastasis. 
  
It should be noted that this observation applies to the membrane-bound form of betaglycan. 
As previously discussed, soluble betaglycan is believed to have an opposing effect (Velasco-
Loyden et al. 2004; López-Casillas et al. 1994), and thus it is considered beneficial to down-
regulate soluble betaglycan early in disease, however the ability to sequester TGFβ away 
from metastatic cells may have an anti-cancer effect in advanced disease. Through this 
mechanism soluble betaglycan has been identified as a potential therapeutic agent in 
metastatic cancer, with inhibitory effects on tumour progression demonstrated in breast cancer 
cell lines (Bandyopadhyay et al. 1999): 
 
The human breast cancer cell line MDA-MB-231 was cultured with and without expression of 
a truncated soluble extracellular domain of betaglycan (sTGFβRIII). Soluble betaglycan was 
able to antagonise the tumour promoting activity of TGFβ by sequestering that produced by 
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proliferating cancer cells, as demonstrated by a reduction in the amount of active TGFβ1 and 
TGFβ2 in the growth media. Mink lung epithelial CCL64 cells cultured in the resulting media 
showed reduced growth inhibition in the presence of soluble betaglycan compared to control. 
To assess the effect of soluble betaglycan in vivo, athymic nude mice were inoculated with 
either control MDA-MB-231 cells, or cells with induced expression of sTGFβRIII. Four of 
five mice receiving control cells developed lung metastases. None of the ten mice receiving 
cells expressing sTGFβRIII were observed to develop metastatic disease. 
 
1.4.6 Immune regulation 
 
Despite this wealth of data highlighting the importance of betaglycan as a co-factor in TGFβ 
signalling, it is surprising that no literature exists describing the role of betaglycan in the 
context of TGFβ function in immune regulation in the mature immune system. 
 
1.4.6.1 Genetic polymorphism in inflammatory disease 
 
Studies of single nucleotide polymorphisms (SNP) in the betaglycan gene provide indirect 
evidence of a role in immune regulation. SNP have been identified in a number of diseases 
with an inflammatory or infective aetiology, including Crohn’s disease (The Wellcome Trust 
Case Control Consortium 2007), chronic obstructive pulmonary disease (COPD) (Hersh et al. 
2009) and Behcet’s disease (BD) (Chen et al. 2012). SNP have also been implicated in the 
clearance of hepatitis B virus (HBV) and the subsequent development of hepatocellular 
carcinoma (HCC) (Kim et al. 2011). 
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The association of betaglycan SNP with BD appears particularly significant; BD may be 
considered at least partially TGFβ dependent, as Treg and Th17 cells have been implicated in 
its pathogenesis (Na et al. 2013). Furthermore, BD is often characterised by frequent episodes 
of severe uveitis (Wechsler et al. 1990), which as previously discussed appears highly 
dependent on TGFβ2 signalling.  
 
A particular SNP (RS1805110) in the betaglycan gene (TGFBR3) has previously been 
identified in Han Chinese patients with BD, with the CC genotype suggested to confer a 
protective effect against developing disease (Chen et al. 2012). This SNP is a non-
synonymous mutation located in the signal sequence that may affect secretion or expression 
of betaglycan, although this has not been directly addressed. No association was observed 
with a disease control group of Voygt Kayanagi Harada (VKH) disease – another common 
cause of uveitis in the Han Chinese population. 
 
1.4.6.2 Betaglycan in thymocyte development 
 
One recent paper linked betaglycan to survival of thymocytes in foetal thymic organ culture 
(FTOC) from betaglycan-deficient mouse embryos (Aleman-Muench et al. 2012): 
 
In this study, embryos were harvested from pregnant females following timed mating of 
betaglycan heterozygote mice at time-points E14 onwards and grown under culture 
conditions. Embryos were genotyped by polymerase chain reaction (PCR) to allow 
comparison between betaglycan-null and wild-type embryos. Real-time PCR was utilised to 
quantify betaglycan expression in different populations of developing T lymphocytes (double 
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negative CD4-CD8-, double positive CD4+CD8+, single positive CD4+ and CD8+) at a range 
of gestational time-points; FTOC were set up with and without betaglycan blocking 
antibodies to examine T lymphocyte survival and apoptosis.  
 
Betaglycan was found to be expressed in the thymus throughout development, and was most 
highly expressed on CD4+ T lymphocytes and in the thymic stroma. Expression increased in 
the early stages of T lymphocyte maturation, suggesting a possible role for betaglycan in the 
pre-TCR phase of development.  
 
Wild-type FTOC blocking assays using antisera against the extracellular domain of 
betaglycan resulted in a reduced proportion of double positive thymocytes and a 
corresponding increase in double negative subsets by day 7 of culture. A more pronounced 
reduction in double positive thymocyte proportions was observed in betaglycan-null E14 
FTOC compared to wild-type controls, with a statistically significant difference in cellularity 
observed under conditions of absolute betaglycan deficiency. The difference between cell 
numbers under conditions of betaglycan blockade and absolute deficiency suggests that the 
antisera against betaglycan resulted in incomplete blockade, perhaps due to an inability to 
block soluble betaglycan.  
 
Finally, thymocyte apoptosis was measured by expression of active caspase 3 in FTOC of 
either wild-type or betaglycan-null E14 embryos. Caspase 3 was increased in both double 
positive and double negative subsets in betaglycan-null cultures, however this only achieved 
statistical significance for the more mature double positive population.  
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The authors conclude that betaglycan is crucial to T lymphocyte development, regulating the 
transition from more immature double negative to relatively mature double positive cells by 
protecting double positive cells from apoptosis.  
 
Whilst this paper once again adds to the body of evidence supporting the role of betaglycan in 
embryological development, and provides an interesting link to T lymphocyte biology, the 
effect of betaglycan in peripheral T lymphocytes remains unknown.  
 
1.4.7 Clinical significance 
 
As previously discussed, uveitis is thought to result from aberrant trafficking and activation of 
CD4+ T lymphocytes in the intra-ocular microenvironment (Zhou et al. 2011; Zhou et al. 
2012; Gasparin et al. 2012). TGFβ2 is present at high levels in the aqueous humour of un-
inflamed eyes (Curnow et al. 2005; Denniston et al. 2011), and thus the inflammation 
observed in episodes of uveitis is thought to result from disruption of TGFβ2-mediated 
immunoregulation of intra-ocular T lymphocytes. Uveitis is therefore of particular clinical 
significance when considering the role of betaglycan in TGFβ-mediated T lymphocyte 
responses. 
 
The literature review presented throughout sections 1.4.7.1 to 1.4.7.5 has previously been 
published in a peer-reviewed scientific journal (Barry et al. 2014), comprising the 
introduction to the paper. See section 8.1 for the full citation and a reproduction of the 
published version.  
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1.4.7.1 Introduction to uveitis 
 
Uveitis, a significant cause of blindness worldwide, is a term applied to a wide range of 
conditions that are characterized by intraocular inflammation. Many cases of ‘uveitis’ do 
indeed involve inflammation of the uvea (which comprises the iris, ciliary body and choroid), 
but may also involve adjacent structures such as the retina or vitreous. Uveitis is highly 
heterogeneous, varying in aetiology, pattern, tissue involved and extent. The uveitis specialist 
may be confronted by a small, localized area of inflammation in a single tissue in a non-sight-
threatening location, or widespread blinding inflammation involving almost all ocular tissues. 
Visual impairment is common, affecting between 2.8 and 10% of patients (Darrell et al. 1962; 
Suttorp-Schulten & Rothova 1996; Goldstein 1980), and may result directly from damage to 
uveal tract structures, or may occur due to secondary effects on neighbouring tissues, for 
example accelerated cataract formation, glaucoma, and macular oedema (Forrester 1991).  
 
The Standardization of Uveitis Nomenclature (SUN) working group classifies uveitis 
according to the site of primary inflammation (Jabbs et al. 2005). Anterior chamber 
inflammation is categorized as ‘anterior uveitis’, and includes iritis, iridocyclitis and anterior 
cyclitis. Inflammation primarily affecting the vitreous is referred to as ‘intermediate uveitis’, 
and includes pars planitis, posterior cyclitis and hyalitis. ‘Posterior uveitis’ describes 
inflammation of the retina or choroid. Finally, ‘pan-uveitis’ describes the situation where 
inflammation is seen throughout the anterior chamber, vitreous and retina or choroid. 
According to the SUN criteria, disease is further classified according to onset (sudden or 
insidious), duration (limited or persistent), and course (acute, recurrent or chronic).  
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1.4.7.2 Pathophysiology of uveitis 
 
Uveitis can be either infectious or non-infectious; whilst both may present with similar 
clinical features, they are best considered as distinct disease entities since the underlying 
pathophysiology and treatment strategies are very different.  
 
Whilst common in the developing world, infective causes account for the minority of uveitis 
cases presenting to tertiary referral centres in the West. Infectious causes include organisms 
such as toxoplasma, cytomegalovirus, syphilis and herpes viruses (Miserocchi et al. 2013; 
Cimino et al. 2010). Local infection results in foreign antigen presentation to ocular immune 
cells, with appropriate immune activation aimed at clearing the invading organism. Uveitis 
occurs as a secondary effect of this immune activation. 
 
Non-infective uveitis is thought to result from inappropriate activation of the immune system 
(Curnow et al. 2004) and it is therefore not surprising that it is often associated with systemic 
autoimmune or auto-inflammatory diseases such as ankylosing spondylitis (AS), sarcoidosis 
or BD. In the remainder, however, no such systemic association is identified; these cases are 
generally labelled as ‘idiopathic’ in recognition of the fact that the 
autoimmune/autoinflammatory origin of most of these cases is presumed rather than proven. 
Human data and experimental models indicate parallel changes in the inflammatory milieu of 
the intra-ocular microenvironment. Uveitis may be induced in animal models by a range of 
mechanisms which cause differentiation of naïve CD4+ T-cells to pathogenic effector cells, 
resulting in tissue damage (Denniston et al. 2011; Takeuchi et al. 1998; Takeuchi et al. 1997; 
Taylor et al. 2000; Taylor et al. 1992). Although similar pathogenic effector cells have been 
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recovered from ocular fluids and tissue in human uveitis, the evidence for autoreactive T-cells 
(such as seen in the animal models) is much more limited (Gocho et al. 2001; de Smet et al. 
2001). 
 
Such idiopathic cases account for the largest cohort of patients seen in most clinical practices 
in the West. In a retrospective study of all uveitis cases presenting to a tertiary centre, 
Rodriguez reported 34% to be idiopathic, 10.4% to be associated with seronegative 
spondyloarthropathies and 9.6% to be associated with sarcoidosis (Rodriguez et al. 1996), 
although it should be noted that certain conditions are typically associated with particular 
anatomical groups such as anterior uveitis with seronegative spondyloarthropathies. It is also 
of interest to note that in a report from the SITE retrospective study of US tertiary uveitis 
services, the leading systemic associations in 4911 patients with uveitis were sarcoidosis 
(7%), seronegative spondyloarthropathy (5%), juvenile idiopathic arthritis (JIA, 5%) and BD 
(3%) (Zaidi et al. 2010). 
 
1.4.7.3 Overview of treatment strategies 
 
For infective causes, treatment is aimed at eradicating the pathogenic organism with 
appropriately targeted anti-microbial therapy. In severe cases, such agents may be delivered 
directly to the eye by intravitreal injection, or are more frequently administered systemically 
by an oral or intravenous route. Once the infective agent is considered to be under control, 
immunosuppressive agents such as corticosteroids may be used judiciously to limit tissue 
damage. 
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For non-infective causes, treatment involves suppression of the local immune response. It is 
useful to consider the concept of disease activity versus damage when treating inflammatory 
disease (Barry et al. 2008; Skopouli et al. 2000). ‘Activity’ refers to the on-going immune 
response, which may be acute or chronic, but is usually reversible. ‘Damage’ refers to the 
effect of active inflammation on native tissues; it is usually irreversible. In simple terms, 
persistent activity will lead to accumulation of damage. In theory, effective therapy should 
suppress all activity and prevent or halt accumulation of damage. 
 
Therapy in non-infectious uveitis is aimed at suppressing the immune system, and ranges 
from topical therapy (commonly corticosteroid eye drops) to systemic immunosuppression 
with either high-dose corticosteroids (oral, intravenous, intramuscular or subcutaneous) or a 
wide range of corticosteroid-sparing immunomodulatory therapeutic (IMT) agents (Tempest-
Roe et al. 2013; Durrani et al. 2011). Ideally, treatment should be targeted to the mechanism 
and localized to the tissue to maximize the efficacy/side-effect profile. However, this is often 
not achieved and new therapies should therefore aim to suppress disease activity, prevent 
accumulation of damage, and preserve visual function for patients with the minimum possible 
adverse events (Denniston & Dick 2013; Gallego-Pinazo et al. 2013; Larson et al. 2012).  
 
1.4.7.4 Epidemiology of uveitis 
 
Uveitis is considered a rare disease (Barisani-Asenbauer et al. 2012), with an estimated 
incidence between 17 and 52 people per 100,000 population in Europe and the USA (Cimino 
et al. 2010; Gritz & Wong 2004; Suhler et al. 2008; Darrell et al. 1962), although a higher 
incidence of disease may be observed in Chinese and Japanese populations (Hwang et al. 
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2012). Despite this rarity, it is a disproportionately common cause of legally-recognized 
visual impairment, and is the fourth most common cause of blindness in the working age 
population in the developed world (Read et al. 2001; Bodaghi et al. 2001; Suttorp-Schulten & 
Rothova 1996). Uveitis can occur in any age group, however it is particularly prevalent in 
younger people, with a mean age at onset of less than 40 years (Bodaghi et al. 2001). 
 
Epidemiological studies in uveitis are particularly prone to bias. Most notably, a range of 
criteria exist for diagnosis and categorization of different uveitis entities; the relatively recent 
introduction of SUN working group anatomical classification has helped standardize practice, 
however clinical, etiological and pathological classification criteria have been used variably 
throughout the literature, and it is often difficult to compare published data from multiple 
sources (Bloch-Michel & Nussenblatt 1987; Holland 1994; Engstrom et al. 1994; Read et al. 
2001; Mandeville et al.). In addition, since the majority of research in uveitis is generated 
from tertiary referral centres with relatively little data from community-based practice, there 
is bias towards severe disease and a relative under-representation of more straightforward 
cases (McCannel et al. 1996). Furthermore, given the heterogeneity of uveitis entities and the 
wide geographic variation in both clinical features and disease aetiology, comparison between 
different regions is difficult (Miserocchi et al. 2013). 
 
Disease aetiology shows significant variation with age, with some forms of uveitis affecting 
specific groups. For example, in European populations, uveitis due to JIA occurs almost 
exclusively in children (Heiligenhaus et al. 2013; Smith et al. 2009), HLA-B27 positive 
disease is seen in young adults (Rothova et al. 1987), and masquerade syndromes and 
lymphoma are more commonly seen in the elderly (Barisani-Asenbauer et al. 2012).  
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Infectious uveitis is relatively rare in developed countries, accounting for 13-21% of cases, 
and is thought to be mostly due to infection by herpes viruses (Miserocchi et al. 2013; 
Barisani-Asenbauer et al. 2012). This is in stark contrast with developing countries, where up 
to 50% of uveitis is thought to have an infectious aetiology. The most common infectious 
causes in these populations are toxoplasmosis, tuberculosis (TB), onchocerciasis, cysticerosis, 
leprosy and leptospirosis (London et al. 2010). 
 
In Western countries, anterior uveitis accounts for at least half of all cases (Wakefiled & 
Chang 2005), of which idiopathic disease accounts for approximately 50% (Suhler et al. 
2008). The most common clinical associations in those countries are HLA-B27 positive 
disease, AS and Fuchs heterochromic iridocyclitis (FHC) (Miserocchi et al. 2013). It is 
estimated that up to 55% of Caucasian patients with acute anterior uveitis are HLA-B27 
positive, compared to only 5-10% in the general population (Brewerton et al. 1973). In 
contrast, the prevalence of anterior uveitis is much lower in Asian populations, which is 
thought to be due to the lower frequency of HLA-B27 positivity and AS (Chang & Wakefield 
2002). 
 
Intermediate uveitis is the least common form of disease across all geographic regions, with 
an estimated incidence of 1.5-2.08 per 100,000 population in Western populations 
(Miserocchi et al. 2013). There is thought to be a strong association with Human T-cell 
Lymphotropic Virus Type 1 (HTLV-1) (Ohguro et al. 2012), and several authors have noted 
an association between pars planitis and MS, although this has yet to be fully characterized 
(Zein et al. 2004; Zierhut & Foster 1992). 
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Posterior uveitis accounts for 15-30% of diagnoses. The most common cause worldwide is 
toxoplasmosis, followed by idiopathic disease (Miserocchi et al. 2013; Wakefiled & Chang 
2005; Chang & Wakefield 2002). It follows that posterior uveitis is more common in 
developing countries, owing to the higher prevalence of infectious diseases in these 
populations.(London et al. 2010) BD and VKH are two rare but important non-infectious 
causes of posterior uveitis (Yang et al. 2005; Rathinam & Namperumalsamy). 
Cytomegalovirus (CMV) retinitis is associated with HIV infection, but its incidence is 
decreasing with the use of modern Highly Active Anti-Retroviral Therapy (HAART) 
(Miserocchi et al. 2013). 
 
It is difficult to accurately estimate the prevalence of panuveitis; in one recent large-scale 
review of epidemiological studies, the prevalence varied from 1% to 69% depending on 
geographic location (Miserocchi et al. 2013). It is probable that panuveitis is more heavily 
affected by the biases described above than other types of uveitis, particularly referral bias 
skewing patient populations towards more severe disease in tertiary referral centres, and as a 
result, these figures are unlikely to be representative of the general population. Idiopathic 
disease is most common in Europe, USA, Australia and India, whilst infective causes are 
again more common in most developing countries, and BD is an important cause in Asia and 
countries along the historic ‘silk route’ (Middle East and Mediterranean regions) (Bodaghi et 
al. 2001; Chung et al. 1988; Kotake et al. 1996; Wakabayashi et al. 2003; Tugal-Tutkun 
2010). 
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1.4.7.5 Current treatment options 
 
Any treatment strategy for uveitis needs to consider a number of factors (Jabs & Busingye 
2013). First: the aetiology (i.e. infectious vs. non-infectious) which will define the type of 
treatment required (antimicrobial vs. anti-inflammatory/immunosuppressive). Second: extent 
of uveitis and associated inflammation. This includes (a) anatomical location within the eye 
(as per SUN classification) (Jabbs et al. 2005), (b) unilaterality or bilaterality and (c) presence 
of systemic disease. These factors are important considerations when deciding whether 
topical, local or systemic treatments are likely to be required. Third: severity of disease which 
may necessitate ‘rescue’ therapy or additional treatment. Fourth: potential complications of 
either the disease itself or of treatments of the disease. 
 
1.4.7.5.1 Infectious vs. Non-infectious Uveitis 
 
One of the most important (and sometimes difficult) challenges to confront the uveitis 
specialist is whether the inflammatory process is the result of an infectious agent. Establishing 
or excluding this may sometimes be possible on clinical appearance alone (Mandelcorn 
2013), but is often supplemented by investigations on the peripheral blood (commonly 
serology, interferon gamma release assays for Mycobacterium tuberculosis, haematological 
and biochemical markers) or ocular fluids (PCR for suspected microbes; less commonly 
Goldmann-Witmer coefficient); imaging is also commonly used to characterize associated 
systemic disease (Guly & Forrester 2010; De Groot-Mijnes et al. 2006).  
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In some cases treatment may need to be started before the results of such investigations are 
available. For example, in the presence of suspected acute retinal necrosis (ARN), samples of 
aqueous humour and vitreous humour should be taken and sent for PCR concurrently with 
starting treatment (commonly intravitreal foscarnet and either oral valacyclovir or intravenous 
acyclovir) (Wong et al. 2013). This case also highlights another issue: that some cases of 
infectious uveitis may provoke a strong inflammatory reaction both at the time and sometimes 
beyond the infectious component of disease; this may in turn require cautious 
immunosuppression to limit tissue damage and maximize visual potential following 
treatment.  
 
1.4.7.5.2 Extent and severity of uveitis and associated inflammation 
 
In general, isolated uncomplicated anterior uveitis (whether unilateral or bilateral) can often 
be managed by topical therapy alone; frequent topical corticosteroids are used for rescue 
treatment, and then titrated down to complete cessation (in acute disease) or to a low 
frequency maintenance regimen (chronic disease or frequent recurrences); a mydriatic is 
commonly prescribed to reduce the risk of posterior synechiae (Guly & Forrester 2010).  
 
In cases of posterior segment uveitis (intermediate, posterior or panuveitis), the topical route 
provides inadequate penetration to the inflamed tissue, although topical therapies may still 
have an adjunctive role. For these cases the choice of treatment will depend on whether the 
disease is unilateral or bilateral, and whether it is isolated or is a manifestation of a systemic 
inflammatory process. Unilateral and increasingly bilateral disease may be treated by local 
therapies (peribulbar, sub-Tenon’s or intravitreal routes); corticosteroids are the most 
common drugs given by these routes although the role of other agents is also being assessed. 
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Local therapy may be sufficient to control the disease, but in more severe inflammation, or in 
the presence of systemic disease, systemic therapy is likely to be necessary. In addition, there 
may be contraindications to the use of local therapies in some cases (Jabs et al. 2000). 
 
Recognition and treatment of any associated systemic disease is a priority. Therapy initiated 
for co-existent systemic inflammatory disease may ameliorate any active uveitis, reducing the 
need for direct ophthalmic intervention. Once again, rescue therapy is traditionally with 
corticosteroids (either intravenous or oral) with maintenance therapy comprising either lower 
dose of corticosteroid or a steroid-sparing IMT agent (Jabs et al. 2000). The range of steroid-
sparing IMT agents available (including biologics) is steadily increasing, although the 
evidence of their efficacy and safety in uveitis is often lacking (Denniston & Dick 2013). 
Current options include anti-metabolites (such as methotrexate and mycophenolate mofetil), 
T-cell inhibitors (such as cyclosporin), and alkylating agents (such as cyclophosphamide). 
More recently, biological therapies (such as infliximab) have been utilized in the management 
of severe and refractory uveitis (Durrani et al. 2011; Gallego-Pinazo et al. 2013; Pato et al. 
2011; Cordero-Coma et al. 2013; Saadoun et al. 2013).  
 
1.4.7.6 Betaglycan as a potential therapeutic target in uveitis 
 
Episodes of severe uveitis, in which sight-threatening inflammation is localised to the eye, 
often necessitate systemic treatment resulting in a state of immunosuppression throughout all 
organ systems. This has the potential to cause significant additional morbidity and mortality 
to patients through the occurrence of severe side effects. It is thus desirable to develop 
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treatment strategies in which a therapeutic immunosuppressive effect can be localised to the 
intra-ocular microenvironment. 
 
As previously discussed, TGFβ2 is considered an important immunoregulatory molecule in 
the eye, being thought to regulate the activity of local T lymphocytes and determine the 
balance between immunosuppressive iTreg and pathogenic Th17-driven processes. The 
predominance of TGFβ2 is unusual, with TGFβ1 being the most widely expressed isoform in 
the human immune system. The ability to specifically modulate TGFβ2-driven immune 
responses thus confers the potential to influence pathways of intra-ocular immune regulation, 
with little effect in other organ systems. Since betaglycan is strongly implicated in signal 
transduction by TGFβ2 but appears redundant in signal transduction by TGFβ1 and TGFβ3, it 
is possible that modulation of betaglycan activity may allow manipulation of only TGFβ2-
dependent processes, and thus localise an immunosuppressive effect to the eye. 
  
Such modulation of betaglycan-dependent responses has already been exploited in control of 
metastatic disease processes through the systemic administration of soluble betaglycan 
(Section 1.4.5), and it is possible that similar modulation may be useful in controlling 
inflammatory diseases such as uveitis. 
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1.5 Hypotheses 
 
Betaglycan is necessary for TGFβ2 signalling to lymphocytes via the cell-surface TGFβ 
receptor and is therefore an absolute requirement for TGFβ2-mediated immune responses; 
TGFβ2-mediated T lymphocyte immune responses will be completely abrogated in the 
absence of betaglycan.  
 
Betaglycan increases the affinity of both TGFβ1 and TGFβ3 for the cell-surface TGFβ 
receptor on lymphocytes, but is not an absolute requirement for TGFβ1 or TGFβ3-mediated 
immune responses; TGFβ1 and TGFβ3-mediated T lymphocyte immune responses will be 
reduced in the absence of betaglycan.  
 
No spontaneous immune dysregulation will be observed in vivo under conditions of 
betaglycan deficiency in environments where TGFβ1 or TGFβ3 signalling predominates, 
however disordered immune responses will be observed under conditions of antigenic 
challenge. Since TGFβ is primarily involved in immunosuppressive responses, this will be 
observed by increases in T lymphocyte activation levels, with alteration in the relative 
proportions of Th17 and Treg cells involved in immune responses.  
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1.6 Objectives 
 
In this thesis, I set out to achieve the following objectives: 
 
1. To develop a novel experimental animal model of betaglycan deficiency in which to 
study peripheral immune responses in vivo, and mature immune cells in vitro, focusing 
on T and B lymphocyte responses.  
 
2. To characterise these animals, observing for evidence of spontaneous immune 
dysregulation or autoimmune disease. Investigation will focus on peripheral T and B 
lymphocyte populations, with assessment of both circulating (blood) populations, and 
those resident in secondary lymphoid organs. Structure of secondary lymphoid organs 
will also be assessed. 
 
3. To assess for evidence of immune dysregulation in response to controlled, traceable 
antigenic challenge. Given the role of betaglycan in the TGFβ receptor complex, 
particular attention will be paid to TGFβ-dependent Treg and Th17 responses, 
determined by levels of FoxP3 expression and IL-17 secretion respectively.  
 
4. To investigate TGFβ signalling to T lymphocytes in the presence or absence of 
betaglycan through in vitro iTreg polarization assays. Naïve CD4+ T lymphocytes will 
be exposed to all three isoforms of TGFβ, and FoxP3 induction compared in 
conditions of betaglycan sufficiency and deficiency. 
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5. Whilst an association has been observed between betaglycan SNP and the 
development of BD in a Han Chinese population, no equivalent analysis exists for 
Caucasian patients. This will be addressed through association analysis of betaglycan 
SNP RS1805110 with BD in a population of Caucasian patients, with comparison to 
other forms of ocular inflammatory disease and healthy controls.  
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2 MATERIALS AND METHODS 
 
2.1 Materials 
 
See tables 2.1 to 2.4 for a comprehensive list of all media, reagents, cytokines and antibodies 
used for experimental procedures described in the following methods (Section 2.2). 
 
Description Details Source 
Culture media 
  
RPMI (Roswell Park Memorial 
Institute) 1640  
Sigma Aldrich, Dorset, UK 
1% GPS (2mM l-glutamine, 100 U/ml 
penicillin, 100ug/ml streptomycin) 
HyClone, Northumberland, 
UK 
1% HEPES (1M 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid) 
Sigma Aldrich, Dorset, UK 
10% HIFCS (Heat Inactivated Foetal 
Calf Serum) 
Biosera, Ringmer, UK 
   
0.5% Flow 
Cytometry Buffer 
PBS (see below) Oxoid, Basingstoke, UK 
0.5% BSA (Bovine Serum Albumin) Sigma Aldrich, Dorset, UK 
   
2.0% Flow 
Cytometry Buffer 
PBS (see below) Oxoid, Basingstoke, UK 
2% BSA (Bovine Serum Albumin) Sigma Aldrich, Dorset, UK 
Table 2.1 Commonly used media. (1 of 2).  
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Description Details Source 
Gey's Solution 
  
(1) 20ml Solution A; in 1.0l dH2O Sigma Aldrich, Dorset, UK 
NH4Cl 35.0g, KCl 1.85g, Na2HPO4.12 
H2O 0.119g, Glucose 5g, Gelatin 25g, 
1% Phenol Red 1.5ml 
 
 
(2) 5ml Solution B; in 1.0l dH2O  
MgCL2.6H20 4.2g, MgSO4.7H2O 1.4g, 
CaCl2 3.4g 
 
(3) 5ml Solution C; in 1.0l dH2O  
NaHCO3 22.5g 
(4) 70ml dH20 
 
   
MACS Buffer 
  
PBS (See below) Oxoid, Basingstoke, UK 
0.5% BSA (Bovine Serum Albumin) Sigma Aldrich, Dorset, UK 
2mM EDTA (Ethylenediamine tetra-
acetic acid) 
Sigma Aldrich, Dorset, UK 
   
Phosphate 
Buffered Saline 
(PBS) 
  
8g/l NaCL, 0.26g/l KCl, 1.15g/l 
Na2HPO4, 0.2 g/ml KH2PO4 in dH2O 
Sigma Aldrich, Dorset, UK 
Prepared as 1 PBS tablet per 100ml 
dH2O 
 
Table 2.1 Commonly used media. (2 of 2).  
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Specificity Isotype Clone Fluorochrome Dilution Source 
CyAn Fortessa 
Surface stains 
B220 Rat IgG2a RA3-6B2 FITC - 1/300 eBioscience 
PE-Cy7 - 1/500 eBioscience 
CD3 Rat IgG2b 17A2 APC-eFluor780 1/50 1/100 eBioscience 
 Hamster IgG 145-2C11 PE-Cy7 1/50 1/100 eBioscience 
CD4 Rat IgG2b GK1.5 APC - 1/500 eBioscience 
Rat IgG2a RM4-5 PerCP-Cy5.5 1/200 - eBioscience 
CD8 Rat IgG2a 53-6.7 V500 1/100 1/200 BD 
Biosciences 
CD11b Rat IgG2b M1/70 FITC - 1/300 eBioscience 
PE 1/160 - eBioscience 
PE-Cy7 - 1/500 eBioscience 
CD11c Hamster IgG N418 eFluor450 1/50 - eBioscience 
FITC - 1/300 eBioscience 
PECy7 - 1/500 eBioscience 
CD19 Rat IgG2a eBio1D3 eFluor450 1/100 - eBioscience 
   PE - 1/200 eBioscience 
CD25 Rat IgG1 PC61.5 APC 1/160 - eBioscience 
 
Table 2.2 Antibodies used for flow cytometry analyses. Fluorochromes and dilutions 
shown for analysis on both Dako-CyAn flow cytometer (CyAn) and BD LSRFortessa 
(Fortessa) where appropriate. Source details: eBioscience, Hatfield UK; BD Biosciences, 
Oxford, UK; Biolegend, London, UK (1 of 2). 
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Specificity Isotype Clone Fluorochrome Dilution Source 
CyAn Fortessa 
Surface stains (continued) 
CD44 Rat IgG2b IM7 APC-eFluor780 1/160 - eBioscience 
BV785 - 1/200 Biolegend 
FITC 1/300 - eBioscience 
CD45.2 Mouse 
IgG2a 
104 FITC 1/200 - eBioscience 
PerCP-Cy5.5 1/200 - eBioscience 
CD62L Rat IgG2a MEL-14 PE 1/400 - eBioscience 
GR1 Rat IgG2b RB6-8C5 APC - 1/160 eBioscience 
NK1.1 Mouse 
IgG2a 
PK136 PE-Cy7 - 1/500 eBioscience 
Transcription factor stains 
FoxP3 Rat IgG2a FJK-16S FITC 1/50 1/50 eBioscience 
RORγ Rat IgG2a AFKJS-9 PE - 1/50 eBioscience 
Cytokine stains 
IFNγ  Rat IgG1 XMG1.2 eFluor450 1/50 - eBioscience 
PE-Cy7 - 1/200 eBioscience 
IL17 Rat IgG2a eBio17B7 APC 1/100 - eBioscience 
PE - 1/100 eBioscience 
Table 2.2 Antibodies used for flow cytometry analyses. Fluorochromes and dilutions 
shown for analysis on both Dako-CyAn flow cytometer (CyAn) and BD LSRFortessa 
(Fortessa) where appropriate. Source details: eBioscience, Hatfield UK; BD Biosciences, 
Oxford, UK; Biolegend, London, UK (2 of 2). 
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Specificity Isotype Clone Fluorochrome Dilution Source 
Primary stains 
B220 Rat IgG2a RA3-6B2 Biotin 1/200 eBioscience 
CD3 Hamster IgG eBio500A2 FITC 1/200 eBioscience 
CD4 Rat IgG2b GK1.5 AF647 1/100 eBioscience 
IgD Rat IgG2a 11-26c FITC 1/200 eBioscience 
IgM Donkey IgM Polyclonal Rhodamine 
Red 
1/200 Stratech Scientific 
PNA Rat - Biotin 1/200 Vector 
Laboratories 
Secondary / amplification stains 
FITC Rabbit-anti-
FITC 
- AF488 1/200 Invitrogen 
Rabbit Donkey-anti-
rabbit 
- AF488 1/200 Invitrogen 
Biotin Streptavidin - AF555 1/500 Invitrogen 
Biotin Streptavidin - AF647 1/400 Invitrogen 
 
 
Table 2.3 Antibodies and stains used for immunohistochemical analyses. Dilutions 
presented for analysis by Zeiss LSM 510 Meta Confocal microscope. Source details: 
eBioscience, Hatfield, UK; Stratech Scientific, Suffolk, UK; Vector Laboratories, 
Peterborough, UK; Invitrogen, Paisley, UK.  
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Description Isotype Clone / source Concentration Source 
AccuCheck 
Counting Beads 
- - - ThermoFisher 
Scientific 
Anti-CD16/CD32   Rat IgG2a 93 0.25µg/well eBioscience 
Anti-CD3  Rat IgG2b 17A2 5µg/ml eBioscience 
Anti-CD28  Hamster IgG 37.51 1µg/ml eBioscience 
Anti-CD3 / Anti-
CD28 DynaBeads 
Hamster IgG - Variable Life Technologies 
PMA - - 50ng/ml Sigma-Aldrich 
Ionomycin - - 500ng/ml Sigma-Aldrich 
Brefeldin A - - 3 µg/ml Sigma-Aldrich 
IL2 - E. Coli 50U/ml Immunotools 
TGFβ1  - Hek293 0-10ng/ml Peprotech 
TGFβ2  - Hek293 0-10ng/ml Peprotech 
TGFβ3  - E. Coli 0-10ng/ml Peprotech 
Reddymix PCR 
Master-mix  
- - 1.1x (2.0mM 
MgCl2) 
ThermoFisher 
Scientific 
Qiagen DNEasy 
Blood & Tissue Kit 
- - - Qiagen 
 
Table 2.4 Miscellaneous cytokines and reagents. Source details: eBioscience, Hatfield, UK; 
Immunotools, Friesoythe, Germany; Life Technologies, Paisley, UK; Peprotech, London, 
UK; Qiagen Limburg, Netherlands; Sigma-Aldrich, Dorset, UK; ThermoFisher Scientific, 
Massachusetts, USA.  
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2.2 Methods 
 
All experiments involving animals were performed in accordance with UK Home Office 
regulations under project licences 40/3072 (Professor P.J.L. Lane) and 30/2961 (Dr D.W. 
Withers). All experiments were performed under the personal licence 30/9567 (Dr R.J. 
Barry). 
 
2.2.1 Observation of mouse colonies 
 
Animal colonies were housed in the Biomedical Support Unit of the University of 
Birmingham. All animals were observed daily and assessed for signs of illness according to 
UK Home Office criteria, including greater than 10% weight loss from baseline, display of 
stereotypical behaviour, development of starry coat or external evidence of systemic disease 
(Bleby 1986). Animals displaying signs of illness were culled by an approved schedule 1 
procedure.  
 
Survival curves were created for mouse colonies. ‘Survival’ was defined as animals 
displaying no evidence of illness according to the above criteria by the time of schedule 1 cull 
for use in planned experiments (at which point survival data was censored). ‘Death’ was 
defined as the cull of an animal due to evidence of illness according to the above criteria.  
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2.2.2 Genotyping of mouse colonies 
 
Animal genotype was determined by PCR according to the following method. 
 
2.2.2.1 DNA extraction 
 
Ear clippings of mature mice, or tail samples of murine embryos were frozen at -20°C for 
later genotyping. DNA was extracted using the Qiagen DNeasy Blood & Tissue Kit  (Qiagen 
Limburg, Netherlands) according to the protocol ‘Purification of Total DNA from Animal 
Tissues (Spin-Column Protocol)’. 
 
Frozen tissue was defrosted at room temperature, then incubated at 56°C in 180µl tissue lysis 
buffer (ATL) and 20µl proteinase K for three hours or until completely lysed, vortexing 
occasionally. 200µl lysis buffer (AL) and 200µl ethanol (100%) were added and the mixture 
pipetted into a DNeasy Mini Spin Column placed in a 2ml collection tube. This was 
centrifuged at 6,000g for one minute before the flow through and collection tube are 
discarded. The spin column was placed in a fresh 2ml collection tube, 500µl wash buffer 
(AW1) added, again centrifuged at 6,000g for one minute before discarding the flow through 
and collection tube. The spin column was placed in another 2ml collection tube and 500µl of 
wash buffer (AW2) added. This was centrifuged for three minutes at 16,000g before the flow 
through and collection tube were discarded. Finally, the spin column was placed in a 1.5ml 
Eppendorf, 200µl elution buffer (AE) added and incubated at room temperature for one 
minute before centrifuging at 6,000g for one minute. The elute of this final step contained 
DNA ready for PCR analysis. DNA samples were stored at 2-8°C until required. 
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2.2.2.2 PCR preparation 
 
Forward and reverse primers (Invitrogen, Paisley, UK) were diluted 1:2 in sterile water from a 
stock solution at 100ρmol/µl. 2µl DNA was added to 0.5µl of each primer, 18µl pre-mixed 
PCR master-mix buffer (ThermoFisher Scientific, Massachusetts, USA) and 2µl nuclease-free 
water for each sample.  
 
2.2.2.3 PCR protocol 
 
PCR followed the following protocol: Initial denaturing at 95°C for five minutes, followed by 
32 cycles of (1) denaturing at 95°C for 30 seconds (2) annealing at 58°C for 30 seconds (3) 
DNA synthesis at 72°C for 40 seconds, followed by a final cycle at 72°C for four minutes. 
Processed samples were stored at 8°C until use, at which point they were run on a 1.4% 
aragose gel at 75V for 20 minutes. 
 
2.2.3 Tissue sample preparation 
 
For all experiments involving the use of murine tissues, experimental animals were first 
culled by an approved schedule 1 method (either cervical dislocation or rising concentration 
of inhaled CO2) in accordance with UK Home Office regulations (Bleby 1986). Where serum 
samples were required, these were obtained through cardiac puncture under terminal 
anaesthesia. Lymph nodes (cervical, brachial, axillary, inguinal and mesenteric) and spleen 
were harvested via a midline incision and transferred to RPMI prior to further processing. 
Excess adipose tissue was removed from tissues prior to further processing. 
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2.2.3.1 Generation of cell suspensions 
 
2.2.3.1.1 Blood 
 
Blood was collected either by cardiac puncture under terminal anaesthesia (if an animal was 
to be sacrificed for experimental analysis) or by tail bleed of live animals; to prevent clotting, 
blood was collected in 1.5ml Eppendorfs containing 50µl 0.1mM ethylebediaminetetraacetic 
acid (EDTA) and was mixed thoroughly. 1ml of red cell lysis buffer (Gey’s solution; Table 
2.1) was added and the sample incubated at 2-8°C in the dark for five minutes. Next, the 
sample was centrifuged at 400g for five minutes and the supernatant removed by pipetting. 
The lysis step was repeated if significant red cell contamination was noted after the first cycle. 
The resulting pellet was re-suspended in RPMI and stored at 2-8°C until required. 
 
2.2.3.1.2 Serum 
 
Blood was collected by cardiac puncture under terminal anaesthesia in a 1.5ml Eppendorf in 
the absence of EDTA and stored at room temperature for 30 minutes until completely clotted. 
The sample was centrifuged at 16,000g for 10 minutes; the resulting supernatant comprised 
the serum, which was removed by pipette and stored at -20°C until required. 
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2.2.3.1.3 Spleen 
 
Splenic tissue was first cut into small fragments before being transferred to a 70µm cell filter 
placed in a 50ml Falcon tube, and crushed using a sterile plunger from a 2ml syringe. The 
filter was rinsed twice with 10ml sterile RPMI to maximise cell yield. 
 
The resulting suspension was centrifuged at 400g at 4°C for six minutes to pellet the 
splenocytes. The supernatant was removed, and the pellet re-suspended in 5ml sterile Gey’s 
solution to lyse the red blood cells, then incubated at 2-8°C in the dark. After five minutes, 
10ml sterile RPMI was added, and the suspension centrifuged at 400g at 4°C for a further six 
minutes. The lysis step was repeated if significant red cell contamination was noted after the 
first cycle, and the pellet re-suspended in 5ml sterile RPMI. This was passed through a fresh 
70µm filter into a new 50ml Falcon tube, and the filter rinsed with a further 5ml sterile RPMI. 
Cells were stored at 2-8°C until required. Cell counts were performed with a haemocytometer 
where appropriate. 
 
2.2.3.1.4 Lymph node 
 
Lymph nodes were prepared according to the above method for splenic tissue, however since 
lymph nodes contain almost entirely lymphocytes with no significant red blood cells, the red 
blood cell lysis steps were not necessary, and cell count could be performed as soon as the 
tissue has been crushed through the 70µm filter.  
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For experiments requiring maximal cell yield, lymph nodes were manually disaggregated in 
RPMI using micro-forceps under a microscope, then underwent enzymatic lysis by collagen 
dispase and DNAse at 36°C for 20 minutes before being transferred to the 70µm filter.  
 
Cell counts were performed with a haemocytometer where appropriate. 
 
2.2.3.2 Generation of tissue sections 
 
2.2.3.2.1 Spleen 
 
Whole spleen was cut into two segments along its short axis, snap-frozen in liquid nitrogen 
and stored at -80°C until required. Tissue sections were cut to a thickness of 7µm using a 
cryostat maintained between -15 and -20°C, mounted on glass slides and fixed in acetone for 
20 minutes at 4°C. Slides were stored at -20°C until required. 
 
2.2.3.2.2 Lymph node 
 
Lymph nodes were mounted in OCT compound (Agar Scientific, Stansted, UK), frozen in 
liquid nitrogen and stored at -80°C until required. Tissue sections were cut to a thickness of 
7µm using a cryostat maintained between -15 and -20°C, mounted on glass slides and fixed in 
acetone for 20 minutes at 4°C. Slides were stored at -20°C until use. 
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2.2.4 Flow cytometry 
 
Where cell numbers permitted, 1-2 x106 cells were suspended in 2% flow cytometry buffer, 
and stained in a volume of 50µl in round-bottom 96-well plates. All antibody dilutions, rinse 
cycles and cell suspensions were performed using 2% flow cytometry buffer unless otherwise 
stated. Cell rinse cycles were performed with 150µl buffer followed by centrifugation. All 
centrifugation was performed at 300g at 4°C for 4 minutes. Cell suspensions were maintained 
at 2-8°C and shielded from light unless otherwise stated. Stained cells were re-suspended in 
300µl buffer prior to analysis on the flow cytometer. Counting beads were added to samples 
prior to analysis where appropriate (AccuCheck Counting Beads, ThermoFisher Scientific, 
Massachusetts, USA). See table 2.2 for a list of antibodies used. 
 
For all non-purified cell samples, anti-mouse CD16/CD32 Fc receptor block (eBioscience, 
Hatfield, UK) was first added to prevent non-specific binding of antibodies to the Fc gamma 
III (CD16) and Fc gamma II (CD32) receptors expressed by any resident B lymphocytes, 
monocytes, macrophages, NK cells and neutrophils. These receptors will bind mouse IgG via 
the Fc portion, resulting in false positive staining for any antibody of this isotype. 10µl of Fc 
receptor block was added to all samples before incubating for ten minutes at 2-8°C prior to 
adding further antibodies.  
 
Multi-colour cytometry compensation was performed using either wild-type murine T 
lymphocytes (derived from either lymph node or spleen as described above), or anti-mouse or 
anti-rat staining beads (AbC kits, Invitrogen, Paisley, UK) as appropriate, individually stained 
with each fluorochrome-conjugated antibody. This allowed for compensation of spectral 
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overlap by adjusting for false positive staining from other fluorochromes. The number of 
events analysed per sample was between 10,000 and 500,000. 
 
Samples were analysed using the Dako-CyAn flow cytometer (Dako, Colorado, USA) and 
Summit 4.3 analysis software for Microsoft Windows (Dako, Colorado, USA, 2007), or BD 
LSRFortessa flow cytometer (BD Biosciences, San Jose, California, USA) and FlowJo 8.8.6 
analysis software for Mac (FlowJo LLC, Oregon, USA). Calibration was checked on a daily 
basis with Flowcheck Fluorospheres (Beckman Coulter Inc.). Isotype controls were used to 
determine the level of background non-specific binding where appropriate.  
 
2.2.4.1 Surface staining 
 
Cells and beads were centrifuged, the supernatant removed and the plate gently vortexed to 
re-suspend the resulting pellet. Cells and beads were stained with surface marker antibodies as 
indicated in table 2.5 and incubated for 20 minutes before performing two cell rinse cycles 
and analysing on the flow cytometer. 
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Description Flow Cytometer Antibodies 
Lymphocyte phenotype CyAn Surface antibodies: CD3, CD4, CD8, 
CD19, CD25, CD44, CD45.2, CD62L 
Treg CyAn Surface antibodies: CD3, CD4, CD25, 
CD44, CD62L 
Transcription factor: FoxP3 
Fortessa Surface antibodies: B220, CD3, CD4, 
CD8, CD11b, CD11c, CD44 
Transcription factor: FoxP3, RORγ 
Th17 CyAn Surface antibodies: CD3, CD4, CD8, 
CD44, CD62L 
Cytokine antibodies: IFNγ, IL17 
Fortessa Surface antibodies: B220, CD3, CD4, 
CD8, CD11b, CD11c, CD44 
Cytokine antibodies: IFNγ, IL17 
Non-T / Non-B populations CyAn or Fortessa Surface antibodies: CD3, CD19, 
CD11b, CD11c, CD45.2, GR1, NK1.1 
Naïve CD4+ T cell sort CyAn Surface antibodies: CD4, CD25, CD44, 
CD62L 
 
Table 2.5 Antibody combinations used in flow cytometry analyses. Combinations shown 
for analysis on both Dako-CyAn flow cytometer (CyAn) and BD LSRFortessa (Fortessa) 
where appropriate.  
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2.2.4.2 Transcription factor staining 
 
Cells were initially stained for surface marker antibodies as indicated in table 2.5 according to 
the method described above.  
 
Cells were fixed in 200µl 1x fixation/permeabilisation solution (1:3 dilution of FoxP3 
fixation/permeabilisation 4x concentrate and diluent, eBioscience, Hatfield, UK) and 
incubated for 30 minutes. The cells were next centrifuged and rinsed once, then permeabilised 
by two rinse cycles in 150µl 1x permeabilisation buffer (10x permeabilisation buffer, 
eBioscience, Hatfield, UK diluted 1:9 in distilled water).  
 
Intracellular transcription factor antibodies were diluted in 1x permeabilisation solution and 
added both to the cells for analysis and also to the appropriate compensation well. 50µl 1x 
permeabilisation solution was added to all other compensation wells. Cells were incubated for 
30 minutes, before two further rinse cycles in 150µl 1x permeabilisation fluid. Samples were 
finally re-suspended in flow cytometry buffer for analysis. 
 
2.2.4.3 Cytokine staining 
 
Cells were re-suspended in 200µl complete medium and transferred to a round bottom 96-
well plate. Cells were re-stimulated using PMA (Sigma-Aldrich, Dorset, UK) at a 
concentration of 50ng/ml and ionomycin (Sigma-Aldrich, Dorset, UK) at 500ng/ml. To 
prevent cytokine release, Brefeldin A was also added at a concentration of 3µg/ml (Sigma-
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Aldrich, Dorset, UK). The plate was sealed and transferred to an incubator at 37°C 5% CO2 
for 3 hours. 
 
The plate was centrifuged and the supernatant discarded. Cells were stained according to the 
protocols detailed in table 2.5. Cells were initially stained for surface marker antibodies 
according to the method described above.  
 
Cells were fixed in 50µl of fixation reagent A (Fix / Perm reagents, Invitrogen, Camarillo, 
California, USA) and incubated at room temperature or 15 minutes, shielded from light. A 
single rinse was performed in flow cytometry buffer and centrifuged as before. 
 
Antibodies for intracellular staining were diluted in 50µl permeabilisation reagent B (Fix / 
Perm reagents, Invitrogen, Camarillo, California, USA) and added to the cells and appropriate 
compensation wells.  50µl flow cytometry buffer was added to surface antibody compensation 
wells. This was incubated at room temperature for 15 minutes shielded from light, before a 
final rinse cycle in flow cytometry buffer.  
 
Samples were finally resuspended in flow cytometry buffer for analysis. 
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2.2.5 Immunohistochemistry 
 
2.2.5.1 Autoantibody screen 
 
Serum from experimental animals was screened for autoantibodies using a commercial rat 
liver, kidney, and stomach indirect immunofluorescence kit and slides (Cambridge Life 
Sciences, Ely, Cambridgeshire, UK) according to the manufacturers instructions. This kit 
contains slides which contain aggregate sections of rat stomach, liver and kidney to show 
anti-nuclear, anti-mitochondrial, anti-smooth muscle and anti-gastric parietal cell antibodies, 
which can easily be seen through comparison of the different tissues displayed. Serum from a 
roquin knock-out mouse was used as positive control.  
 
Serum samples were collected as described in section 2.2.3.1.2. After defrosting the serum at 
room temperature, serial dilutions were made (1/10, 1/40, 1/160) in PBS containing 10% goat 
serum to block cross-reactivity through non-specific Fc receptor binding. 50µl 10% goat 
serum was added to each test specimen and incubated at room temperature in a dark chamber 
for 10 minutes. Next, 50µl of each serum dilution was added to each test specimen and 
incubated at room temperature in a dark chamber for 20 minutes. Slides were rinsed in PBS, 
then 50µl of 1:100 FITC-conjugated goat-anti-mouse IgG (Southern Biotech, Alabama, USA) 
applied to each specimen, and the slide was again incubated in darkness at room temperature 
for 20 minutes. Slides were again washed in PBS, a coverslip applied, then examined under 
an immunofluorescent microscope.  
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2.2.5.2 Immunofluorescent staining 
 
Slides from betaglycan knock-out, heterozygous and wild-type chimeras were stained 
according to the protocol illustrated in table 2.6. Specimens from a RAG/BoyJ mouse were 
used as negative control. 
 
Before staining, slides were defrosted at room temperature and hydrated for 10 minutes in 
PBS. To prevent non-specific binding of antibodies, a block of 75µl of 10% horse serum in 
PBS / 1% BSA was applied to each spot, and the slides were then incubated for 15 minutes in 
a dark, humidified environment at room temperature.  
 
Excess horse serum was aspirated from each spot, then 75µl of the primary antibody solutions 
were added to their relevant spots on the slides. The slides were incubated for a further 40 
minutes, then washed in PBS. Next, 75µl of the secondary antibody solution was added to 
each spot. The slides were again incubated for 30 minutes before being removed and washed 
once more in PBS. 75µl of the tertiary antibodies added to the relevant spots. The slides were 
incubated for 30 minutes then washed in PBS. 
 
Finally, each slide was placed in DAPI stain for 30 seconds before three consecutive PBS 
washes. Slides were allowed to partially air dry then fixed with ProLong Gold (ThermoFisher 
Scientific, Massachusetts, USA) to preserve fluorescence and cover slips applied. Slides were 
stored in darkness at -200C until required for analysis. 
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Spot 1 Spot 2 
Step 1 
Block all spots with 10% horse serum in autoclaved PBS with 1% BSA 
Step 2 
Hamster-anti-mouse CD3 FITC Rat-anti-mouse IgD FITC 
Rat-anti-mouse B220 biotin Rat-anti-mouse PNA biotin 
Rat-anti-mouse CD4 AF647 Donkey-anti-mouse IgM Rhodamine Red 
Step 3 
Block with 10% mouse serum in autoclaved PBS with 1% BSA. 
Rabbit-anti-FITC  AF488 
Step 4 
Block with 10% mouse serum in autoclaved PBS with 1% BSA. 
Donkey-anti-rabbit AF488 Donkey-anti-rabbit AF488 
Streptavidin, AF555 Conjugate Streptavidin, AF647 Conjugate 
Step 5 
DAPI (4', 6-diamidino-2-phenylindole) stain 5mg/ml, Invitrogen, Paisley, UK 
 
Table 2.6 Protocol for immunofluorescent staining. 
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2.2.5.3 Image analysis 
 
Imaging of frozen sections was performed using a Zeiss LSM 510 confocal microscope under 
standardised conditions of 10x magnification and 0.7x zoom. Laser gain was adjusted to 
minimise background staining. Three representative white-pulp areas were imaged for each 
spleen section, and a single view of each lymph node was captured. 
 
Images were analysed using ImageJ software (nih.gov); for splenic sections, white pulp area, 
T-zone area, and number and area of germinal centres were calculated for each of the three 
white-pulp zones captured for each section. Images were assessed by two masked observers, 
and results compared to ensure measurements were within 10%. If a discrepancy of greater 
than 10% was encountered, both observers reassessed the image until agreement was reached. 
The mean of the two measurements was then taken as the final value. 
 
IgM and IgD co-expression was calculated using the ImageJ software ‘co-localisation plug-
in’. This enabled separation of each image to its component channels, and counting of the 
number of pixels which were positive for the immunofluorescent stain in question. Imaging 
intensity was first standardised to control for any background staining; mean pixel intensity 
was calculated for each image, then a gate applied to each image from 0 to 1.5x this mean 
intensity, and the percentage of positive pixels in each resulting image calculated. Co-
localization was determined by combining the resulting IgM and IgD images and calculating 
the percentage of bright pixels appearing in both channels. 
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2.2.6 In-vivo antigenic challenge 
 
Mice underwent controlled antigenic challenge at day 0 and were sacrificed for analysis at 
day 7; secondary lymphoid tissues were harvested and processed to cell suspensions as 
described in section 2.2.3.1. Animals were immunised a peptide antigen and either attenuated 
Listeria monocytogenes (L. monocytogenes), incomplete Freund’s adjuvant (IFA) or 
Salmonella typhi (S. typhi) outer membrane porins as adjuvants. For all experiments, a 
maximum of three non-chimeric mice were immunised as antigen controls, and a maximum 
of three chimeric mice immunised with PBS as negative controls. 
 
For all experiments, 2W1S peptide was used as an antigen. TCR binding to antigen-derived 
peptide-MHC (pMHC) ligands induces naïve T lymphocytes to proliferate and differentiate to 
an effector phenotype (Jenkins et al. 2001). 2W1S peptide consists of amino acids 52-68 from 
the I-E alpha chain (Rees et al. 1999), and is highly immunogenic in C57BL/6 mice due to the 
presence of a relatively large population of naïve T lymphocytes capable of recognising 
2W1S:I-Ab (Moon et al. 2007). Immunisation by 2W1S peptide thus allows assessment of a 
peptide-specific T lymphocyte response, by staining cells with a fluorochrome-labelled 
2W1S:I-Ab tetramer.   
 
2W1S:I-Ab tetramer staining of cell suspensions was performed prior to further surface, 
cytokine and/or transcription factor staining according to the methods as described in section 
2.2.4. For tetramer staining, cells were incubated at room temperature for 1 hour shielded 
from light in BV421-conjugated 2W1S:I-Ab at a dilution of 1/40. 
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2.2.6.1 Attenuated Listeria monocytogenes 
 
Animals were either immunised with 2W1S peptide and attenuated L. monocytogenes 
adjuvant engineered to secrete a fusion protein containing a portion of chicken ovalbumin and 
the 2W1S peptide (Pepper et al. 2010) or PBS alone. Bacteria were grown at 37°C in a 
shaking incubator to concentration OD600 = 0.1 in Luria-Bertani broth supplemented with 20 
µg/mL chloramphenicol. Either 107 bacteria in 200µl or PBS alone was injected via a tail vein 
at day 0, and spleen harvested at day 7.  
 
2.2.6.2 IFA 
 
Animals were immunised with either a 1:1 mix of 20µl IFA (Sigma-Aldrich, Dorset, UK) and 
20µl 2W1S peptide in a total volume of 50µl or PBS alone, administered via subcutaneous 
injection to the right and left flank at day 0. Draining inguinal lymph nodes were harvested at 
day 7. 
 
2.2.6.3 Salmonella typhi porins 
 
Animals were immunised with either a 1:1 mix of 20µl S. typhi outer-membrane protein C– 
and F–based subunit vaccine (porins) and 20µl 2W1S peptide in a total volume of 25µl or 
PBS alone, administered via subcutaneous injection to right and left front paw pads at day 0. 
Draining inguinal axillary and brachial lymph nodes were harvested at day 7. 
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2.2.7 In-vitro assays of T lymphocyte differentiation 
 
2.2.7.1 Cell purification 
 
Cell suspensions were first generated from secondary lymphoid tissues under sterile 
conditions as described above. Naïve T lymphocytes were purified through either magnetic 
bead isolation (magnetic activated cell sorting - MACS) using the CD4+CD62L+ T cell 
Isolation Kit II (Miltenti Biotech Inc, California, USA), or by fluorescence activated cell 
sorting (FACS), using the ‘lymphocyte phenotype’ panel as illustrated in table 2.5 but 
staining only for purification of CD4+CD25-CD44lowCD62L+ (naïve CD4+) T lymphocytes.  
Samples of 2 x 105 cells were taken before and after sorting to confirm purity, again being 
analysed according to the ‘lymphocyte phenotype’ flow cytometry protocol as described in 
table 2.5. 
 
MACS purification followed a two-step process. Firstly, non-CD4+ cells were removed 
through magnetic bead labelling with a cocktail of biotin-conjugated antibodies against CD8a, 
CD45R, CD11b, CD23, CD49b, TCRγ/δ and Ter-119. These labelled cells were depleted by 
separation over a MACS column to remove any non-CD4+ cells from the sample. Secondly, 
the remaining CD4+ cells were directly labelled using monoclonal anti-mouse CD62L 
microbeads, and labelled cells isolated by positive selection from the pre-enriched fraction to 
generate a purified CD4+CD62L+ sample.  
 
This process aims to purify a naïve T lymphocyte phenotype by assuming a low population of 
“central memory” T cells expressing both CD62L and CD44, and also that all CD62L+ cells 
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will be CD25-. FACS enables positive selection of CD4+CD25- cells, allowing the central 
memory component to be excluded by positively selecting the CD44lowCD62L+ from this 
population.  
 
FACS therefore results in a sample of considerably greater purity, however there is a greater 
risk of microbial contamination as the FACS sorter is not maintained in a sterile environment, 
and cell recovery and viability is reduced compared to MACS. There is thus a trade-off 
between the risk of sample infection, and the degree of sample purity, and the cell yield 
between the two techniques. 
 
2.2.7.2 Culture conditions 
 
Where indicated, purified naïve T lymphocytes were first labelled with an eFluor 450 
proliferation dye (eBioscience, Hatfield, UK) according to the following protocol: 
 
The proliferation dye was first reconstituted with 165µl anhydrous dimethyl sulfoxide 
(DMSO) to give a 10mM stock solution. Cells were washed twice in PBS (300g, 8 minutes 
per wash) and resuspended in 0.5ml sterile PBS per 5 million cells. A 1/500 dilution of stock 
solution was then added to the cell suspension at a volume ratio of 1:1, and the mixture 
incubated in darkness at room temperature for 10 minutes. Cold complete media was then 
added to stop the labelling, and incubated on ice in darkness for 5 minutes. Cells were finally 
washed three times in complete media as above.   
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Following labelling, cells were resuspended in complete media and transferred to sterile 96-
well plates. Cells were stimulated with either plate-bound anti-CD3 5µg/ml (eBioscience, 
Hatfield, UK) and soluble anti-CD28 1µg/ml (eBioscience, Hatfield, UK), or anti-CD3 / anti-
CD28 coated activation beads at a ratio between 2:1 and 1:4 beads:cells (Dynabeads Mouse 
T-activator CD3/CD28, Life Technologies, Paisley, UK).  
 
Flat-bottomed 96-well plates were coated with anti-CD3 (200µl 1/200 anti-CD3 in sterile 
PBS) for a minimum of 6 hours at 2-6°C; PBS was removed by pipetting and excess un-
bound anti-CD3 removed by two washes with 1ml sterile PBS. Care was taken at each 
pipetting step not to disturb the bound anti-CD3. Round-bottomed 96-well plates were used 
for cultures involving anti-CD3 / anti-CD28 coated activation beads. 
 
For all experiments cells were cultured at a concentration of 2 x 105 cells per 200µl. Cells 
were incubated at 37°C in an environment of 5% CO2 for four days and cultured either under 
iTreg polarizing conditions (IL2 50 U/ml, TGFβ 3.0-0.1ng/ml in Log3 dilutions) or control 
(Th0) conditions (IL2 50U/ml). Further control conditions were tested in the absence of 
stimulation. Recombinant TGFβ1, 2 or 3 was tested in appropriate assays.  
 
2.2.8 Single nucleotide polymorphism screening 
 
2.2.8.1 Sample preparation 
 
After informed consent, blood samples were collected by venepuncture by research nurses 
and doctors working in outpatient clinics at the Birmingham & Midland Eye Centre and 
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Medical Eye Unit at St Thomas’ Hospital London. DNA was prepared by proteinase K 
digestion, and salt extraction and stored at -70˚C until use.  
 
2.2.8.2 Real-time genotyping and analysis 
 
The SNP RS1805110 (Applied Biosystems, Warrington, UK) in TGFBR3 was genotyped in 
all subjects using a PCR restriction length polymorphism assay (Table 2.7). PCR was 
performed in 384-well plates with a 10µl total reaction volume containing 20pg/µl DNA 
(samples) or water (controls) and 2x LC480 probe master (Roche, West Sussex, UK). 
Analysis was conducted using the Roche LC480 system (Roche, West Sussex, UK) according 
to the ‘endpoint genotyping PCR read’ protocol, comprising pre-incubation of 1 cycle at 95° 
for 10 minutes, followed by 40 amplification cycles at 95° for 10 seconds, 60° for 1 minute 
and 72° for 1 second, and finally 1 cooling cycle at 40° for 30 seconds. Genotypes were 
determined as either homozygous (TT or CC) or heterozygous (CT) according to the presence 
or absence of fluorescence for each genotype.  
 
 
 
Table 2.7 SNP RS1805110 probe used for analysis. Substitution in context sequence shown 
in square brackets; Applied Biosystems, Warrington, UK. 
 
  
RS number Context sequence
RS1805110 CAACTTACCTGCAGTGGCTAAACAG
[A/G]
AGCTCATCAGGGCAAAGATGGCAAT
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2.3 Statistical analysis 
 
All data was entered into a Microsoft Excel spread sheet for initial processing. Statistical 
analysis and graphical representations were then generated using Graphpad Prism 5 
(Graphpad, California, USA). 
 
Descriptive statistics comprising median, mean, standard error, and 95% confidence intervals 
were calculated where appropriate. Illness and survival amongst experimental animals was 
assessed using a Kaplan-Meier survival analysis with a Mantel-Cox test for curve 
comparison. 
 
Non-parametric tests were employed to compare cell populations between experimental 
groups of animals, using the Mann-Whitney U test for comparisons of two groups, and 
Kruskal-Wallis test with Dunn’s multiple comparison post-test for analyses involving three or 
more groups. Non-parametric tests were favoured as data could not be considered normally 
distributed, and therefore non-parametric tests were considered more rigorous (Altman 1991).  
 
For association analysis of SNP with human disease groups, Hardy-Weinberg equilibrium 
(HWE) was assessed using the Chi-square test. Allele frequencies were estimated by direct 
counting, and distribution of alleles and genotypes between patients and controls compared. 
Odds ratio (OR) and 95% confidence intervals were calculated, and the association of this 
SNP with disease phenotype analysed using Fisher’s exact test.  
 
Statistical significance was accepted for p<0.05 throughout all analyses.  
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3 DEVELOPING AN EXPERIMENTAL MODEL TO 
ENABLE INVESTIGATION OF THE ROLE OF 
BETAGLYCAN IN PERIPHERAL LYMPHOCYTE 
RESPONSES 
 
3.1 Introduction 
 
Absolute deficiency of any of the three isoforms of TGFβ, or any components of the TGFβ 
receptor is incompatible with life. This is due to the wide distribution of TGFβ and its 
involvement in a multitude of life-essential signalling pathways across all organ systems, and 
the importance of TGFβ to the developing embryo. In mice, TGFβ1 deletions result in two 
distinct phenotypes; approximately 50% of embryos die around mid-gestation due to defects 
in yolk sac vasculogenesis and haematopoiesis (Dickson et al. 1995), whilst the remainder 
survive beyond birth, possibly due to transfer of maternal TGFβ1 across the placenta. Mice 
surviving to birth proceed to experience spontaneous activation of a self targeted immune 
responses leading to death between three and four weeks of age (Kulkarni et al. 1993; Shull et 
al. 1992). TGFβ2 deletions also result in perinatal death, although this is due to extensive 
developmental defects in the cardiac, pulmonary, musculoskeletal, craniofacial and urogenital 
systems (Sanford et al. 1997). Loss of TGFβ3 results in cleft palate and abnormal pulmonary 
development with death within a few hours of birth (Kaartinen et al. 1995; Proetzel et al. 
1995).  
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Similarly, murine models of complete TGFβRI or II gene knock-out are characterised by 
embryonic lethal defects in vascular development in the placenta and yolk sac (Larsson et al. 
2001; Dickson et al. 1995; Oshima et al. 1996), whilst betaglycan knock-out (TGFβRIII-/-) 
mice display embryonic-lethal cardiac and hepatic defects arising around mid-gestation 
(Stenvers et al. 2003). 
 
Whilst absolute betaglycan deficiency is thus incompatible with life, animals with targeted 
deletions of betaglycan restricted to specific cells and organ systems have the potential to be 
viable and offer opportunities for studying the role of betaglycan in mature organ systems in 
vivo. Wild-type mice possess two copies of the betaglycan gene; heterozygotes with a single 
copy of the betaglycan gene have previously been generated, proving to be both viable and 
fertile, allowing a colony of betaglycan heterozygotic mice to be established (Stenvers et al. 
2003). Embryos generated through mating between two betaglycan heterozygotic mice follow 
a Mendelian pattern of inheritance, with a 1:2:1 ratio of wild-type (TGFβRIII +/+) : 
heterozygote (TGFβRIII +/-) : knock-out (TGFβRIII -/-) progeny. As previously discussed, 
absolute deficiency of betaglycan as observed in TGFβRIII -/- progeny results in death of 
mice in utero due to cardiovascular developmental defects; embryogenesis proceeds 
unaffected until day 12 gestation, after which gradual accumulation of cardiovascular 
developmental defects results in death of all TGFβRIII -/- embryos. Survival is rarely 
observed beyond day 18 gestation (E18).  
 
The survival of TGFβRIII -/- embryos to mid gestation has previously enabled observation of 
betaglycan-deficient foetal thymic organ cultures, which have shown deficiencies in thymic T 
lymphocyte development (Aleman-Muench et al. 2012). Due to the difficulties in developing 
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suitable experimental models, there have been no previous studies of betaglycan deficiency in 
mature animals. 
 
In the previously described foetal thymic organ cultures, developing TGFβRIII -/- embryos 
were harvested at a time point prior to embryonic death, and grown in culture to allow the 
resident population of embryonic stem cells to mature. This enabled observation of mature 
betaglycan-deficient T lymphocytes in an ex vivo system. We observed that such populations 
of embryonic stem cells could be transferred to a host animal in which they could proliferate 
and differentiate in vivo, allowing investigation of mature, peripheral TGFβRIII -/- T 
lymphocytes in a physiological system.   
 
We subsequently adopted this approach to develop a novel experimental model of betaglycan 
deficiency, through generation of mixed foetal liver chimeric mice. 
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3.2 Experimental design 
 
3.2.1 Generation of betaglycan-deficient foetal liver chimeric mice 
 
Our requirements were to develop an experimental model in which the role of betaglycan 
could be investigated in peripheral lymphocyte responses, whilst avoiding the embryonic 
lethality observed in conditions of absolute betaglycan deficiency. We therefore employed a 
technique of generating animals with targeted deletion of betaglycan, restricted primarily to 
the lymphocyte populations of interest. 
 
Haemopoietic chimeras are created when embryonic stem cells are harvested from a ‘donor’ 
source and transferred to a ‘host’ mouse. Haematopoietic stem cells populate the embryonic 
liver, which is thus a rich source of lymphocyte precursors. Provided both the donor and host 
animal are of a similar genetic background, graft versus host disease is avoided, and the donor 
lymphocyte precursor cell populations will mature and persist in the host mouse. We utilised 
this concept to generate a model of targeted betaglycan deficiency, where TGFβRIII -/- foetal 
liver stem cells were transferred to a sub-lethally irradiated RAG -/- host mouse (Figure 3.1).  
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Figure 3.1 Generation of foetal liver chimeras. Flowcharts illustrating maintenance of stock 
colonies and co-ordination of foetal liver chimera generation. Experimental animals were 
created following of transfer of embryonic liver stem cells from the products of timed mating 
between betaglycan heterozygote mice to sub-lethally irradiated RAG/BoyJ hosts between 
day 12 and 14 gestation. All animals were maintained on a C57BL/6 background.  
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3.2.2 Animal selection and generation of stock colonies 
 
A population of RAG/BoyJ mice was maintained as hosts for cell transfer; these mice lack the 
recombinase activating genes which are required for V(D)J gene rearrangement during 
generation of Ig and the TCR (Schatz et al. 1989). In the absence of V(D)J rearrangement, 
lymphocyte development is arrested and RAG -/- mice have no circulating T or B 
lymphocytes. Since the bone marrow of these knock-outs is otherwise functionally normal, 
lymphocytes will develop if embryonic stem cells are transferred from mice with functioning 
RAG genes (Chen et al. 1993). 
 
TGFβRIII +/- mice (129/Sv background) were kindly donated by Kaye Stenvers (Head of 
Reproductive Development and Cancer, Prince Henry’s Institute of Medical Research, 
Clayton, Victoria, Australia). A colony of betaglycan heterozygote mice was maintained for 
use as donors for cell transfer through mating with wild-type C57BL/6 mice. The offspring of 
each mating were genotyped according to the PCR method as described in section 2.2.2. 
 
In creating the original heterozygotic mouse, a 2.55-kb phosphoglycerokinase-neomycin 
(PGK-Neo) expression cassette was inserted in place of the betaglycan gene. Mice or embryos 
could be identified as TGFβRIII +/+ if only the betaglycan gene was detected by PCR, 
TGFβRIII -/- if only the neomycin gene was identified, and TGFβRIII +/- if both genes were 
identified by PCR (Figure 3.2).  
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Figure 3.2 Identification of donor cell genotype by PCR. Tissue samples were retained 
from all donor embryos to enable accurate genotyping following cell transfer. Examples of 
PCR results are shown for TGFβRIII wild-type (+/+), TGFβRIII heterozygote (+/-) and 
TGFβRIII knock-out (-/-) tissue samples. In each example, betaglycan probes are loaded in 
the first column, and neomycin probes loaded in the second column; animals were thus 
identified as either TGFβRIII wild-type (+/+) if only the betaglycan gene was identified, 
heterozygote (+/-) if both betaglycan and neomycin genes were identified and knock-out (-/-) 
if only the neomycin gene was identified. 
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TGFβRIII!+/+ TGFβRIII!+/- TGFβRIII!-/- 
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Since all TGFβRIII -/- embryos die in utero, this breeding achieved a TGFβRIII +/+ to 
TGFβRIII +/- ratio of 1:2 in live births. All +/+ mice were sacrificed, and breeding pairs 
created between the remaining TGFβRIII +/- mice and C57BL/6 mates: The original 
betaglycan heterozygote mouse was created on a 129/Sv background, however the host 
RAG/BoyJ mouse had a C57BL/6 background. To avoid graft-versus-host disease in the 
resulting chimeras it was important to back-cross the betaglycan heterozygotes to a 
genetically similar C57BL/6 background. After a minimum of five back-crosses the mice 
were considered sufficiently close to a C57BL/6 genotype for further experiments to 
commence. In addition to ensuring genetic compatibility, the back-crossing of betaglycan 
heterozygotes to a C57BL/6 background also enabled discrimination of donor and host cells 
in chimeric mice; C57BL/6 mice express the CD45.2 congenic marker, whereas the host 
RAG/BoyJ mice express CD45.1. By ensuring that donor and host cells express different 
isoforms of CD45, the two cell populations could be distinguished by flow cytometric 
analysis at a later stage. 
 
3.2.3 Generation of experimental mice 
 
Embryos were generated through timed mating between TGFβRIII +/- animals. Pregnant 
females were sacrificed by a UK Home Office-approved schedule 1 method between E12 and 
E14 and the embryos extracted by caesarean section. Each embryo was transferred to a 
separate well of a sterile six-well plate in 2ml sterile RPMI, and the liver removed and 
transferred to a separate well of a sterile 24 well plate in 1ml sterile RPMI. A sample of tissue 
was retained from the tail of each embryo and immediately frozen at -20°C for later 
genotyping according to the PCR method described in section 0. 
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Foetal liver specimens were disaggregated to a cell suspension by repeated pipetting, then 
transferred to a flow cytometry tube via a 70µm filter. Cells were centrifuged to a pellet, the 
supernatant removed and cells resuspended in 200µl of sterile PBS in preparation for transfer 
to a host mice, with cells from each embryo being transferred to a separate host. To maximise 
the chance of successful reconstitution in chimeric mice, all available cells from each foetal 
liver sample were transferred to host mice. 
 
To reduce the potential risk of bacterial infection and reduce the risk of death from 
overwhelming sepsis following sub-lethal irradiation and subsequent bone marrow 
suppression, RAG/BoyJ drinking water was supplemented with Baytril (active ingredient 
enrofloxacin, Bayer, Newbury, UK) for seven days prior to the planned procedure. Mice were 
irradiated at a dose of 4.5Gy up to four hours prior to cell transfer. Hosts were weighed to 
give a baseline measurement, earmarked for traceability, then donor cells were transferred via 
injection to a tail vein. Baytril supplementation continued for 1 week following cell transfer. 
Host animals were observed daily for signs of distress following cell transfer (weight loss, 
starry coat, stereotypical behaviour, orbital tightening (Bleby 1986)); animals deemed 
‘distressed’ were culled by a UK Home Office-approved schedule 1 procedure. 
 
In the resulting chimeric mice, all mature T and B lymphocytes had differentiated from the 
donor stem cells, and thus in this model, absolute deficiency of betaglycan deficiency was 
achieved for all T and B lymphocytes. For all other haemopoietic cell populations, a mixed 
population of mature donor and host cells was observed. All non-haemopoietic cells of the 
host mouse also expressed betaglycan within the cell surface TGFβ receptor complex.  
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3.3 Results 
 
3.3.1 Betaglycan-deficient T and B lymphocytes populate circulating 
compartments within 6 weeks of donor cell transfer 
 
In order to allow assessment of the effect of betaglycan deficiency on mature lymphocyte 
populations, it was first necessary to confirm that donor cell populations were able to both 
persist and populate peripheral compartments in host mice. To confirm this, blood samples 
were collected via tail bleed of all chimeric mice 6 weeks post cell transfer according to the 
method described in section 2.2.3. Blood samples were processed for flow cytometric analysis 
according to the ‘lymphocyte phenotype’ protocol as described previously (Table 2.5).  
 
Reconstitution of donor cell populations was confirmed by the presence of circulating 
CD3+CD45.2+ (T lymphocyte) and CD19+CD45.2+ (B lymphocyte) populations, with these 
populations absent in un-reconstituted RAG/BoyJ mice. Un-reconstituted mice were culled 
according to a UK Home Office-approved schedule 1 technique at 6 weeks post cell transfer 
(Figure 3.3). Failure of reconstitution was attributed to transfer of insufficient numbers of 
donor cells. 
 
 
  
 107 
  
Figure 3.3 Successful reconstitution of foetal liver chimeras is confirmed by the 
persistence of circulating CD45.2+ cell populations. Example flow cytometric analysis of 
circulating blood cell populations in RAG/BoyJ host mice 6 weeks after irradiation and cell 
transfer showing A successful reconstitution and B unsuccessful reconstitution. Lymphocytes 
were first identified by forward scatter (FSc) / side scatter (SSc) profile, then T lymphocytes 
identified by staining for CD3 and B-lymphocytes identified by staining for CD19. Where T 
and B lymphocytes were successfully identified, the origin of these cells was confirmed by 
staining for CD45.2, with >99.9% of CD3+ and CD19+ cells displaying CD45.2 positivity. 
CD3-CD19- cell populations in successfully reconstituted mice displayed both CD45.2 
positivity and negativity. Numbers in gates represent percentages for displayed sample.  
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Based on our observations, we conclude that betaglycan-deficient cells of donor origin are 
able to persist and circulate in the blood of our chimeric mice, enabling further investigation 
of peripheral lymphocyte populations. Overall, 289 chimeric mice were successfully 
generated, with chimera genotype closely following the expected ratio of Mendelian 
inheritance (1 : 1.94 : 1.19 TGFβRIII -/- : TGFβRIII +/- : TGFβRIII +/+ respectively). 
 
3.3.2 Reconstitution of host bone-marrow is not impaired in betaglycan 
deficient foetal liver chimeras 
 
To confirm that targeted betaglycan deficiency did not adversely affect reconstitution of host 
cell populations, an assessment was also made of resident non-T lymphocyte / non-B 
lymphocyte populations following irradiation and cell transfer. Whilst all lymphocyte 
populations in reconstituted chimeras must have originated from CD45.2+ donor cell 
populations, all other bone-marrow derived cells may have originated either from donor 
CD45.2+ cell populations, or host CD45.2- populations which repopulated bone-marrow 
compartments following sub-lethal irradiation of host mice. Thus, the presence of lymphocyte 
populations confirmed persistence of donor cell populations, but gave no indication of host 
bone-marrow reconstitution.  
 
Flow cytometric analysis was performed to compare proportions of resident splenic non-
lymphocyte populations of donor and host origin according to the ‘Non-T / Non-B 
lymphocyte’ staining protocol as previously described (Table 2.5). 
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All T and B lymphocytes were first excluded from analysis by gating on CD3-CD19-CD4-
CD8- populations, then macrophages, dendritic cells and neutrophils identified through 
selection of CD11b+, CD11c+ and GR1+ populations respectively (Figure 3.4). Median ratio 
CD45.2+:CD45.2- populations ranged from 0.68 to 2.05. No statistically significant 
difference in ratio was observed for any cell type between genotypes, although a non-
statistically significant trend towards impaired reconstitution of donor cell populations in 
knock-out chimeras was seen. 
 
Based on these observations, we conclude that our experimental conditions of targeted 
betaglycan deficiency result in no impairment of bone-marrow haematopoiesis in host mice, 
and reconstitution of non-T lymphocyte and non-B lymphocyte populations is similar 
between mice of different genotypes. We find no evidence for a role of betaglycan in 
establishment of cell populations in the bone marrow.   
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Figure 3.4 Reconstitution of non-T lymphocyte and non-B lymphocyte cell populations is 
not affected by chimera genotype. Example flow cytometry data plots showing gating 
strategy and associated column charts illustrating pooled results of analysis (flow cytometry 
data shown for heterozygote mouse; pooled data n=4 knock-out, n=4 heterozygote, n=2 wild-
type; all animals assessed at 6 weeks post-transfer). Live cells were identified by forward 
scatter (FSc) / side scatter (SSc) profile, T and B lymphocytes excluded by gating on CD3-
CD19-CD4-CD8- populations, then macrophages, dendritic cells and neutrophils identified 
through selection of CD11b+, CD11c+ and GR1+ populations respectively. Numbers in gates 
represent percentages for displayed sample. Line indicates median value; all comparisons 
non-significant (p>0.05) using Kruskal-Wallis test.  
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3.3.3 Animals with betaglycan deficient T and B lymphocytes are viable 
and display no external evidence of systemic disease 
 
Having confirmed reconstitution of cell populations in host mice, it was also necessary to 
confirm viability of these animals for use in further experiments. Viability was confirmed by 
gross observations of mouse colonies, with assessment of general health according to 
recognised UK Home Office criteria (Bleby 1986). 
 
No significant difference in percentage weight gain was observed at either 4 or 6 weeks post 
cell transfer, or at time of schedule 1 cull (Figure 3.5). This suggests that neither the process 
of irradiation or transfer of betaglycan-deficient cell populations results in development of 
significant gastrointestinal disease. 
 
A slow rate of spontaneous illness as defined by Home Office criteria and described in section 
2.2.1 was observed in chimeric mice (Prevalence 6.92% overall); whilst the survival curves 
for knock-out, heterozygote and wild-type mice are statistically significantly different 
according to Mantel-Cox curve analysis (p<0.05), the overall prevalence of spontaneous 
illness in each group were similar when comparing all animals. Experimental mice were 
observed for up to 24 weeks post cell transfer, allowing sufficient survival to allow for further 
experimental investigation (Figure 3.6). 
 
We therefore conclude that restriction of betaglycan deficiency to T and B lymphocytes 
results in no gross external disease phenotype, and this is a suitable model on which to base 
further investigation of peripheral lymphocyte responses.  
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Figure 3.5 Chimera weight gain following irradiation and cell transfer is not affected by 
betaglycan deficiency. Percentage weight gain shown for A 4 weeks post irradiation and cell 
transfer and B 6 weeks post irradiation and cell transfer (data for one experiment involving 3x 
timed matings shown; n=5 knock out, n=14 heterozygote, n=8 wild type mice), and C at 
schedule 1 cull (all available data pooled). Data points represent individual animals. Line 
indicates median value; all comparisons non-significant (p>0.05) using Kruskal-Wallis test.  
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Chimera genotype Total  %a M  %b F %b 
TGFβRIII -/- 70 24.22 39 55.71 31 44.29 
TGFβRIII +/- 136 47.06 70 51.47 66 48.53 
TGFβRIII +/+ 83 28.72 54 65.06 29 34.94 
Overall 289 100.00 163 56.40 126 43.60 
 
 
Chimera genotype Total %b M %c F %c 
TGFβRIII -/- 9 12.86 3 33.33 6 66.67 
TGFβRIII +/- 9 6.62 2 22.22 7 77.78 
TGFβRIII +/+ 2 2.41 1 50.00 1 50.00 
Overall 20 6.92 6 30.00 14 70.00 
 
%a: expressed as a percentage of total number of animals 
%b: expressed as a percentage of total number of animals stratified by genotype 
%c: expressed as a percentage of total number of animals developing spontaneous 
illness stratified by genotype 
 
 
Figure 3.6 No difference in survival is observed between chimeras of different genotype. 
A Survival curves for chimeric mice where survival is defined as absence of spontaneous 
illness by time of schedule 1 cull for use in an experiment, and summary statistics showing 
overall prevalence of spontaneous illness stratified by gender and genotype for B all animals 
and C only those showing signs of spontaneous illness. 
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3.4 Discussion 
 
We successfully generated an experimental mouse model in which absolute betaglycan 
deficiency was observed in all T and B lymphocytes. Experimental animals were viable, with 
no obvious evidence of immune-mediated disease detected on observation of resulting animal 
colonies. We were able to demonstrate successful reconstitution of bone marrow 
haematopoiesis following irradiation and cell transfer, with persistence of donor lymphocyte 
populations and population of circulating compartments by T and B lymphocytes (Figure 
3.3). We can conclude that betaglycan is not an absolute requirement for successful bone-
marrow T or B lymphocyte lymphopoiesis, or for the transit of immune cells from the bone 
marrow to the blood compartment. 
 
We were also able to confirm the persistence of non-T / non-B lymphocyte cell populations of 
both donor and host origin, confirming the absence of gross defects in bone marrow 
reconstitution following irradiation (Figure 3.4). Whilst we observed no statistically 
significant differences in donor:host ratios, we recognised a subtle trend towards impaired 
reconstitution of donor cells in betaglycan knock-out chimeras, as illustrated by a median 
ratio of CD45.2:CD45.1 populations of less than 1 for all non-T / non-B lymphocyte 
populations in knock-out chimeras, compared to a median ratio of greater than 1 for all 
similar populations in wild-type animals. We speculate that this difference may have become 
statistically significant with larger sample sizes, raising the possibility that betaglycan may be 
involved in regulation of these cell populations in the bone marrow.  
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In experimental models of disease, TGFβ has been implicated in a range of conditions 
including uveitis (EAU) (Caspi 2003; Caspi et al. 2008), inflammatory bowel disease 
(experimental colitis) (Fantini et al. 2006) and multiple sclerosis (EAE) (Rangachari & 
Kuchroo 2013). Whilst we made no specific examination of ocular, gastrointestinal or neural 
tissues, we observed no external evidence of any of these disease processes. Spontaneous 
ocular inflammation would be expected to present with ocular surface disturbance and 
eventual globe perforation, colitis would present with gastrointestinal disturbance and weight 
loss, and animals suffering encephalomyelitis display well recognised abnormalities of 
movement and locomotion. No such features were observed in our experimental animals. 
 
This contrasts with other animal models of altered TGFβ signalling. For example, complete 
knock-out of TGFβ1 through disruption of the TGFβ1 gene results in development of a 
wasting syndrome accompanied by tissue necrosis around three weeks of age, characterised 
by a gross phenotypic observations of “dishevelled appearance, hunched posture and skin 
irritation (Shull et al. 1992).” Death occurs within a few days of developing this phenotype 
(Kulkarni et al. 1993). Mice deficient in TGFβ2 or TGFβ3 show obvious developmental 
defects of multiple organ systems, resulting in death in the immediate peri-natal period 
(Kaartinen et al. 1995; Proetzel et al. 1995; Sanford et al. 1997).  
 
In each of these models, there is complete deficiency of signalling by TGFβ1, 2 or 3; given 
the widespread functions of TGFβ across multiple organ systems, the severe nature of such 
deletions is unsurprising, and would not be expected in our model. Gorelik and Flavell 
developed a murine model with great similarity to ours, in which a dominant-negative 
TGFβRII was expressed under a T lymphocyte-specific promoter. In this model, the TGFβRII 
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component of the TGFβ receptor complex was absent on all T lymphocytes, but present on all 
other cell types (Gorelik & Flavell 2000). Mice expressing the dominant-negative form of 
TGFβRII were observed to develop normally to 3-4 months of age, at which point they began 
to develop a spontaneous phenotype of “sickness, wasting and diarrhoea.” As expected, 
targeted disruption of TGFβ signalling to T lymphocytes led to a much milder external 
phenotype than complete deletion of TGFβ.  
 
Since our betaglycan-deficient chimeras appeared grossly healthy to a maximum age of 6 
months post-cell transfer, with no statistically significant difference in percentage weight gain 
either immediately following cell transfer or at the point of schedule 1 cull (Figure 3.5), we 
conclude that targeted betaglycan deficiency on T and B lymphocytes does not induce 
obvious systemic TGFβ-mediated immune disease. This is unsurprising, as betaglycan has 
primarily been implicated in TGFβ2 signalling (Cheifetz et al. 1990; Sankar et al. 1995; 
Sarraj et al. 2013), whilst TGFβ1 is the predominant isoform acting in the murine immune 
system (Rubtsov & Rudensky 2007). The effect of betaglycan deficiency on TGFβ1-
dependent T lymphocyte responses was therefore expected to be small, and was not expected 
to result in an obvious phenotype of spontaneous immune disease. 
 
A slow rate of spontaneous attrition of experimental animals was however observed across 
our colonies; experimental animals were observed on a daily basis, and recognised evidence 
of illness or distress including loss of weight, hunched appearance and stereotypical 
behaviour recorded by trained staff. Animals considered ‘unwell’ were sacrificed by a UK 
Home Office-approved schedule 1 method (Bleby 1986). These losses were considered most 
likely to have resulted from infection by commensal pathogens present in the animal facility. 
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Experimental colonies were maintained in a specific pathogen free (SPF) environment; this 
implies that the environment is free of a selection of specified pathogens, but not completely 
sterile, and thus animals may still be infected by unspecified pathogens.  
 
A statistically significant difference in the rate of spontaneous attrition was observed between 
animals of different genotype, with increased early attrition of knock-out chimeras compared 
to wild-type animals. Despite this, the overall prevalence of spontaneous attrition was similar 
between genotypes by the end of our maximum period of observation. This suggests that 
knock-out mice displayed an increased susceptibility to commensal pathogens compared to 
their heterozygote and wild-type litter-mates in the immediate period following irradiation 
and cell transfer, but overall were no more likely to succumb to disease than heterozygote or 
wild-type littermates (Figure 3.6).  
 
Our data confirms the presence of CD3+ cell populations in the blood within 6 weeks of cell 
transfer in all animals, suggesting no gross deficit in immune reconstitution in knock-out 
chimeras. It is however possible that there was a delay in development of mature effector 
cells, or a functional defect in the resulting lymphocyte populations which may explain the 
early attrition of knock-out animals (further investigated in chapter 4).  
 
On closer inspection, we observed that episodes of disease clustered around two time points 
between November 2011 – February 2012, and August 2012 (data not shown). This suggests 
there may have been some variation in the level of background commensal pathogens in the 
animal facility at these times, which may have been sufficient to induce disease in our 
chimeras. The impact of commensal pathogens on disease development has previously been 
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reported: In a paper by Goverman et al. a T cell transgenic mouse was created in which to 
study experimental autoimmune encephalitis (EAE). Two populations of this T cell transgenic 
mouse model were maintained in two separate animal facilities, yet spontaneous disease was 
only observed in knock-out mice from one facility. The authors attributed this to differences 
in environment and the level of local bacterial colonisation, and acknowledged that 
commensal bacteria may be sufficient to trigger a spontaneous immune response in certain 
strains of T cell transgenic mice (Goverman et al. 1993).  
 
Based on these results, we concluded that betaglycan deficient mice were viable and showed 
no obvious external manifestations of immune disease. To our knowledge, this animal model 
provided the first opportunity to study mature animals with absolute betaglycan deficiency 
restricted to T and B lymphocytes, and provided a useful basis for further investigation of 
betaglycan in immune regulation. 
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4 INVESTIGATING THE ROLE OF BETAGLYCAN IN 
REGULATION OF RESTING T LYMPHOCYTE 
POPULATIONS 
 
4.1 Introduction 
 
Whilst betaglycan has a widely reported role in TGFβ2-dependent responses (Bilandzic & 
Stenvers 2011; Chu et al. 2011; Hanks & Holtzhausen 2013; López-Casillas et al. 1994; 
López-Casillas et al. 1993), there is a paucity of evidence for its role in TGFβ2 signalling to T 
lymphocytes. Existing immunological data is limited to the study of foetal thymic organ 
cultures, demonstrating a role for betaglycan in regulation of lymphocyte maturation and 
protection of developing lymphocytes from apoptosis (Aleman-Muench et al. 2012). 
Assessment of the role of betaglycan in mature lymphocyte populations have been limited due 
to the absence of a suitable model in which to study peripheral immune populations.  
 
In our animal model, betaglycan deficiency is restricted to bone-marrow-derived cell 
populations of donor origin, whilst all host tissues are betaglycan sufficient. Since our host 
RAG/BoyJ animals are unable to generate T and B lymphocytes under normal conditions, the 
resulting chimeras display absolute deficiency of betaglycan in all T and B lymphocytes 
(since these are derived solely from donor cell populations), and partial betaglycan deficiency 
in all other bone-marrow-derived cell populations (since these may originate from either 
donor or host cell populations). This model therefore permits assessment of the role of 
betaglycan in mature lymphocyte populations. 
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In order to circumvent the lethality of complete TGFβ receptor component knock-outs and 
enable investigation of peripheral lymphocyte responses, models of targeted deficiency of 
TGFβ receptor components have previously been developed and studied. For example, when 
TGFβRII deletion is restricted to only CD4+ and CD8+ T lymphocytes, a dramatic increase in 
T lymphocyte activation is observed under resting conditions (Gorelik & Flavell 2000). This 
is attributed to impairment of the ability of TGFβ to signal to lymphocytes under conditions 
of TGFβRII deficiency; since TGFβ has a predominantly immunosuppressive effect in the 
periphery through the induction of iTreg from naïve T lymphocytes (Yoshimura et al. 2010; 
Li & Flavell 2008; Wan & Flavell 2007; Ming O Li et al. 2006; Chen et al. 2003), an 
impairment of TGFβ signalling thus appears to have a pro-inflammatory effect. 
 
TGFβRII is required for signal transduction across the cell membrane, being necessary to 
phosphorylate the kinase domain of TGFβRI (Souchelnytskyi et al. 1996; Kang et al. 2009) 
which in turn initiates the intracellular signalling cascade through the phosphorylation of 
Smad proteins (Santibañez et al. 2011). The absence of TGFβRII from T lymphocytes thus 
completely abrogates TGFβ signalling, and the consequential severity of the auto-
inflammatory phenotype is therefore unsurprising. In contrast, betaglycan has no intrinsic 
enzyme activity, and is considered a co-factor in signal transduction across the TGFβRI / 
TGFβRII receptor complex. Whilst betaglycan is strongly expressed on CD4+ T lymphocytes 
and in the placenta (Pakula et al. 2007), it is absent from certain myoblasts, epithelial, 
endothelial, and haematopoietic cells which still respond to TGFβ suggesting that betaglycan 
is not an absolute requirement for TGFβ signalling (López-Casillas et al. 1991). Furthermore, 
betaglycan has been primarily implicated in TGFβ2-mediated signalling, with a seemingly 
redundant role in TGFβ1 and TGFβ3-mediated processes (Bilandzic & Stenvers 2011; Chu et 
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al. 2011; Hanks & Holtzhausen 2013; López-Casillas et al. 1994; López-Casillas et al. 1993). 
Since TGFβ1 is the predominant isoform acting in the immune system (Wan & Flavell 2007), 
targeted deletion of betaglycan on T and B lymphocytes may thus be expected to result in a 
far more subtle phenotype of immune dysregulation than that of similarly-targeted TGFβRII 
deletion.  
 
4.2 Experimental design 
 
We wished to determine whether the absence of betaglycan from the cell-surface TGFβ 
receptor on T and B lymphocytes resulted in any deficit in the establishment or regulation of 
the peripheral immune system in our experimental model of targeted betaglycan deficiency. 
Having proven that donor cells were able to populate circulating compartments with CD3+ T 
lymphocytes and CD19+ B lymphocytes, we now wished to further phenotype these cells, 
comparing levels of spontaneous activation between betaglycan deficient and betaglycan 
sufficient lymphocytes, and comparing relative proportions of T lymphocyte subsets between 
betaglycan knock-out and wild-type chimeras under resting conditions. Lymphocyte 
populations were assessed in circulating (blood), splenic and lymph node compartments. For 
analysis of lymph node populations, cells were pooled from all available nodes (including 
cervical, brachial, axillary, inguinal and peritoneal lymph nodes).  
 
We also wished to assess whether betaglycan was necessary for the establishment of 
secondary lymphoid tissues, which would be otherwise absent in RAG/BoyJ hosts, and 
determine whether betaglycan deficiency in T and B lymphocyte compartments resulted in 
autoimmunity in chimeric animals.  
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Experimental animals were culled by a UK Home Office-approved schedule 1 procedure after 
confirming successful reconstitution, between 6 and 18 weeks following cell transfer. To 
maximise data collection and avoid wastage of experimental animals, phenotypic analysis of 
peripheral lymphocyte populations was performed on an opportunistic basis as experimental 
animals were culled for use in other experiments, with all available results pooled. All 
experimental animals were included in analysis where cell number permitted. Animals subject 
to controlled antigenic challenge were not included in this analysis, but were analysed 
separately (Section 5.3.3). 
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4.3 Results 
 
4.3.1 Wide variation is observed in the activation level of resting 
lymphocyte populations in experimental animals 
 
In order to assess the role of betaglycan in the regulation of activation levels of resting 
lymphocyte populations, cell suspensions were generated from blood, lymph node and spleen 
according to the method described previously (Section 2.2.3.1) and comparison made between 
cells of betaglycan knock-out and wild-type origin. Example flow cytometric data is 
presented in figure 4.1.  
 
To first determine whether there was any deficit in establishment of overall T and B 
lymphocyte compartments, ratios of CD3+:CD19+ and CD4+:CD8+ lymphocytes were 
compared between experimental mice of different genotypes. No statistically significant 
differences or obvious trends were observed, suggesting that there was no underlying deficit 
in resting populations of either T lymphocytes or B lymphocytes in the absence of betaglycan, 
and furthermore, betaglycan deficiency resulted in no alteration of gross T lymphocyte 
subsets at rest (Figure 4.2).  
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Figure 4.1 Identification of resting lymphocyte activation levels by flow cytometry. 
Lymphocytes were first identified by their forward scatter (FSc) and side scatter (SSc) profile, 
doublets excluded by gating on pulse width, T and B lymphocytes identified by gating on 
CD3+ and CD19+ respectively, T lymphocytes separated to CD4+ and CD8+ lymphocytes 
and naïve (CD44lowCD62L+) and effector memory (CD44highCD62L-) populations 
identified for each. Data shown for splenocytes of wild-type chimeric mice at 8 weeks post 
cell transfer. Numbers in gates represent percentages for displayed sample. FSc / SSc 
presented on linear axes. All other plots presented on logarithmic axes.  
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Figure 4.2 Betaglycan deficiency results in no significant alteration in the phenotype of 
resting lymphocyte populations. Ratios of T lymphocytes (CD3+): B lymphocytes (CD19+) 
and CD4+:CD8+ T lymphocytes shown for blood, lymph node and splenic populations. 
Lymph node samples were pooled from all available nodes. Results of flow cytometric 
analysis by surface staining shown. Pooled data displayed for all animals culled at time points 
6-18 weeks post-reconstitution; n=11-21 TGFβRIII+/+, n=11-36 TGFβRIII +/-, n=15-23 
TGFβRIII-/-. Data points represent individual animals; line indicates median value. p>0.05 
for all comparisons using Kruskal-Wallis test with Dunn’s multiple comparison post test. 
 
 
  
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
2
4
6
8
30
35
40
Genotype
Ra
tio
 C
D
3+
:C
D
19
+
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
1
2
3
4
Genotype
Ra
tio
 C
D
4+
:C
D
8+
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
5
10
15
Genotype
Ra
tio
 C
D
3+
:C
D
19
+
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
1
2
3
4
Genotype
Ra
tio
 C
D
4+
:C
D
8+
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
1
2
3
4
Genotype
Ra
tio
 C
D
3+
:C
D
19
+
TG
FB
R3
 +/
+
TG
FB
R3
 +/
-
TG
FB
R3
 -/-
0
1
2
3
4
5
Genotype
Ra
tio
 C
D
4+
:C
D
8+
Blood Lymph node Spleen
T:B
CD4:CD8
 126 
Ratios of cell populations were favoured over percentages, since variable quantities of non-
CD3+ / non-CD19+ and non-CD4+ / non-CD8+ populations were demonstrated in cell 
suspensions by flow cytometry, reducing the calculated percentages of events in CD3+ or 
CD19+ and CD4+ or CD8+ gates respectively. Presentation of data as ratios of events 
CD3+:CD19+ and CD4+:CD8+ eliminated the effect of these non-CD3+ / non-CD19+ and 
non-CD4+ / non-CD8+ populations, and were felt to be more directly comparable between 
samples than raw percentages. 
 
To next determine whether betaglycan was involved in regulation of activity levels in these 
resting T lymphocyte populations, proportions of naïve (CD44lowCD62L+), central memory 
(CD44highCD62L+) and effector memory (CD44highCD62L-) CD4+ and CD8+ T 
lymphocytes were compared between experimental mice of different genotypes.  
 
When expressed as a percentage of the total T lymphocyte population, a statistically 
significant increase in the percentage of resident splenic effector memory CD8+ T 
lymphocytes was observed in TGFβRIII -/- chimeras compared to TGFβRIII +/+ chimeras 
(median 23.76% and 12.50% respectively, p<0.05). Similarly, a non-statistically significant 
trend towards increased percentages of effector memory CD4+ and CD8+ T lymphocytes and 
reduced percentages of naïve CD4+ and CD8+ T lymphocytes was also observed in 
TGFβRIII -/- chimeras compared to TGFβRIII +/+ chimeras across all tissues (Figures 4.3 to 
4.4). 
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Figure 4.3 Betaglycan deficiency results in no statistically significant difference in CD4+ 
T lymphocyte activation levels at rest. Relative proportions of effector memory 
(CD44highCD62L-), central memory (CD44highCD62L+) and naïve (CD44lowCD62L+) 
CD4+ T lymphocytes shown for blood, lymph node and splenic populations. Lymph node 
samples were pooled from all available nodes. Results of flow cytometric analysis by surface 
staining shown. Pooled data displayed for all animals culled at time points 6-18 weeks post-
reconstitution; n=11-21 TGFβRIII+/+, n=11-36 TGFβRIII +/-, n=15-23 TGFβRIII-/-. Data 
points represent individual animals; line indicates median value. p>0.05 for all comparisons 
using Kruskal-Wallis test with Dunn’s multiple comparison post test.  
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Figure 4.4 Betaglycan deficiency results in a statistically significant increase in splenic 
CD8+ effector memory populations at rest. Relative proportions of effector memory 
(CD44highCD62L-), central memory (CD44highCD62L+) and naïve (CD44lowCD62L+) 
CD8+ T lymphocytes shown for blood, lymph node and splenic populations. Lymph node 
samples were pooled from all available nodes. Results of flow cytometric analysis by surface 
staining shown. Pooled data displayed for all animals culled at time points 6-18 weeks post-
reconstitution; n=11-21 TGFβRIII+/+, n=11-36 TGFβRIII +/-, n=15-23 TGFβRIII-/-. Data 
points represent individual animals; line indicates median value. *p<0.05 comparisons using 
Kruskal-Wallis test with Dunn’s multiple comparison post test.  
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Our phenotypic analysis of resident lymphocyte populations revealed the presence of a small 
number of significant outliers in our data; some experimental animals displayed significantly 
elevated T:B lymphocyte ratios, elevated CD4:CD8 ratio, increased effector memory CD4+ 
and CD8+ populations and reduced naïve CD4+ and CD8+ populations. Following 
calculation of Pearson’s product-moment correlation coefficient (Pearson’s r), we observed 
positive correlation between several of these parameters (Table 4.1). In particular, we 
observed a statistically significant positive correlation between blood T:B lymphocyte ratio 
and percentage effector memory CD4+ and CD8+ populations in blood (CD4+ r=0.50, CD8+ 
r=0.47), lymph node (CD4+ r=0.58, CD8+ r=0.70) and spleen (CD4+ r=0.44, CD8+ r=0.69), 
and strong positive correlation between percentage effector memory CD4+ and CD8+ T 
lymphocytes throughout all tissues (Pearson r values between 0.59 and 0.94). 
 
Of the seven chimeras with a blood T:B lymphocyte ratio greater than 2.0, four had been 
identified as showing signs of spontaneous illness and were culled according to UK Home 
Office regulations (Figure 3.6, discussed in sections 2.2.1 and 3.3.3). 
 
Based on these observations, we conclude that deletion of betaglycan from T lymphocytes 
results in no significant deficit in resting lymphocyte populations, but may induce a variable 
state of increased lymphocyte activation at rest. 
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Table 4.1 Correlation matrix for pooled phenotypic data. Pearson r value (r) and p-value 
for correlation between T;B (CD3:CD19) ratio, percentage effector memory 
(CD44highCD62L-) CD4+ and CD8+. NS p>0.05 * p<0.05, ** p<0.01.  
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4.3.2 Betaglycan deficiency has a variable effect on Th1 polarisation in 
resting T lymphocyte populations but has no influence on Treg or 
Th17 proportions 
 
Having demonstrated a variable role for betaglycan in regulation of T lymphocyte activation 
levels at rest, we next wished to determine whether betaglycan had a role in maintenance of 
CD4+ T lymphocyte subsets at rest. Cell suspensions were generated from lymph node and 
spleen according to the method described previously (Section 2.2.3.1) and comparison made 
between cells of betaglycan knock-out and wild-type origin.  
 
Proportions of Treg (CD3+CD4+FoxP3+) were determined in both naïve and effector 
memory populations, and proportions of Th1 (CD3+CD4+IL17-IFNγ+) and Th17 
(CD3+CD4+IL17+IFNγ-) determined in both naïve (CD44low) and memory (CD44high) 
populations according to the flow cytometry protocols as previously described (Table 2.5). 
Since it was necessary to re-stimulate cells prior to staining for secreted cytokines (section 
2.2.4.3), CD62L was down regulated for all samples and it was therefore not possible to 
distinguish between effector memory and central memory populations in these analyses. 
Example flow cytometry gating strategies are shown in figures 4.5 to 4.6. 
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Figure 4.5 Identification of FoxP3+ Treg lymphocyte populations by flow cytometry. 
Lymphocytes were first identified by their forward scatter (FSc) and side scatter (SSc) profile, 
doublets excluded by gating on pulse width, CD4+ T lymphocytes identified by gating on 
CD3+ and CD4+, and FoxP3+ Treg populations identified for both the total CD4+ T 
lymphocyte population and the effector memory (CD44highCD62L-) populations. Data 
shown for splenocytes of wild-type chimeric mice at 8 weeks post cell transfer. Numbers in 
gates represent percentages for displayed sample. FSc / SSc presented on linear axes. All 
other plots presented on logarithmic axes.  
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Figure 4.6 Identification of IFNγ+ Th1 and IL17+ Th17 lymphocyte populations by flow 
cytometry. Lymphocytes were first identified by their forward scatter (FSc) and side scatter 
(SSc) profile, doublets excluded by gating on pulse width, CD4+ T lymphocytes identified by 
gating on CD3+ and CD4+, and IFNγ+ Th1 populations and IL17+ Th17 populations 
identified for both the total CD4+ T lymphocyte population and memory (CD44high 
populations). Data shown for splenocytes of wild-type chimeric mice at 8 weeks post cell 
transfer. Numbers in gates represent percentages for displayed sample. FSc / SSc presented on 
linear axes. All other plots presented on logarithmic axes. 
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A statistically significant increase in the percentage of resident lymph node IFNγ+ Th1 
lymphocytes was observed between TGFβRIII -/- and TGFβRIII +/+ chimeras when 
expressed both as a percentage of total CD3+CD4+ T lymphocytes (median 2.65% and 1.15% 
respectively, p<0.05) (Figure 4.7), and when expressed as a percentage of only the memory 
CD3+CD4+CD44+ T lymphocyte population (median 7.10% and 3.00% respectively, 
p<0.05) (Figure 4.8). A similar trend was observed for resident splenic Th1 lymphocyte 
populations in these analyses, although this did not achieve statistical significance. We 
observed no statistically significant difference in percentages of FoxP3+ Treg or IL17+ Th17 
lymphocytes between genotypes in either spleen or lymph node cell suspensions.  
 
Based on these observations, we conclude that betaglycan has no role in regulation of Treg or 
Th17 lymphocyte populations at rest, but may have a subtle role in regulation of Th1 
lymphocyte subsets, perhaps acting to limit both Th1 polarisation and activation to an effector 
phenotype under resting conditions. 
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Figure 4.7 Betaglycan deficiency results in a statistically significant increase in lymph 
node Th1 populations at rest. Relative proportions of Treg (FoxP3+), Th17 (IL17+IFNγ-) 
and Th1 (IL17-IFNγ+) T lymphocytes shown for blood, lymph node and splenic populations 
expressed as percentage of total CD3+CD4+ population. Lymph node samples were pooled 
from all available nodes. Results of flow cytometric analysis by transcription factor (FoxP3) 
and cytokine (IL17 and IFNγ) staining shown. Pooled data displayed for all animals culled at 
time points 6-18 weeks post-reconstitution; n=6-11 TGFβRIII+/+, n=6-11 TGFβRIII +/-, n=6-
15 TGFβRIII-/-. Data points represent individual animals; line indicates median value. 
*p<0.05 comparisons using Kruskal-Wallis test with Dunn’s multiple comparison post test.  
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Figure 4.8 Betaglycan deficiency results in a statistically significant increase in lymph 
node memory Th1 populations at rest. Relative proportions of Treg (FoxP3+) expressed as 
percentage of the effector memory T lymphocyte population (CD3+CD4+CD44+CD62L-), 
and Th17 (IL17+IFNγ-) and Th1 (IL17-IFNγ+) expressed as percentage of memory T 
lymphocyte population (CD3+CD4+CD44+) shown for blood, lymph node and splenic 
populations. Lymph node samples were pooled from all available nodes. Results of flow 
cytometric analysis by transcription factor (FoxP3) and cytokine (IL17 and IFNγ) staining 
shown. Pooled data displayed for all animals culled at time points 6-18 weeks post-
reconstitution; n=6-11 TGFβRIII+/+, n=6-11 TGFβRIII +/-, n=6-15 TGFβRIII-/-. Data points 
represent individual animals; line indicates median value. *p<0.05 comparisons using 
Kruskal-Wallis test with Dunn’s multiple comparison post test.  
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4.3.3 Loss of betaglycan does not result in an autoimmune phenotype 
 
In order to determine whether betaglycan was involved in maintenance of immune tolerance 
and protection from autoimmune pathology, we wished to assess the level of circulating 
autoantibodies in our experimental animals, comparing antibody titres between betaglycan 
knock-out and control animals. Serum from chimeric animals was extracted according to the 
method described previously (Section 2.2.3.1.2) and tested for the presence of circulating 
autoantibodies according to the previously described protocol (Section 2.2.5.1). Comparison 
was made between knock-out, heterozygous and wild-type chimeras (n=4 per genotype), 
using serum collected from animal 8 weeks post-reconstitution. 
 
No autoantibody staining was observed with serum of TGFβRIII -/-, TGFβRIII +/- or 
TGFβRIII +/+ chimeras at any of the tested dilutions (Figure 4.9). No differences were 
observed between serum samples of any two of the tested samples. 
 
These observations suggest that there is no evidence of autoimmune mediated pathology in 
our betaglycan-deficient chimeras. 
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Figure 4.9 Circulating autoantibodies were not demonstrated in the serum of 
experimental mice. Commercial rat liver, kidney and stomach slides and staining kit 
(Cambridge Life Sciences, Ely, Cambridgeshire, UK) were used to assess for anti-nuclear, 
anti-mitochondrial, anti-smooth muscle and anti-gastric parietal cell antibodies in serum from 
betaglycan chimeric mice. Example tissue sections showing positive control staining with 
serum from a roquin knock-out mouse and no discernible staining using serum from 
TGFβRIII -/-, TGFβRIII +/- or TGFβRIII +/+ chimeras at 1/10 dilution (n=4 per genotype, 
serum extracted at 8 weeks post-reconstitution). For each chimeric sample, two areas of the 
slide are shown to include stomach (top row), liver (top row) and kidney tissue (bottom row) 
confirming no staining in any area at 20x magnification. 
  
Positive control 
TGFβRIII -/- TGFβRIII +/- TGFβRIII +/+ 
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4.3.4 Secondary lymphoid tissue anatomy is preserved under conditions of 
betaglycan deficiency 
 
To determine whether betaglycan was necessary for establishment of secondary lymphoid 
tissues, we investigated splenic and lymph node anatomy in our experimental mice, 
comparing tissues derived from animals of different genotype. 
 
Our first objective was to determine the cellularity of secondary lymphoid tissues. The size 
and cellularity of a lymph node varies with the level of immune activation, whilst the size of 
the spleen remains relatively constant under normal resting conditions. We therefore chose to 
assess only splenic cellularity in our experimental mice. Cell counts were performed 
following generation of splenic lymphocyte suspensions according to the method as 
previously described (section 2.2.3.1).  
 
Splenic cell count was assessed at a range of time points from 6 to 18 weeks and data pooled, 
demonstrating no statistically significant difference in spleen cell count between knock-out, 
heterozygous or wild-type chimeras (Figure 4.10). This suggests that betaglycan is not 
required for establishment or maintenance of splenic cellularity at rest. 
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Figure 4.10 Betaglycan is not involved in regulation of splenic cellularity. Column chart 
illustrating pooled splenic cell count stratified by genotype. Data points represent individual 
animals; line indicates median value. P>0.05 for all comparisons using Kruskal-Wallis test 
with Dunn’s multiple comparison post test. n=12 TGFβRIII -/-, n=7 TGFβRIII+/-, n=15 
TGFβRIII+/+. 
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Having demonstrated that there was no difference in splenic cellularity between genotype, we 
next wished to determine whether betaglycan was necessary for establishment of normal 
tissue micro-anatomy in secondary lymphoid organs. 
 
Spleen and lymph node tissue sections were generated according to the method described 
previously (Section 2.2.3.2) and stained with a selection of T lymphocyte markers (antibodies 
to CD3 and CD4), B lymphocyte markers (antibodies to B220, IgM, and IgD) and germinal 
centres (PNA) according to the previously described method (Section 2.2.5.2). Tissue sections 
from 4 TGFβRIII -/- chimeras were compared with sections from 4 age-matched control 
animals (age 12 weeks post-cell transfer, n=2 TGFβRIII +/- chimeras, n=2 TGFβRIII +/+ 
chimeras). Spleen sections were quantitatively analysed to calculate white pulp, T zone, B cell 
and germinal centre areas, and co-expression of IgD and IgM as previously described (Section 
2.2.5.3) 
 
Chimeric mice developed secondary lymphoid tissues with no obvious architectural defects. T 
and B-zones were observed in both spleen (Figure 4.11) and lymph node sections (Figure 
4.12). On qualitative review, both spleen and lymph node sections appeared anatomically 
‘normal’ across all genotypes, with spleen sections demonstrating identifiable red pulp areas, 
white-pulp areas, marginal zones and germinal centres, and lymph nodes demonstrating 
identifiable B lymphocyte (primary lymphoid follicles) and T lymphocyte (paracortical) 
areas. 
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Figure 4.11 Betaglycan is not required for development of normal splenic micro-
anatomy. Representative splenic tissue sections from TGFβRIII -/- (n=4), TGFβRIII +/- 
(n=2) and TGFβRIII +/+ (n=2) chimeras assessed at 12 weeks post cell transfer. Example 
immunofluorescent staining for CD3 (green) / CD4 (red) / B220 (blue) (top row) and IgM 
(green) / PNA (red) / IgD (blue) (bottom row). Images acquired at 10x magnification. 
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Figure 4.12 Betaglycan is not required for development of normal lymph node micro-
anatomy. Representative lymph node tissue sections from TGFβRIII -/- (n=4), TGFβRIII +/- 
(n=2) and TGFβRIII +/+ (n=2) chimeras assessed at 12 weeks post cell transfer. Example 
immunofluorescent staining for CD3 (green) / CD4 (red) / B220 (blue) (top row) and IgM 
(green) / PNA (red) / IgD (blue) (bottom row). Images acquired at 10x magnification. 
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No statistically significant differences were observed in T zone, B zone or germinal centre 
area (measured in um2) between splenic sections from TGFβRIII -/-, TGFβRIII +/- or 
TGFβRIII +/+ chimeras. Furthermore, no statistically significant difference was observed in 
co-expression of IgM and IgD between splenic sections from chimeras of different genotype 
(Figure 4.13). 
 
These observations suggest that betaglycan is not required for development of secondary 
lymphoid tissues in our experimental mice.  
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Figure 4.13 No statistically significant differences were observed in quantitative 
assessment of splenic anatomy between animals of different genotype. Tissue sections 
from 4 TGFβRIII -/- chimeras, 2 TGFβRIII +/- chimeras and 2 TGFβRIII +/+ chimeras. Two 
independent assessors each reviewed three pre-determined representative white pulp areas on 
each slide. Assessors were masked to the genotype of the animals. Measurements of area were 
accepted if the difference between independent assessors was within 10% of the smaller 
measurement. For differences greater than 10%, tissue sections were reassessed until 
agreement was reached. Data points represent the mean average measurement of both 
assessors; line indicates median value. Data shown for A white pulp area B T-zone area C B-
zone area and D germinal centre area. E Data points represent % total slide area for IgD and 
IgM co-expression. p>0.05 for all comparisons using Kruskal-Wallis test with Dunn’s 
multiple comparison post test. 
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4.4 Discussion 
 
We present the first data describing the role of betaglycan in lymphocyte responses in an 
experimental animal model. Under resting conditions we have been able to characterise T 
lymphocyte activation levels, relative proportions of T lymphocyte subsets and secondary 
lymphoid organ structure in the presence and absence of betaglycan. We have also been able 
to assess for the role of betaglycan in development of autoimmune disease. 
 
We observed no statistically significant difference in T:B lymphocyte or CD4:CD8 T 
lymphocyte ratios across our experimental groups (Figure 4.2). We can therefore conclude 
that naïve betaglycan-deficient foetal liver chimeras show no obvious deficit in resident 
proportions of either T or B lymphocytes, or CD4+ or CD8+ T lymphocytes, being 
phenotypically similar to heterozygous and wild-type chimeras. Betaglycan thus appears to 
play no role in the establishment of resting lymphocyte populations in naïve animals. We did 
however observe a statistically significant increase in the percentage of resident splenic 
effector memory CD8+ T lymphocytes in betaglycan-deficient animals (Figure 4.4), with a 
trend towards increased percentages of effector memory CD4+ and CD8+ T lymphocytes 
accompanied by a reciprocal reduction in naïve T lymphocyte percentages across all tissues, 
although this did not achieve statistical significance (Figures 4.3 to 4.4). This suggests that 
betaglycan may be involved in regulation of activity levels of resident T lymphocytes, 
although any potential role appears highly variable, and subtle at best.  
 
This consequences of betaglycan deficiency appear similar to those of targeted TGFβRII 
deletion on CD4+ and CD8+ T lymphocytes as previously reported (Gorelik & Flavell 2000); 
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mice expressing dnTGFβRII under the control of a CD4 promoter demonstrated almost 
complete absence of naïve CD44lowCD62L+ CD4+ and CD8+ T lymphocytes in secondary 
lymphoid tissues with a dramatic increase in effector memory CD44highCD62L- populations. 
Over 90% of T lymphocytes displayed a memory phenotype (CD44high) in this model. 
Similar, less dramatic alteration of activation levels were observed under conditions of 
betaglycan deficiency, suggesting that betaglycan is involved in similar TGFβ-dependent 
lymphocyte responses, but has a more minor role in the signalling process. 
 
Significant populations of outliers emerged in our data; these outliers could be observed 
across all genotypes, and were characterised by increased percentages of CD3+ T 
lymphocytes, increased percentages of CD4+ lymphocytes with a reciprocal reduction in 
CD8+ proportions, and increased effector memory CD4+ and CD8+ T lymphocytes with a 
reciprocal reduction in naïve T lymphocyte populations (Table 4.1). These outliers can thus 
be described as displaying a state of high immune activation, suggesting the occurrence of 
sporadic disease within our experimental colonies. As previously discussed (Section 3.4), 
animals were housed in a ‘specific pathogen free’ facility, which whilst free of a specified list 
of potential pathogens was not completely sterile, and animals remained susceptible to 
infection by other non-specified pathogens. The occurrence of spontaneous immune 
activation correlates with the observation of a rate of spontaneous attrition across 
experimental colonies as previously described (Figure 3.6). Furthermore, of the seven animals 
identified with blood T:B lymphocyte fraction greater than 2.0, four had been culled after 
being identified as showing external evidence of illness according to Home Office criteria. 
We therefore conclude that these outliers represent animals succumbing to disease caused by 
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resident pathogens in the animal facility, and cannot attribute this to the presence or absence 
of betaglycan on resident T and B lymphocytes. 
 
Even after accounting for these extreme outliers, significant variation was still observed 
within similar genotypic groups of experimental animals across all experiments, which 
reduced our ability to draw statistically significant conclusions from our data. This is likely to 
represent variable reconstitution of our chimeric mice following irradiation and cell transfer. 
As previously discussed, chimeras were generated through transfer of foetal liver cell 
suspensions, derived from embryos produced through timed mating between betaglycan 
heterozygote mice, with donor embryos harvested between day 12 and 14 gestation. The 
gestational age of the embryos at the point of maternal sacrifice determined the size of the 
developing liver and the number of cells available for transfer to a RAG/BoyJ host, with 
animals sacrificed at day 12 having smaller embryonic livers than those sacrificed at day 14.  
 
The process whereby start-dates of successful pregnancies were determined introduced further 
variation in the number of cells available for transfer. Timed matings were created by 
technicians working within ; animals identified as mates 
were housed together until a vaginal plug was observed in the female, at which point mating 
was deemed to have taken place. The number of days of gestation were counted from this 
point, with the day of first observation of the vaginal plug being counted as day zero. Since 
animals were only usually observed once daily, there was potential for up to a 24 hour delay 
in noticing the vaginal plug. Furthermore, whilst the presence of a vaginal plug is a reliable 
indicator of mating, this may not correspond to the day of implantation of a fertilised embryo. 
This again introduced variation in the size of the embryonic liver by the time of sacrifice. 
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To maximise the chance of successful reconstitution, the entire cell suspension generated 
from the foetal liver was transferred to the host RAG/BoyJ mouse; there was no 
standardisation of the number of cells transferred, with some hosts potentially receiving 
significantly larger numbers of embryonic stem cells than others. This is likely to have 
affected the speed and extent of reconstitution of lymphocyte populations following cell 
transfer, and may further explain the variability in our experimental groups. 
 
A statistically significant increase in the percentage of resident lymph node Th1 lymphocytes 
was observed in betaglycan deficient chimeras compared to wild-type chimeras, with a 
similar non-statistically significant trend observed in splenic populations (Figures 4.7 to 4.8). 
This is consistent with observations of previous murine studies. Experimental autoimmune 
uveitis (EAU), is characterised by a predominant Th1-driven immune response within the eye 
(Xu et al. 1997); TGFβ has been shown to suppress both IFNγ production and proliferation of 
Th1 cells derived from lymph nodes of recently immunised mice with EAU (Xu et al. 2003). 
Furthermore, TGFβ1 from local T lymphocytes has been shown to down-regulate Th1 
differentiation in experimental autoimmune encephalomyelitis (EAE) and experimental colitis 
(Li et al. 2007; Gutcher et al. 2011). Our data suggests that betaglycan deficiency impairs this 
immunosuppressive function of TGFβ on Th1 lymphocytes, and provides evidence that 
betaglycan is therefore involved in TGFβ signalling to lymphocytes.  
 
No statistically significant differences were observed in the percentage of Th17 or Treg 
lymphocytes in either spleen or lymph node, suggesting that betaglycan is not involved in 
Th17 or Treg responses in naïve animals (Figure 4.7 to 4.8). These results are surprising, 
since TGFβ has been implicated in differentiation of naïve T lymphocytes in vitro to both 
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Th17 (Korn, Oukka, et al. 2007; Rubtsov & Rudensky 2007; Mangan et al. 2006; Bettelli et 
al. 2006; Veldhoen et al. 2006) and Treg (Li & Flavell 2008; Wan & Flavell 2007; Ming O Li 
et al. 2006; Chen et al. 2003). It is possible that no difference was observed in these subsets as 
a result of our experimental animals being naïve; in the absence of antigenic challenge it is 
unlikely that animals would display a strong polarisation of either a pathogenic Th17 or 
immunosuppressive Treg response, and thus differences between genotypes may exist but not 
be apparent. This theory is investigated in more detail through controlled antigenic challenge 
of our animals in section 5.3.3. 
 
The observed differences in lymphocyte subsets do not appear to be a manifestation of 
autoimmunity, since we were unable to demonstrate the presence of anti-nuclear, anti-
mitochondrial, anti-smooth muscle or anti-gastric parietal cell antibodies in the serum of our 
chimeras at a range of dilutions from 1/10 to 1/160 (Figure 4.9). Furthermore, no significant 
differences were observed in size or functional anatomy of spleens between animals of 
different genotypes (Figures 4.10 to 4.11, figure 4.13). Quantitative assessment of lymph 
node anatomy was not possible due to wide variation in the quality of tissue sections, however 
again, no obvious gross differences in T or B lymphocyte areas were observed between 
animals of different genotype (Figure 4.12). The subtle phenotypic differences observed in 
our betaglycan-deficient chimeras and lack of obvious secondary tissue damage is also in 
stark contrast to previously published models of autoimmunity, such as those resulting from 
knock-out of FoxP3 (Brunkow et al. 2001), TGFβ1 (Wahl et al. 2000; Kulkarni et al. 1993; 
Shull et al. 1992) and CTLA-4 (Waterhouse et al. 1995), each of which results in lethal 
lymphoproliferative disease in all knock-out offspring. If betaglycan deficiency did induce 
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autoimmune lymphoproliferative disease, it would be expected in all betaglycan knock-outs, 
with similar severity in every example. 
 
Collectively, these observations suggest that betaglycan may have a role in immune 
regulation, potentially facilitating TGFβ signalling in regulation of CD4+ and CD8+ T 
lymphocyte activation levels, and contributing to the control of Th1 immune responses. The 
degree of immune dysregulation induced in our betaglycan deficient chimeras was however 
considered mild, with no gross external evidence of inflammatory disease, and no evidence of 
inflammatory infiltrates in secondary lymphoid tissues (see also section 3.3.3). The absence 
of widespread systemic inflammatory disease in betaglycan-deficient chimeras is consistent 
with our current understanding of the role of betaglycan in TGFβ-mediated processes; since 
betaglycan has been shown to be predominantly required for signal transduction by TGFβ2 
(Cheifetz et al. 1990; Sankar et al. 1995; Sarraj et al. 2013), we would expect betaglycan 
deficiency to cause significant immune dysregulation in environments where TGFβ2 is the 
predominant isoform, but not in those where TGFβ1 or TGFβ3 predominates. Since TGFβ1 is 
thought to be the predominant isoform acting in the murine immune system (Rubtsov & 
Rudensky 2007), any potential effect of betaglycan deficiency on TGFβ2 signalling is likely 
to be masked when assessing systemic immune responses.  
 
The interpretation of our experimental findings is limited by the predominantly negative data, 
and wide variability between genotypically similar experimental animals. We therefore 
conclude that betaglycan may have a role in regulation of T lymphocyte activation and 
polarisation, but acknowledge that any potential role for betaglycan in the regulation of 
resting lymphocyte populations is likely to be subtle.   
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5 INVESTIGATING THE ROLE OF BETAGLYCAN IN 
REGULATION OF ACTIVATED T LYMPHOCYTE 
POPULATIONS 
 
5.1 Introduction 
 
In-vitro assays of the role of TGFβ in lymphocyte biology have demonstrated it to act as a 
negative regulator of cell proliferation with the ability to induce iTreg differentiation of naïve 
T lymphocytes; TGFβ was first shown to suppress T lymphocyte proliferation through 
inhibition of IL-2 receptor expression (Kehrl et al. 1986), and later to induce FoxP3 
expression and differentiation of naïve T lymphocytes to a regulatory phenotype (iTreg) (Li & 
Flavell 2008; Wan & Flavell 2007; Ming O Li et al. 2006; Chen et al. 2003). More recently, it 
has been suggested that TGFβ dampens the effect of CD28 signalling to T lymphocytes, 
inhibiting growth and proliferation of CD4+ T lymphocytes (Delisle et al. 2013). 
Paradoxically, TGFβ is also able to mediate pro-inflammatory lymphocyte responses; when 
present at lower levels than those necessary for FoxP3 induction, and with co-stimulation by 
IL-6, TGFβ will induce differentiation of naïve T lymphocytes to a potentially destructive 
Th17 phenotype (Korn, Oukka, et al. 2007; Rubtsov & Rudensky 2007; Mangan et al. 2006; 
Bettelli et al. 2006; Veldhoen et al. 2006). 
 
Extrapolation of these in vitro observations suggests that lymphocyte responses to TGFβ 
signalling in vivo are highly dependent on the nature of co-stimulation at the time of ligand 
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binding, enabling both disease and site-specific effects. Indeed, TGFβ is considered a crucial 
cytokine in diverse disease processes such as uveitis and EAE (Zhou et al. 2012; Zhou et al. 
2011; Denniston et al. 2011; Curnow et al. 2005), MS and EAE (Axtell et al. 2010; Issazadeh 
et al. 1996; O’Connor et al. 2007; Zorzella-Pezavento et al. 2013; Yoshida et al. 2014), and 
inflammatory bowel disease and murine colitis (Dignass & Podolsky 1993; Babyatsky et al. 
1996; Kobayashi et al. 2008; Olsen et al. 2011; Siakavellas & Bamias 2012; Wedebye 
Schmidt et al. 2013; Mottet et al. 2003; Fantini et al. 2006), with variable involvement of 
Th17 and Treg CD4+ lymphocytes in all examples. In each of these disease processes, TGFβ 
mediates its varying effects by signalling through a common cell surface receptor, where 
intracellular signalling is initiated after phosphorylation of TGFβRI and TGFβRII by TGFβ  
(Souchelnytskyi et al. 1996; Kang et al. 2009; Santibañez et al. 2011).  
 
The role of betaglycan has not yet been investigated in these processes, either in vitro or in 
vivo. It has previously been shown that whilst all isoforms of TGFβ have a similar affinity for 
betaglycan, TGFβ2 is of significantly lower affinity for TGFβRI and TGFβRII than TGFβ1 or 
TGFβ3. Furthermore, in cell lines lacking betaglycan, TGFβ2 has reduced potency in growth 
inhibition assays whilst the relative potency of TGFβ1 and TGFβ3 is unaffected (Cheifetz et 
al. 1990). It has thus been suggested that betaglycan is necessary for TGFβ2 signalling via the 
cell surface receptor, acting to concentrate ligand in a favourable conformation at the cell 
surface, but may be considered unnecessary for signalling by TGFβ1 and TGFβ3. Existing 
data is however limited to investigation of non-lymphocyte cell lines (López-Casillas et al. 
1993; Cheifetz et al. 1990) and the role of betaglycan in TGFβ signalling has not previously 
been investigated in T lymphocyte-specific assays. Furthermore, due to the lack of a suitable 
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experimental system, there have been no in vivo studies of betaglycan in either site or disease-
specific models. 
 
We wished to address these shortcomings; using our novel experimental model of targeted 
betaglycan deficiency, we first created in vitro iTreg polarisation assays using purified 
lymphocyte populations derived from lymph node and spleen of betaglycan-deficient and 
betaglycan-sufficient mice. Induction of iTreg from naïve T lymphocytes is accurately 
quantified by assessment of FoxP3 expression (Vignali et al. 2009); FoxP3 induction in naïve 
T lymphocytes can thus be considered a surrogate marker of successful TGFβ signalling. We 
therefore compared FoxP3 induction in naïve T lymphocytes by all isoforms of TGFβ in the 
presence and absence of betaglycan.  
 
We next wished to assess the role of betaglycan in TGFβ-dependent T lymphocyte responses 
in vivo, using an experimental model of controlled antigenic challenge in which Treg and 
Th17 polarisation could be compared between betaglycan-deficient and betaglycan-sufficient 
animals. To determine the most appropriate model in which to assess Treg and Th17 
responses, a series of pilot experiments were initially performed assessing T lymphocyte 
induction following antigenic challenge by 2W1S peptide and adjuvants of either attenuated 
L. monocytogenes, IFA or S. typhi porins according to the methods described in section 2.2.6. 
 
L. monocytogenes is a gram-positive bacterium which is widely used as an adjuvant in 
antigenic challenge in mammals, allowing detailed study of the immune response to bacterial 
infection.  It is known to induce a strong CD8+ T lymphocyte response, with a relatively 
small CD4+ T lymphocyte component (Pamer 2004). This model was not expected to induce 
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a strong Th17 or Treg response; it was however included in pilot studies as a baseline 
assessment with which to compare more targeted antigenic challenges.  
 
IFA has been widely used as an adjuvant in experimental protocols for induction of immune 
disease in laboratory animals; it is an emulsion of paraffin oil containing mannide mono-
oleate as a surfactant (Billiau & Matthys 2001). It is known to induce a strong CD4+ Th1 / 
Th2 response (Chang et al. 1998), and has been shown to induce Th17 cells in C57BL/6 mice 
(Nian et al. 2012).  
 
Many gram-negative bacteria express outer membrane proteins, which are highly 
immunogenic and able to elicit strong immune responses in mice (Singh et al. 1999; Isibasi et 
al. 1992; Secundino et al. 2006; Cervantes-Barragán et al. 2009). In humans, antibodies 
against pore forming outer membrane proteins (porins) can be found in patients recovering 
from S. typhi infection, which can be purified and produced on a large scale (Salazar-
González et al. 2004). Such porins have been demonstrated to promote CD4+ T lymphocyte 
responses when used as an adjuvant in antigenic challenge of C57BL/6 mice, characterised by 
production of both IFNγ and IL-17 (Perez-Shibayama et al. 2014).  
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5.2 Experimental design 
 
For all in vitro polarisation assays, cell suspensions were generated from lymph node and 
spleen according to the method described in section 2.2.3.1. For all experiments, betaglycan 
knock-out (KO) samples were pooled from between 3-6 TGFβRIII -/- chimeras, and 
betaglycan wild-type (WT) samples pooled from between 3-6 TGFβRIII +/+ chimeras, 
enabling between 2-6 replicates for each culture condition depending on total cell number 
available.  All experimental animals were matched for age and gender. Naïve T lymphocytes 
were stimulated and grown under the iTreg polarising conditions as described in section 
2.2.7.2 and FoxP3 assessed at day 4. Cells were cultured with individual isoforms of TGFβ 
(1,2 or 3) at physiological dilutions (3.0ng/ml to 0.1ng/ml at Log3 dilutions). Control 
conditions of un-stimulated cells and cultures lacking TGFβ were also assessed.  
 
Naïve CD4+ T lymphocytes were initially purified using the MACS CD4+CD62L+ T 
Lymphocyte II kit according to the previously described method (Section 2.2.7.1) however 
the resulting purity of cell samples was deemed to be unacceptably low, with a mean post-sort 
purity of naïve CD4+ T lymphocytes of 59.15%, and a lowest recorded purity of 20.87%. As 
a result, purification was subsequently performed by FACS according to the method 
described previously (Section 2.2.7.1) resulting in a mean purity of naïve CD4+ T 
lymphocytes of 89.14%, and a minimum purity of 77.19% (Figure 5.1).  
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Figure 5.1 Identification of naïve CD4+ T lymphocytes by flow cytometry and purity of 
sorted cells. A Example flow cytometry data shown for pooled cell sample pre-sort (top row) 
and post-sort (bottom row) for FACS-sorted wild-type cells. Cell suspension generated from 
lymph node and spleen as previously described (section 2.2.3.1). Live lymphocytes were first 
identified according to their forward-scatter (FSs) / side-scatter (SSs) profile, doublets 
excluded according to pulse-width, then CD4+ populations identified by positive selection. 
Naïve cells were identified first by lack of CD25 expression (CD25-), and further defined by 
positive selection of L-selectin positive CD44 low populations (CD44lowCD62L+). Numbers 
in gates represent percentages as a proportion of events on each individual plot for displayed 
sample. FSc / SSc presented on linear axes. All other plots presented on logarithmic axes. B 
Mean purity (range shown in brackets) of CD4+, CD25-, and naïve (CD44lowCD62L+) 
CD4+CD25- cell populations pre- and post-sort, comparing MACS and FACS sorted 
populations. Percentages expressed as a proportion of total cell population. n=number of 
samples analysed. 
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T lymphocyte responses in chimeric mice were assessed following controlled immune 
challenge according to the methods described previously (Section 2.2.6). For all 
immunisations, a known quantity of adjuvant was administered with a known quantity of 
2W1S peptide antigen; this allowed assessment of both the peptide-specific T lymphocyte 
response (quantifying T lymphocyte responses specific for the 2W1S peptide, by staining 
cells with a fluorochrome-labelled 2W1S:I-Ab tetramer), and the non-specific T lymphocyte 
response. 
 
To avoid wastage of experimental animals, models of antigenic challenge were first tested in 
non-chimeric C57BL/6 mice to assess the efficacy of each adjuvant in induction of TGFβ-
dependent T lymphocyte responses. For these experiments 3-4 mice were immunised with 
antigen, and 3-4 age-matched mice immunised with PBS as control. Experiments were 
performed on two separate occasions and results pooled. All immune responses were assessed 
at day 7 following immunisation. 
 
For experiments involving chimeric mice, comparison was made between age-matched 
TGFβRIII +/+ (WT) and TGFβRIII -/- (KO) chimeras. For all experiments, 3 KO and 3 WT 
chimeric mice were immunised with antigen and adjuvant. In addition, 1-2 WT chimeras were 
immunised with PBS as negative controls, and 1-2 non-chimeric C57BL/6 mice were 
immunised with antigen and adjuvant as positive controls. All experiments were performed 
on two separate occasions and results pooled. All immune responses were assessed at day 7 
following immunisation. 
 
  
 159 
5.3 Results 
 
5.3.1 Betaglycan is not required for TGFβ-mediated iTreg induction in 
naïve T lymphocytes 
 
To first confirm viability of the assay and assess the effect of varying levels of stimulation, 
wild-type cell proliferation assays were created under iTreg polarising conditions as described 
in section 2.2.7.2 with anti-CD3 / anti-CD28 coated activation beads at a range of ratios from 
2:1 to 1:4 beads:cells, and TGFβ1 added across a range of physiological dilutions (Log3 
dilutions from a maximum of 3.0ng/ml to a minimum of 0.1ng/ml). Results were compared to 
control conditions in the absence of both TGFβ and activation beads. Cells were stained with 
an eF450 proliferation dye and proliferation assessed at day 4 (Figure 5.2). 
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Figure 5.2 Proliferation of wild-type naïve CD4+ T lymphocytes under varying levels of 
stimulation with Log3 dilutions of TGFβ1. Wild-type lymph node cell suspensions derived 
from C57BL/6 mice and FACS sorted to naïve CD4+CD25-CD44lowCD62L+ population 
stimulated with anti-CD3 / anti-CD28 coated activation beads at range of ratios shown. IL2 
added to all cultures at concentration of 50U/ml. TGFβ added at Log3 dilutions from 
3.0mg/ml to 0.1ng/ml. Control conditions in absence of activation beads and TGFβ also 
shown. Proliferation assessed at day 4. A Flow cytometry gating strategy used for 
identification of proliferating lymphocytes in all in vitro assays: Live lymphocytes were first 
identified according to their forward-scatter (FSc) / side-scatter (SSc) profile, doublets 
excluded according to pulse-width, then CD4+ T lymphocytes identified by positive selection 
of CD3+CD4+ cells. FSc / SSc presented on linear axes. All other plots presented on 
logarithmic axes. B Cell proliferation was assessed at day 4 by reducing intensity of eF450 
proliferation dye staining. Proliferation presented on linear scale.  
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Level of stimulation was determined by the percentage of proliferating cells, and differential 
response to varying concentrations of TGFβ assessed by calculating the range of percentage 
proliferating cells for each level of stimulation (maximum – minimum) (Table 5.1).  
 
Whilst a ratio of 2:1 beads:cells achieved the highest levels of stimulation (65.41% – 
71.73%), the differential response to varying concentrations of TGFβ was small (9.62%), 
suggesting that this level of stimulation was sufficient to overcome any subtle influence of 
additional TGFβ. The greatest differential response was observed with a ratio of 1:1 
beads:cells (34.55%), with stimulation ranging from 44.40% - 59.32%%. Both level of 
stimulation and differential response decreased with lower levels ratios of beads:cells.  
 
Interestingly, the number of proliferating cells increased with the addition of TGFβ in most 
assays, with the greatest number of proliferating cells observed on the addition of TGFβ at a 
concentration of 1.0ng/ml and a 1:1 ratio of beads:cells. This is perhaps surprising since 
TGFβ is usually considered a potent suppressor of lymphocyte proliferation (Kehrl et al. 
1986), and most likely represents an effect of TGFβ-restriction of activation-induced cell 
death (Chen et al. 2001; Sanjabi et al. 2009). 
 
A ratio of 1:1 stimulation beads:cells was therefore adopted for all subsequent assays, with 
cells grown under iTreg polarising conditions as described previously (Section 2.2.7.2), and 
FoxP3 induction assessed at day 4. 
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Table 5.1 Cell proliferation increases with the concentration of activation beads whilst 
increasing concentration of TGFβ1 has variable effects. Table illustrating percentage and 
absolute number of proliferating cells in iTreg cultures used for assay optimisation. Wild-type 
lymphocytes derived from C57BL/6 mice and FACS sorted to naïve CD4+CD25-
CD44lowCD62L+ population stimulated with anti-CD3 / anti-CD28 coated activation beads 
at range of ratios shown. IL2 added to all cultures at concentration of 50U/ml. TGFβ added at 
Log3 dilutions from 3.0mg/ml to 0.1ng/ml. Control conditions in absence of activation beads 
and TGFβ also shown. Proliferation assessed at day 4. Range of values for percentage and 
absolute cell number shown for each level of stimulation (n=1 for each culture condition).  
Conc. 
TGFb1 
(ng/ml) 
Ratio stimulation beads : cells 
2:1 1:1 1:2 1:4 0 
% n % n % n % n % n 
3.00 71.73 81657 59.32 57438 51.29 44552 29.00 19862 3.67 2151 
1.00 72.75 72026 78.95 111238 39.42 24834 31.26 19841 1.89 1030 
0.30 75.03 76393 52.21 42171 61.33 54220 36.77 23939 2.04 928 
0.10 65.72 45336 58.48 41894 40.70 25917 34.22 18642 1.83 829 
0.00 65.41 41328 44.40 27922 44.01 30480 36.13 26829 2.00 1529 
Range 9.62 35065 34.55 83316 21.91 29386 7.77 4077 1.84 1322 
 163 
In order to determine whether betaglycan was necessary for TGFβ signalling to in naïve T 
lymphocytes in vitro, FoxP3 induction was first assessed by all isoforms of TGFβ at a 
concentration of 1.0ng/ml TGFβ. Sample flow cytometry data is shown in figure 5.3 (gating 
strategy as shown in figure 5.2). Data for three individual experiments is presented in figure 
5.4, in addition to graphical representation of pooled data for percentage FoxP3+ cells in 
cultures from all three experiments combined. Data for cell number could not be pooled due 
to the significant variability between experiments performed on different days. 
 
FoxP3 induction was demonstrated with all isoforms of TGFβ in both WT and KO cell 
samples for TGFβ concentrations of 1.0ng/ml. Whilst there was a general trend towards 
TGFβ2 being less potent than either TGFβ1 or TGFβ3, no obvious trends were observed in 
the difference between the response of KO and WT cells to any isoform of TGFβ. 
Furthermore, no statistically significant difference was observed in either percentage or 
absolute number of FoxP3+ T lymphocytes between KO and WT cultures in response to any 
isoform of TGFβ using the Mann-Witney U-test (Figure 5.4).   
 
 164 
 
Figure 5.3 FoxP3 induction by TGFβ in naïve CD4+ T lymphocytes. Representative plots 
illustrating frequency of FoxP3+ iTreg lymphocytes in polarisation assays. Lymphocytes 
identified according to gating strategy shown in figure 5.2. WT Wild-type lymphocytes 
derived from lymph nodes of TGFβRIII +/+ chimeras KO Knock-out lymphocytes derived 
from lymph nodes of TGFβRIII -/- chimeras. Cells FACS sorted to naïve CD4+CD25-
CD44lowCD62L+ population and stimulated with anti-CD3 / anti-CD28 coated activation 
beads at a ratio of 1:1 beads:cells. IL2 added to all cultures at concentration of 50U/ml. 
TGFβ1, 2 and 3 added at concentration of 1.0ng/ml. Control conditions in absence of TGFβ 
also shown. Proliferation assessed at day 4. Range of values for percentage and absolute cell 
number shown for each level of stimulation (n=2-6 for each culture condition). 
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Figure 5.4 Betaglycan is not required for TGFβ-mediated FoxP3 induction in naïve 
CD4+ T lymphocytes in vitro (1). Column charts illustrating percentage FoxP3 induction 
(left) and absolute number of FoxP3+ CD4+ T lymphocytes (right). Data shown for 3 separate 
experiments (top 3 rows) and pooled data presented (bottom row). Lymphocytes identified 
according to gating strategy shown in figure 5.2. WT lymphocytes derived from lymph nodes 
of TGFβRIII +/+ chimeras KO lymphocytes derived from lymph nodes of TGFβRIII -/- 
chimeras. Cells FACS sorted to naïve CD4+CD25-CD44lowCD62L+ population and 
stimulated with anti-CD3 / anti-CD28 coated activation beads at a ratio of 1:1 beads:cells. IL2 
added to all cultures at concentration of 50U/ml. TGFβ1, 2 and 3 added at concentration of 
1.0ng/ml. Control conditions in absence of TGFβ also shown. Proliferation assessed at day 4. 
Data points represent individual cultures; line represents median value; p>0.05 for all 
comparisons between KO and WT samples using Mann-Witney U-test.  
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To determine whether these results were masking a more subtle dose-response effect, FoxP3 
induction was next assessed by culturing naïve T lymphocytes with all isoforms of TGFβ at a 
range of physiological dilutions of TGFβ from 3.0ng/ml to 0.1ng/ml (Log3 dilutions) and 
compared with cells cultured in the absence of TGFβ. Data for two individual experiments is 
presented in Figures 5.5 and 5.6.  
 
FoxP3 induction was demonstrated as a dose-dependent response to TGFβ, with all isoforms 
of TGFβ able to induce FoxP3 in both WT and KO samples. Again, we observed no obvious 
trend between WT and KO samples, and no statistically significant difference in either 
percentage FoxP3 induction or total FoxP3+ cell number between KO or WT cells across the 
range of physiological dilutions of TGFβ tested. We therefore conclude that betaglycan is not 
necessary for TGFβ-mediated iTreg induction in our assays. 
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Figure 5.5 Betaglycan is not required for TGFβ-mediated FoxP3 induction in naïve 
CD4+ T lymphocytes in vitro (2). Line graphs illustrating percentage FoxP3 induction (left) 
and absolute number of FoxP3+ CD4+ T lymphocytes (right). Data presented for experiment 
1 of 2. Lymphocytes identified according to gating strategy shown in figure 5.2. WT 
lymphocytes derived from lymph nodes of TGFβRIII +/+ chimeras (blue line, n=3) KO 
lymphocytes derived from lymph nodes of TGFβRIII -/- chimeras (red line, n=2). Cells FACS 
sorted to naïve CD4+CD25-CD44lowCD62L+ population and stimulated with anti-CD3 / 
anti-CD28 coated activation beads at a ratio of 1:1 beads:cells. IL2 added to all cultures at 
concentration of 50U/ml. TGFβ1, 2 and 3 added at Log3 dilutions from 3.0.0ng/ml to 
0.1ng/ml. Control conditions in absence of TGFβ also shown. Proliferation assessed at day 4. 
Data points represent median values for replicate cultures; p>0.05 for all comparisons 
between KO and WT samples using Mann-Witney U-test. 
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Figure 5.6 Betaglycan is not required for TGFβ-mediated FoxP3 induction in naïve 
CD4+ T lymphocytes in vitro (3). Line graphs illustrating percentage FoxP3 induction (left) 
and absolute number of FoxP3+ CD4+ T lymphocytes (right). Data presented for experiment 
2 of 2. Lymphocytes identified according to gating strategy shown in figure 5.2. WT 
lymphocytes derived from lymph nodes of TGFβRIII +/+ chimeras (blue line, n=2) KO 
lymphocytes derived from lymph nodes of TGFβRIII -/- chimeras (red line, n=2). Cells FACS 
sorted to naïve CD4+CD25-CD44lowCD62L+ population and stimulated with anti-CD3 / 
anti-CD28 coated activation beads at a ratio of 1:1 beads:cells. IL2 added to all cultures at 
concentration of 50U/ml. TGFβ1, 2 and 3 added at Log3 dilutions from 3.0.0ng/ml to 
0.1ng/ml. Control conditions in absence of TGFβ also shown. Proliferation assessed at day 4. 
Data points represent median values for replicate cultures; p>0.05 for all comparisons 
between KO and WT samples using Mann-Witney U-test. 
Experiment 2 
N=2 WT (blue) 
N=2 KO (red) 
Point indicates median 
TGFβ1 
TGFβ2  
TGFβ3 
0
20
40
60
80
100
0.1 0.3 1.0 3.0
Conc. (ng/ml)
%
 C
D
3+
CD
4+
Fo
xP
3+
0.1 0.3 1.0 3.0
0
50000
100000
150000
200000
250000
Conc. (ng/ml)
Ce
ll 
nu
m
be
r (
CD
3+
CD
4+
Fo
xP
3+
)
0
20
40
60
80
100
0.1 0.3 1.0 3.0
Conc. (ng/ml)
%
 C
D
3+
CD
4+
Fo
xP
3+
0.1 0.3 1.0 3.0
0
50000
100000
150000
200000
250000
Conc. (ng/ml)
Ce
ll 
nu
m
be
r (
CD
3+
CD
4+
Fo
xP
3+
)
0
20
40
60
80
100
0.1 0.3 1.0 3.0
Conc. (ng/ml)
%
 C
D
3+
CD
4+
Fo
xP
3+
0.1 0.3 1.0 3.0
0
50000
100000
150000
200000
250000
Conc. (ng/ml)
Ce
ll 
nu
m
be
r (
CD
3+
CD
4+
Fo
xP
3+
)
 169 
5.3.2 The extent of Treg and Th17 polarisation of lymphocyte populations 
in C57BL/6 mice is dependent on the method of antigenic challenge 
 
To determine an appropriate model for assessment of Treg and Th17 lymphocyte responses in 
our experimental mice, control experiments were performed in C57BL/6 mice using 2W1S 
peptide antigen and attenuated L. monocytogenes, IFA or S. typhi porins as adjuvants 
according to the methods described in section 2.2.6. Response to antigenic challenge was 
assessed by observation of T lymphocyte populations in draining lymphoid tissues, calculated 
as absolute number of cells per draining lymph node for challenge by 2W1S peptide with S. 
typhi porin and IFA (mean cell number per lymph node), or absolute number per whole spleen 
for challenge by 2W1S peptide with attenuated L. monocytogenes.  
 
For each method of antigenic challenge, we first determined the number of activated, peptide-
specific CD4+ T lymphocytes present (CD3+CD4+CD44+2W+), to give an overall indication 
of the success of antigenic induction. Within this population, we then determined the number 
of FoxP3+ and RORγ+ lymphocytes present. As previously discussed, both iTreg and nTreg 
can be identified by their expression of the transcription factor FoxP3 (Vignali et al. 2009), 
which is easily assessed through transcription factor staining by flow cytometry. Th17 cells 
can also be identified by transcription factor staining for RORγ, however this is considered 
less specific than staining for the cytokine IL-17 (Dong 2008). RORγ was accepted as a useful 
indicator of Th17 induction for the purpose of our pilot experiments. Example flow cytometry 
plots are shown for pilot experiments in Figures 5.7 to 5.9 with corresponding column charts 
illustrating pooled data for all experiments.  
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Figure 5.7 Polarisation of FoxP3+ and RORγ+ CD4+ T lymphocyte responses in 
C57BL/6 mice by L. monocytogenes and 2W1S peptide. Example flow cytometry gating 
strategy for identification of splenic peptide-specific T lymphocytes. Live lymphocytes were 
first identified according to their forward scatter (FSc) / side-scatter (SSc) profile, doublets 
excluded according to pulse-width (not shown), then CD4+ T lymphocytes identified by 
positive selection of CD3+CD4+ cells. Activated cells were identified by staining for CD44 
(CD44+) and peptide-specific cells identified by staining with 2W tetramer (2W+). Th17 
(FoxP3-RORγ+) and Treg (FoxP3+RORγ-) cells were identified from this population. FSc 
presented on linear axis. All other plots presented on logarithmic axes. Pooled pilot data 
shown for analysis at day 7 following antigenic challenge by attenuated Listeria 
monocytogenes and 2W1s peptide compared to PBS control (data for CD44+2W+ and 
FoxP3+ populations pooled from 2 experiments; n=6 per group. Data for RORγ+ populations 
from single experiment; n=2 per group). Cell number represents absolute number of cells per 
whole spleen. Data points represent individual animals. Line indicates median value.   
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Figure 5.8 Polarisation of FoxP3+ and RORγ+ CD4+ T lymphocyte responses in 
C57BL/6 mice by IFA and 2W1S peptide. Example flow cytometry gating strategy for 
identification of peptide-specific T lymphocytes in draining inguinal lymph nodes. Live 
lymphocytes were first identified according to their forward scatter (FSc) / side-scatter (SSc) 
profile, doublets excluded according to pulse-width (not shown), then CD4+ T lymphocytes 
identified by positive selection of CD3+CD4+ cells. Activated cells were identified by 
staining for CD44 (CD44+) and peptide-specific cells identified by staining with 2W tetramer 
(2W+). Th17 (FoxP3-RORγ+) and Treg (FoxP3+RORγ-) cells were identified from this 
population. FSc presented on linear axis. All other plots presented on logarithmic axes. 
Pooled pilot data shown for analysis at day 7 following antigenic challenge by IFA and 2W1s 
peptide compared to PBS control (data for CD44+2W+ and FoxP3+ populations pooled from 
2 experiments; n=8 per group. Data for RORγ+ populations from single experiment; n=3 per 
group). Cell number represents absolute number of cells per lymph node. Data points 
represent individual animals. Line indicates median value.   
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Figure 5.9 Polarisation of FoxP3+ and RORγ+ CD4+ T lymphocyte responses in 
C57BL/6 mice by S. typhi outer membrane porins and 2W1S peptide. Example flow 
cytometry gating strategy for identification of peptide-specific T lymphocytes in draining 
axillary and brachial lymph nodes. Live lymphocytes were first identified according to their 
forward scatter (FSc) / side-scatter (SSc) profile, doublets excluded according to pulse-width 
(not shown), then CD4+ T lymphocytes identified by positive selection of CD3+CD4+ cells. 
Activated cells were identified by staining for CD44 (CD44+) and peptide-specific cells 
identified by staining with 2W tetramer (2W+). Th17 (FoxP3-RORγ+) and Treg 
(FoxP3+RORγ-) cells were identified from this population. FSc presented on linear axis. All 
other plots presented on logarithmic axes. Pooled pilot data shown for analysis at day 7 
following antigenic challenge by Salmonella typhi outer membrane porins and 2W1S peptide 
compared to PBS control (data for CD44+2W+ and FoxP3+ populations pooled from 2 
experiments; n=6 per group).  Cell number represents absolute number of cells per lymph 
node. Data points represent individual animals. Line indicates median value. 
Po
rin PB
S
0
2000
4000
6000
8000
Antigen
Ce
ll 
nu
m
be
r
Po
rin PB
S
0
100
200
300
Antigen
Ce
ll 
nu
m
be
r
Po
rin PB
S
0
20
40
60
80
100
Antigen
Ce
ll 
nu
m
be
r
FSc 
SS
c 
B220 / CD11b / CD11c 
C
D
3 
CD8 
C
D
4 
CD44 
2W
 
RORγ 
Fo
xP
3 
 173 
Immunisation with attenuated 2W1S peptide and L. monocytogenes adjuvant generated a 
strong immune response as demonstrated by high numbers of peptide-specific activated CD4+ 
T lymphocytes in splenic populations (median 37988 cells, n=6), however of these, there 
were very few Treg cells (median 338 cells, n=6), and similar levels of Th17 cells (median 
509 cells, n=2) (Figures 5.7 and 5.10). 
 
IFA and 2W1S peptide immunisation was poorly antigenic, with very few peptide-specific 
activated CD4+ T lymphocytes in draining lymph nodes (median 343 cells, n=8). Such small 
numbers of activated cells made further assessment of Treg and Th17 populations highly 
unreliable (Figures 5.8 and 5.10). 
 
Antigenic challenge by 2W1S peptide and S. typhi porin adjuvant resulted in a stronger 
immune response than that achieved with IFA and 2W1S peptide, as demonstrated by the 
greater numbers of peptide-specific activated CD4+ T lymphocytes in draining lymph nodes 
(median 2841 cells, n=6). Similar numbers of both Treg (median 219 cells, n=6) and Th17 
lymphocytes (median 69 cells, n=6) were induced compared to those observed in response to 
immunization by attenuated 2W1S peptide and L. monocytogenes in this population (Figures 
5.9 to 5.10). 
. 
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Figure 5.10 Antigenic challenge by S. typhi porins and 2W1S peptide is the most 
effective method of generating peptide-specific FoxP3+ and RORγ+ CD4+ T 
lymphocytes. A Column charts showing percentage FoxP3+ and RORγ+ lymphocytes as a 
proportion of activated (CD44+) peptide-specific (2W+) CD4+ T lymphocytes induced by 
Listeria (L. monocytogenes and 2W1S peptide injected via tail vein, lymphocyte response in 
spleen assessed, n=6 FoxP3+RORγ-, n= 2 FoxP3-RORγ+), IFA (IFA and 2W1S peptide 
administered via subcutaneous injection to flank, lymphocyte response in draining inguinal 
lymph nodes assessed, n=6 FoxP3+RORγ-, n= 2 FoxP3-RORγ+), porin (S. typhi outer 
membrane porins and 2W1S peptide administered via subcutaneous injection to paw pad, 
lymphocyte response in draining axillary and brachial lymph nodes assessed, n=6 
FoxP3+RORγ-, n= 6 FoxP3-RORγ+). All animals assessed at day 7 following challenge. Data 
points represent individual animals. Line indicates median value. * p,<0.05 using Kruskal-
Wallis test. B Table illustrating median, mean and 95% confidence intervals of mean number 
and percentage of cells induced by each method of antigenic challenge. n = absolute number 
of cells per lymph node for IFA / Porin columns (calculated as mean cell number per lymph 
node) and absolute number of cells per whole spleen for Listeria column. 
  
B 
A 
Lis
ter
ia
IFA Po
rin
0
5
10
15
20
Antigen
Fo
xP
3+
RO
Rg
- (
%
 o
f C
D
4+
CD
44
+2
W
+)
*
*
Lis
ter
ia
IFA Po
rin
0
2
4
6
8
Antigen
Fo
xP
3-
RO
Rg
+ 
(%
 o
f C
D
4+
CD
44
+2
W
+)
Population Statistic n % n % n %
Median 37988 0.47 343 0.13 2841 0.24
Mean 48430 0.46 631 0.14 3098 0.23
95% CI lower 13965 0.28 66 0.05 971 0.12
95% CI upper 82896 0.64 1195 0.24 5225 0.34
Median 338 0.90 23 6.64 219 7.94
Mean 372 1.05 40 7.48 191 7.56
95% CI lower 195 0.31 5 3.23 112 4.50
95% CI upper 550 1.80 75 11.74 269 10.62
Median 509 2.10 5 6.10 69 3.11
Mean 509 2.10 4 4.22 69 3.32
95% CI lower -3182 -9.96 -5 -4.88 45 1.06
95% CI upper 4199 14.16 13 13.31 93 5.58
Listeria IFA Porin
CD4+CD44+2W+
FoxP3+RORγ-
CD4+CD44+2W+
FoxP3-RORg+
CD4+CD44+2W+
 175 
In conclusion, IFA and 2W1S peptide was excluded as a suitable method of further antigenic 
challenge based on the very weak peptide-specific immune response. The administration of 
2W1S peptide and either attenuated L. monocytogenes and S. typhi porin adjuvants achieved 
satisfactory levels of immune activation, with immunisation by 2W1S peptide and attenuated 
L. monocytogenes generating a 10-fold greater number of activated peptide-specific CD4+ T 
lymphocytes than that achieved following immunisation with 2W1S peptide and S. typhi 
porin adjuvant. This was expected given the greater number of T lymphocytes in spleen 
compared to a single lymph node. However, of these cells, percentage FoxP3 expression was 
significantly greater following immunisation by 2W1S peptide and S. typhi porins (median 
expression 7.94% S. typhi porin / 2W1S vs. 0.90% l. monocytogenes / 2W1S, p<0.05); 
percentage RORγ expression was similar between the two methods (3.11% vs. 2.10%, 
p>0.05) (Figure 5.10).  
 
Controlled antigenic challenge with 2W1S peptide and S. typhi porin was therefore adopted 
for all subsequent experiments in chimeric mice. 
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5.3.3 Betaglycan is not required for Treg or Th17 polarisation following 
controlled antigenic challenge in vivo but may have a subtle role in 
Th1 polarisation 
 
Having identified a suitable model of controlled antigenic challenge in which to assess Treg 
and Th17 lymphocyte responses in secondary lymphoid organs, we now wished to assess the 
role of betaglycan in polarisation of the resulting immune response. Both peptide-specific and 
non-peptide-specific T lymphocyte responses in draining lymph nodes were assessed 
following immunisation by 2W1S peptide and S. typhi outer membrane porin adjuvant 
according to the method as previously described (Section 2.2.6).  
 
Pooled lymph node cell suspensions from each experimental animal were divided into two 
equal samples; one was analysed according to the transcription factor staining protocol, and 
the other according to the cytokine staining protocol (Table 2.5). For all results, absolute cell 
numbers were expressed per lymph node assuming four equal sized lymph nodes were 
extracted from each animal (cells per lymph node = total cell number / 4). 
 
In order to assess the strength of antigenic induction following controlled challenge, we first 
determined the number of activated (CD44+) CD4+ T lymphocytes present in both peptide-
specific and non-peptide-specific populations, and determined the percentage of peptide-
specific and non-peptide-specific cells as a proportion of the total CD44+ population. We 
next examined the phenotype of responding cells within each population; Treg were identified 
by FoxP3 expression (which identified both iTreg and nTreg in draining lymph nodes), Th17 
cells were identified by both RORγ expression and IL17 secretion (in transcription factor and 
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cytokine analyses respectively), and Th1 identified by IFNγ secretion. In each analysis, 
assessment was also made of cells positive for both FoxP3 and RORγ (following transcription 
factor staining) and both IFNγ and IL17 (following cytokine staining). Example flow 
cytometry data with explanation of the gating strategy used is shown in Figure 5.11.  
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Figure 5.11 Polarisation of Treg and Th17 lymphocyte responses in betaglycan chimeric 
mice by S. typhi outer membrane porins and 2W1S peptide. Example flow cytometry data 
illustrating activated (CD44+) T lymphocyte populations in draining axillary and brachial 
lymph nodes of both betaglycan chimeric mice and C57BL/6 controls. Data analysed at day 7 
following antigenic challenge by Salmonella typhi outer membrane porins and 2W1S peptide 
compared to PBS control. Activated cells were identified as illustrated in figures 5.7 to 5.9; 
peptide-specific and non-peptide-specific cells were separated by the presence or absence of 
staining with 2W tetramer (2W+ / 2W-). Th17 (FoxP3-RORγ+ and IL17+IFNγ-), Treg 
(FoxP3+RORγ-), Th1 (IL17-IFNγ+) and double positive (FoxP3+RORγ+ and IL17+IFNγ+) 
cells were identified from these populations. Numbers in gates represent percentages for 
displayed sample. All plots presented on logarithmic axes.  
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The peptide-specific immune response was considered adequate for experimental mice, with 
similar numbers of active CD4+ cells observed in draining lymph nodes of TGFβRIII -/- and 
TGFβRIII +/+ chimeras compared to C57BL/6 controls (median values 1628, 1366 and 1980 
cells respectively), with very few peptide-specific active CD4+ cells observed in PBS controls 
(median 176 cells) (Figure 5.12). 
 
As with previous observation of resting lymphocyte populations, there was significant 
variation within genotypic groupings. This limited our ability to detect significant 
associations within our data, however no differences were observed in expression of 
transcription factors FoxP3 or RORγ either in absolute number or percentage of either 
peptide-specific (Figure 5.12) or non-peptide-specific populations (Figure 5.13).  
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Figure 5.12 Betaglycan is not necessary for polarisation of peptide-specific FoxP3+ Treg 
or RORγ+ Th17 lymphocyte responses following antigenic challenge with S. typhi outer 
membrane porins and 2W1S peptide. Column charts showing pooled peptide-specific 
(2W+) experimental data following controlled antigenic challenge of betaglycan chimeras and 
non-chimeric C57BL/6 controls with Salmonella typhi outer membrane porins and 2W1S 
peptide compared to PBS control. Results of FoxP3 and RORγ staining shown. Data pooled 
from 2 separate experiments; n=6 per group for chimeric mice; n=2 per group for C57BL/6 
mice. Data analysed at day 7 post challenge. Absolute number of cells per draining lymph 
node (top row) and percentages (bottom row) shown. Data points represent individual 
animals; line indicates median value. p>0.05 for all comparisons using Mann-Witney U-test. 
 
  
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
1000
2000
3000
4000
5000
Genotype (antigen)
Ce
ll 
nu
m
be
r (
CD
4+
CD
44
+2
W
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0.0
0.2
0.4
0.6
Genotype (antigen)
2W
+ 
(%
 o
f C
D
4+
CD
44
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
100
200
300
400
Genotype (antigen)
Ce
ll 
nu
m
be
r 
(C
D
4+
CD
44
+2
W
+F
ox
P3
+R
O
Rg
-)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
5
10
15
20
25
Genotype (antigen)
Fo
xP
3+
RO
Rg
- (
%
 o
f C
D
4+
CD
44
+2
W
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
100
200
300
400
Genotype (antigen)
Ce
ll 
nu
m
be
r 
(C
D
4+
CD
44
+2
W
+F
ox
P3
-R
O
Rg
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
10
20
30
40
Genotype (antigen)
Fo
xP
3-
RO
Rg
+ 
(%
 o
f C
D
4+
CD
44
+2
W
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
20
40
60
80
100
Genotype (antigen)
Ce
ll 
nu
m
be
r 
(C
D
4+
CD
44
+2
W
+F
ox
P3
+R
O
Rg
+)
TG
FB
R3
 -/-
 (P
ori
n)
TG
FB
R3
 +/
+ (
Po
rin
)
C5
7B
l/6
 (P
ori
n)
C5
7B
l/6
 (P
BS
)
0
2
4
6
8
10
Genotype (antigen)
Fo
xP
3+
RO
Rg
+ 
(%
 o
f C
D
4+
CD
44
+2
W
+)
CD44+ CD44+FoxP3+ CD44+RORγ+ CD44+ 
FoxP3+RORγ+ 
C
el
l n
um
be
r 
%
 P
ar
en
t p
op
ul
at
io
n 
 181 
 
 
 
 
         
 
 
Figure 5.13 Betaglycan is not necessary for polarisation of non-peptide-specific FoxP3+ 
Treg or RORγ+ Th17 lymphocyte responses following antigenic challenge with S. typhi 
outer membrane porins and 2W1S peptide. Column charts showing pooled non-peptide-
specific (2W-) experimental data following controlled antigenic challenge of betaglycan 
chimeras and non-chimeric C57BL/6 controls with Salmonella typhi outer membrane porins 
and 2W1S peptide compared to PBS control. Results of FoxP3 and RORγ staining shown. 
Data pooled from 2 separate experiments; n=6 per group for chimeric mice; n=2 per group for 
C57BL/6 mice. Data analysed at day 7 post challenge. Absolute number of cells per draining 
lymph node (top row) and percentages (bottom row) shown. Data points represent individual 
mice; line indicates median value. p>0.05 for all comparisons using Mann-Witney U-test. 
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No statistically significant differences in absolute number of IL17 or IFNγ secreting cells 
were observed between TGFβRIII -/- or TGFβRIII +/+ chimeras, or C57BL/6 controls either 
for peptide-specific or non-peptide-specific populations (Figures 5.14 to 5.15). 
 
Statistically significant differences were however observed between betaglycan deficient and 
wild-type C57BL/6 non-chimeric control animals in the proportion of non-peptide-specific 
populations. Statistically significant increases were detected in IFNγ+ Th1 lymphocytes in 
TGFβRIII-/- chimeras compared to TGFβRIII +/+ chimeras, and double positive IFNγ+IL17+ 
CD4+ T lymphocytes in TGFβRIII -/- chimeras compared to C57BL/6 non-chimeric controls 
(Figure 5.15).  
 
We also observed a statistically significant reduction in the number of peptide-specific IFNγ-
secreting lymphocytes in TGFβRIII +/+ chimeras compared to C57BL/6 controls (Figure 
5.14), and a statistically significant increase in non-peptide-specific IL17-secreting CD4+ T 
lymphocytes in TGFβRIII +/+ chimeras compared to C57BL/6 control animals (Figure 5.15). 
Since these differences were observed between populations of ‘control’ animals, they can not 
be attributed to a deficiency of betaglycan, and the functional significance is therefore 
questionable.  
 
These in vivo experiments provide further evidence that betaglycan is involved in regulation 
of Th1 lymphocyte responses. We must however acknowledge that the response to controlled 
antigenic challenge was again variable in our experimental animals, and any consequence of 
betaglycan deficiency is subtle. 
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Figure 5.14 Betaglycan is not necessary for polarisation of peptide-specific IFNγ+ Th1 
or IL17+ Th17 lymphocyte responses following antigenic challenge with S. typhi outer 
membrane porins and 2W1S peptide. Column charts showing pooled peptide-specific 
(2W+) experimental data following controlled antigenic challenge of betaglycan chimeras and 
non-chimeric C57BL/6 controls with Salmonella typhi outer membrane porins and 2W1S 
peptide compared to PBS control. Results of IFNγ and IL17 staining shown. Data pooled 
from 2 separate experiments; n=6 per group for chimeric mice; n=4 per group for C57BL/6 
mice. Data analysed at day 7 post challenge. Absolute number of cells per draining lymph 
node (top row) and percentages (bottom row) shown. Data points represent individual 
animals; line indicates median value. * p<0.05 using Mann-Witney U-test. 
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Figure 5.15 Betaglycan has variable effects on polarisation of non-peptide-specific 
IFNγ+ Th1 and IL17+ Th17 lymphocyte responses following antigenic challenge with S. 
typhi outer membrane porins and 2W1S peptide. Column charts showing pooled peptide-
specific (2W+) experimental data following controlled antigenic challenge of betaglycan 
chimeras and non-chimeric C57BL/6 controls with Salmonella typhi outer membrane porins 
and 2W1S peptide compared to PBS control. Results of IFNγ and IL17 staining shown. Data 
pooled from 2 separate experiments; n=6 per group for chimeric mice; n=4 per group for 
C57BL/6 mice. Data analysed at day 7 post challenge. Absolute number of cells per draining 
lymph node (top row) and percentages (bottom row) shown. Data points represent individual 
animals; line indicates median value. * p<0.05, **p<0.01 using Mann-Witney U-test. 
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5.4 Discussion 
 
We were able to successfully extract T lymphocytes from the tissues of our betaglycan foetal 
liver chimeric mice, sort the resulting cell suspensions to a highly purified naïve CD4+ T 
lymphocyte population, and grow these in vitro under iTreg polarising conditions achieving 
up to 85% FoxP3+ induction in the resulting cell cultures (Figures 5.4 to 5.6). We observed 
no statistically significant difference in TGFβ-dependent T lymphocyte differentiation and 
proliferation between wild-type or betaglycan knock-out cell populations across the range of 
TGFβ conditions tested. We have demonstrated that all isoforms of TGFβ are able to signal to 
T lymphocytes independently of betaglycan, and have found no evidence of a role for 
betaglycan in TGFβ signalling to T lymphocytes.  
 
This appears to contrast with published data for the role of betaglycan in TGFβ signalling; 
assays of heart endothelial and skeletal muscle cell lines in the presence and absence of 
betaglycan have previously suggested that whilst betaglycan is unnecessary for TGFβ1 and 
TGFβ3 mediated responses, betaglycan is necessary for TGFβ2 signalling (López-Casillas et 
al. 1993; Cheifetz et al. 1990). Our data demonstrates that TGFβ2 is able to signal to T 
lymphocytes in conditions of complete betaglycan insufficiency, with no differences observed 
between betaglycan-sufficient and betaglycan-deficient cells.  
 
This discrepancy is likely to be explained by the differences in each of the assays used. The 
previously cited research groups published findings based on data derived only from cell 
lines; it is often argued that cell lines are unrepresentative of the cells from which they are 
derived, at high risk of both cross-contamination from other cell lines, and microbial 
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contamination by resident pathogens (Masters 2000). Our data is derived from primary cell 
cultures, and we therefore suggest that our assays are likely to be more representative of the 
true situation in vivo. 
 
Furthermore, different end-points were assessed in our assays compared to those in previously 
published literature; both Cheifetz et al. and López-Casillas et al. based their conclusions on 
growth inhibition assays, demonstrating a 50-fold reduced potency of TGFβ2 compared to 
TGFβ1 or TGFβ3 in conditions of betaglycan deficiency (López-Casillas et al. 1993; Cheifetz 
et al. 1990). In contrast, we base our conclusions on FoxP3 induction in live cells after four 
days in cell culture, and did not directly assess growth inhibition. It is possible that cells 
require a stronger TGFβ signal for growth inhibition than for differentiation to an effector 
phenotype. In principle this appears logical, since at times of immunological stress the TGFβ-
dependent signal to differentiate is thus likely to be stronger (and more important) than the 
TGFβ-dependent signal to down-regulate lymphocyte cell populations. Both conclusions may 
therefore be equally valid. 
 
Variation in biological potency of TGFβ2 in the absence of betaglycan has also previously 
been observed in FHBE cell lines. FHBE cells are naturally deficient in betaglycan, and 
whilst they have been shown to display reduced TGFβ2-mediated growth inhibition compared 
to wild-type cells (Cheifetz et al. 1990), they display similar TGFβ2-mediated plasminogen-
activator inhibitor 1 (PAI-1) inhibition (ten Dijke et al. 1988). The difference between 
‘receptor affinity’ and ‘biological potency’ may also be important; whilst TGFβRI and 
TGFβRII have previously been shown to have higher affinity for TGFβ1 and TGFβ3 isoforms 
than for TGFβ2 (Wrana et al. 1992), it may be possible for low affinity binding to induce a 
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strong biological effect (Cheifetz et al. 1990) inducing similar signal transduction across the 
cell surface receptor. 
 
Finally, whilst differences in TGFβ-mediated growth inhibition have been observed in 
betaglycan-deficient fibroblasts, TGFβ-mediated Smad phosphorylation has been 
demonstrated to be similar in knock-out and wild-type cell populations (Stenvers et al. 2003). 
TGFβ-mediated growth inhibition thus appears to proceed independent of Smad signalling 
pathways, and therefore may not directly correlate with the availability of betaglycan at the 
cell surface receptor, or reflect the role of betaglycan in signal transduction. 
 
Collectively, these observations illustrate that in vitro responses to TGFβ2 vary depending on 
the assay used. The impact of betaglycan deficiency on TGFβ signal transduction in vivo may 
therefore be highly context specific, dependent both on the cell type and biological process. 
Ultimately, we conclude that betaglycan is not an absolute requirement for TGFβ1,2 or 3-
mediated FoxP3 induction by naive T lymphocytes. We cannot however exclude the 
possibility that betaglycan is necessary for other TGFβ-mediated processes.  
 
We were able to successfully immunise our betaglycan foetal liver chimeras, using 2W1S 
peptide antigen and S. typhi outer membrane porin adjuvant to induce Th1, Th17, and Treg 
lymphocyte responses in draining lymph nodes (Figure 5.11). Furthermore, we were able to 
identify activated 2W1S peptide-specific CD4+ T lymphocytes, and were thus able to track a 
highly challenge-specific immune response. We observed no statistically significant 
difference in the absolute number of 2W1S peptide-specific or non-specific CD4+ T 
lymphocytes recruited to the site of antigenic challenge between TGFβRIII +/+ or TGFβRIII -
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/- chimeras, or C57BL/6 controls (Figures 5.12 to 5.15). We did however observe statistically 
significant differences in relative proportions of Th1 and Th17 cells across our experimental 
groups. 
 
A statistically significant reduction in the proportion of peptide-specific Th1 lymphocytes was 
observed in TGFβRIII +/+ chimeras compared to C57BL/6 controls (Figure 5.14), with a 
similar, non-statistically significant trend observed in the non-peptide specific response in 
these animals (Figure 5.15). In addition, a statistically significant increase in the proportion of 
non-peptide-specific Th17 lymphocytes was observed in TGFβRIII +/+ chimeras compared to 
C57BL/6 controls (Figure 5.15), with a similar, non-statistically significant trend observed in 
the peptide-specific response in these animals (Figure 5.14). Whilst not statistically 
significant, a similar trend was observed in absolute cell number of Th1 and Th17 cells in 
these experimental groups. 
 
These observations are surprising, since our TGFβRIII +/+ chimeras were considered 
genetically identical to wild-type C57BL/6 mice, and we would therefore expect a similar 
response to antigenic challenge. Our data suggests that the Th1 response is impaired in ‘wild-
type’, betaglycan-sufficient foetal liver chimeric animals compared to wild-type non-
chimeras, with a relative shift towards the Th17 response. This raises the possibility of 
differences in our experimental mice which arise due to the process of generating chimeras; 
perhaps suggesting that the process of sub-lethal irradiation leads to disruption of either the 
bone marrow or thymus which persists following reconstitution, resulting in altered function 
and disruption to the subsequent development of lymphocyte populations.  
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Previous studies of mice subject to sub-lethal irradiation have demonstrated differential radio-
sensitivities of mature T lymphocyte populations, with relative sparing of Treg subsets 
compared to other effector populations in response to any given dose of gamma radiation (Qu 
et al. 2010); since our chimeras were generated in RAG deficient mice which lacked mature 
lymphocyte populations at the time of irradiation, this is unlikely to explain differences in our 
model. More significantly, proliferation of bone marrow stroma in vitro has been shown to be 
significantly suppressed following irradiation (Zhang et al. 2010); it is thus more likely that 
the supportive functions of stromal cells were impaired in our irradiated chimeric mice 
compared to non-irradiated C57BL/6 controls, and this may explain any subsequent 
differences in lymphocyte development between otherwise genetically-identical animals. 
 
In contrast, no significant differences were observed between TGFβRIII -/- chimeras or 
C57BL/6 controls in these comparisons. This could be interpreted in a variety of ways. 
Firstly, betaglycan deficiency may somehow compensate for the detrimental effects of 
irradiation, allowing restoration of more physiologically normal bone marrow and thymic 
lymphocyte compartments, with the resulting chimeras appearing more similar to non-
chimeric C57BL/6 animals than wild-type chimeras. Alternatively, both TGFβRIII -/- and 
TGFβRIII +/+ chimeras may sustain similar disruption of lymphocyte pools following 
irradiation, but there may be polarisation towards a stronger Th1 (and therefore weaker Th17) 
response following antigenic challenge in the absence of betaglycan. Finally, it is possible 
that a significant difference does indeed exist, but our in vivo system was too variable for us 
to demonstrate this. 
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We observed a statistically significant increase in non-peptide-specific Th1 cell proportions in 
TGFβRIII-/- chimeras compared TGFβRIII +/+ chimeras (Figure 5.15), again, with non-
statistically significant trends towards increased Th1 and reduced Th17 proportions across 
both the peptide-specific and non-peptide-specific data (Figure 5.14 to 5.15). This suggests 
that a preferential Th1-driven response may predominate under conditions of betaglycan 
deficiency, with a possible reduction in the Th17 response. This is consistent with published 
data in EAE and experimental colitis, in which TGFβ has been shown to modulate the balance 
between Th1 and Th17 responses, being observed to suppress Th1 mediated inflammation 
whilst promoting Th17-mediated disease (Li et al. 2007). 
 
Indeed, excessive Th1 responses have been widely reported in response to disruption of TGFβ 
signalling. This has largely been considered a secondary effect of reduced Treg differentiation 
in the absence of TGFβ, for example in a murine transfer model, TGFβ from FoxP3+ Treg 
cells was shown to be necessary to suppress Th1 cell differentiation and prevent development 
of experimental colitis (Ishigame et al. 2013). Several studies have demonstrated an 
association between reduced proportions of peripheral Treg lymphocytes and development of 
immune-mediated disease in TGFβ-deficient mice (Ouyang et al. 2010; Gu et al. 2012; 
Takimoto et al. 2010), however these observations do not correlate with our data, since we 
observed no disruption of Treg populations in either our naïve or antigen-experienced mice. 
 
In a mouse model of Th1-mediated type-1 diabetes, Ishigame et al. demonstrated that 
inhibition of TGFβ signalling to CD4+ T lymphocytes through conditional TGFβRII knock-
out resulted in increased Th1 polarisation and development of diabetes, in the presence of 
normal Treg development, maintenance and function (Ishigame et al. 2013). Peripheral Th1 
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and Treg lymphocytes are thought to exist in a state of balance, whereby local Th1 numbers 
are regulated by reciprocal changes in levels of local Treg (Caretto et al. 2010). The 
observations of Ishigame et. al. suggest that Treg-independent mechanisms of Th1 regulation 
exist under conditions of deficient TGFβ signalling, and this may explain the trends in our 
data. It is thus possible that betaglycan deficiency results in direct up-regulation of Th1 
polarisation, in a similar, Treg-independent manner. 
 
Finally, a statistically significant increase in the proportion of non-peptide-specific double-
positive IL17+IFN+ CD4+ T lymphocytes was observed in TGFβRIII -/- chimeras compared 
to C57BL/6 controls (Figure 5.15); since these cells constitute less than 1% of the total 
effector lymphocyte population in each of our comparisons, this is likely to be of minimal 
functional significance, but is further evidence of an exaggerated immune response in 
betaglycan deficient chimeras. 
 
No significant differences were observed in either absolute number or relative proportion of 
FoxP3+ CD4+ lymphocyte populations; this is consistent with our in vitro data (Section 
5.3.1), and provides further evidence that betaglycan is not involved in Treg polarisation. 
 
We conclude that betaglycan may be implicated in Th1-driven responses to antigenic 
challenge, perhaps acting to suppress Th1-mediated immune responses under normal 
conditions, but is not involved in Th17 or Treg responses.  
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6 ASSOCIATION ANALYSIS OF TGFBR3 GENE 
WITH BEHÇET’S DISEASE AND IDIOPATHIC 
INTERMEDIATE UVEITIS IN A CAUCASIAN 
POPULATION 
 
The introduction, methods, results and discussion presented within this chapter have 
previously been published in a peer-reviewed scientific journal (Barry et al. 2015); see section 
8.2 for the full citation and a reproduction of the published version. 
 
6.1 Introduction 
 
Behçet’s disease (BD) and idiopathic intermediate uveitis (IIU) are two diseases characterised 
by sight-threatening intra-ocular inflammation: BD is a multisystem vasculitis characterised 
by inflammatory lesions of the oro-genital mucosa, eyes, skin, central nervous system and 
joints. The underlying cause is unknown, but it is believed to be an autoinflammatory process 
triggered by an infectious or environmental agent. There is significant geographical clustering 
of BD, being most prevalent in countries along the historic ‘Silk Route’ (Mendes et al. 2009). 
IIU is a localized ocular inflammatory disease characterized by breakdown of the blood–
retinal barrier and leucocyte infiltration of the retina with photoreceptor cell loss, often 
leading to blindness. It is usually considered to be an autoimmune, cell mediated, organ 
specific disease based on the findings of autoreactive T lymphocytes and antibodies in 
patients and its response to immunosuppression (Walton & Ashmore 2003). Both conditions 
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have also been associated with HLA and cytokine gene polymorphisms (Verity et al. 1999; 
Stanford et al. 2005). 
 
BD and IIU may be considered to be at least partially TGFβ dependent, as Treg and Th17 
cells have been implicated in the pathogenesis of each (Na et al. 2013; Amadi-Obi et al. 
2007). Furthermore, since TGFβ2 is the predominant intra-ocular isoform, betaglycan may be 
particularly important in the ocular microenvironment, and may be implicated in the 
pathogenesis of both diseases (Curnow et al. 2005). 
 
Single nucleotide polymorphisms (SNP) in the gene controlling TGFβRIII (TGFBR3) have 
been identified in both systemic and ophthalmic disease (Xiong et al. 2009; Khor et al. 2011; 
Ramdas et al. 2011). Several studies in ophthalmology have identified SNP in TGFBR3 in 
patients with glaucoma, demonstrating an association with optic disc area in both Caucasian 
and Asian cohorts, suggesting a role in the onset and progression of glaucomatous optic disc 
damage (Axenovich et al. 2011; Khor et al. 2011; Ramdas et al. 2011). A particular SNP 
(RS1805110) has previously been identified in a Han Chinese population with BD, with the 
CC genotype suggested to confer a protective effect against developing disease. This SNP is a 
non-synonymous mutation located in the signal sequence that may affect secretion or 
expression of TGFBR3, although this has not addressed specifically (Chen et al. 2012).  
 
This finding is of particular interest given the possible importance of the TGFBR3 gene and 
TGFβRIII receptor to ocular immunoregulation. Having investigated the role of betaglycan in 
a series of tightly controlled experimental animal models, we wished to extend our 
investigation to human subjects, and attempt to replicate the findings of Chen et. al. by testing 
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for this association in a population of Caucasian patients with BD, making comparison to 
disease-free controls and patients with IIU.  
 
6.2 Experimental design 
 
Blood samples were collected from 167 consecutive Caucasian patients (75 with BD, 92 
disease control with IIU) attending the Birmingham and Midland Eye Centre, and Medical 
Eye Unit at St. Thomas’ Hospital, London. All patients with BD fulfilled the International 
Study Group criteria for diagnosis (Wechsler et al. 1990) and underwent a prospective clinical 
and ophthalmological examination. IIU was diagnosed clinically by expert ophthalmological 
review. Blood samples were collected from 85 age- and ethnicity-matched healthy controls 
without BD or IIU for comparison.  
 
This study received the approval of the St Thomas’ Hospital and Sandwell Local Ethics 
Research Committees. 
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6.3 Results 
 
6.3.1 TGFBR3 SNP RS1805110 is not associated with Behcet’s Disease in a 
Caucasian population 
 
Representative data plots of the endpoint genotype analysis are shown in figure 6.1 and 
summary statistics are shown in table 6.1. Across all diagnostic groups, the CC genotype was 
most prevalent, ranging from a frequency of 79.35% in IIU samples to 89.41% in control 
samples. A considerably lower frequency of the CT genotype was observed, ranging from 
9.41% in healthy control to 20.65% in IIU samples. A very low frequency of the RS1805110 
T allele was observed across all diagnostic groups (5.88% control, 9.33% BD, 10.33% IIU), 
with complete absence of the homozygous RS1805110 TT genotype in patients with BD and 
IIU in this sample (1.18% control, 0% BD, 0% IIU) (Table 6.1).  
 
No significant difference in RS1805110 allele or genotype frequency was observed between 
either BD or IIU and healthy controls (p>0.05 for all comparisons). Distribution of genotype 
in each group did not deviate from HWE.	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Figure 6.1 Representative plots of endpoint genotyping analysis. Data shown for BD (1), 
IIU (2) and healthy controls (3). Blue triangles CC, red triangles CT, green triangles TT, grey 
circles negative control. 
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Table 6.1 SNP RS1805110 genotype and allele frequency. Data stratified by diagnostic 
group. n = number of samples; OR = Odds Ratio; 95% CI = 95% Confidence Interval of 
Odds Ratio. p-value calculated by Fisher’s exact test. * Unable to calculate statistics with n=0 
in one comparison group.
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6.3.2 The RS1805110 minor allele frequency is low in Caucasian 
populations 
 
The T allele frequency was very low amongst Caucasian patients within our sample, with a 
frequency of only 5.88% in our healthy controls (Table 6.1). Our observed allele frequencies 
differ significantly from those previously published in Han Chinese patients with BD 
(p<0.0001), but are consistent with those observed in Caucasian populations as presented in 
the HapMap database (The International HapMap Consortium 2015) (p=0.149) (Table 6.2). 
 
Stratification analysis according to gender or clinical features of BD did not associate with the 
tested SNP (p>0.05).  
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Table 6.2 SNP RS1805110 allele frequencies in published literature. Comparison of allele 
frequency observed in patients with BD between present study and Chen 2012 (Chen et al. 
2012), and with published background allele frequency in Caucasian patients presented in 
HapMap database (The International HapMap Consortium 2015). n = total number of alleles 
in sample; OR = Odds Ratio; p-value calculated using Fisher’s exact test. a = CEU: Utah 
residents with Northern and Western European ancestry from the CEPH collection. 
 
 
 
 
  
Data source Diagnostic 
group 
n C T OR 95% Confidence 
Interval 
p 
Present study BD 150 136 14 - - - 
Chen et al. 2012 BD 634 330 304 8.95 5.05 - 15.85 <0.0001 
HapMap  CEUa Control 226 214 12 0.52 0.23 - 1.16 0.149 
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6.4 Discussion 
 
We found no statistically significant association between TGFBR3 RS1805110 and either BD 
or IIU. This was probably due to the low prevalence of the RS1805110 T allele observed 
throughout our study populations (Table 6.1). These observations contrast with the results of 
Chen et al. who reported a statistically significant reduction in RS1805110 CC genotype 
frequency in patients with BD compared to control (19.9% vs. 28.8%) and an overall T allele 
frequency of 46.53% in their study sample. It was postulated that the CC genotype conferred 
a potential protective effect against developing BD (Chen et al. 2012). Whilst we also observe 
a lower frequency of the CC genotype in BD patients compared to control in our study 
(81.33% vs. 89.41%), this difference was not statistically significant. As a result, the 
possibility that RS1805110 may influence BD in Caucasian cannot be fully excluded, 
however due to the low frequency of the C allele we conclude that any influence would be 
very weak. 
 
The observed T allele frequency in our study is consistent with that reported for Caucasian 
populations on the HapMap database (The International HapMap Consortium 2015) (5.6% for 
Utah residents with Northern and Western European ancestry from the CEPH collection), 
whilst the results of Chen et al. are consistent with the T allele frequency reported for Chinese 
populations (39.0% for Chinese in Metropolitan Denver and 42.7% for Han Chinese in 
Beijing) and suggests that there is significant genetic variation between patients with BD 
depending on geographic region (Table 6.2). Similar findings have been reported in studies of 
other candidate genes in BD. Recent genome-wide association studies have identified several 
BD associated genes such as HLA-B*51, IL23R, and IL10, in patients cohorts across the 
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geographical range of BD. By comparison, other genes identified in these and candidate gene 
studies are specific to particular regions (Remmers et al. 2010; Mizuki et al. 2010). For 
example, an inverse correlation has been observed between the PTPN22 620W polymorphism 
and BD in the UK population, but this association was not seen in Middle Eastern populations 
where the prevalence of the 620W polymorphism is very low (Baranathan et al. 2007). 
Similarly, no association has been demonstrated between PTPN22 SNP and BD in Han 
Chinese patients (Zhang et al. 2012). This suggests that while HLA-B*51 is the strongest 
association in all BD patient cohorts, different polymorphisms are linked with the condition in 
different geographical areas. 
 
Similar geographic variations in TGFBR3 SNP have been reported in a number of other 
contexts. Studies in primary open angle glaucoma indicate that TGFBR3 SNP RS1192415 is 
a common determinant of optic disc area in patients of Caucasian (European) and Asian 
(Indian and Malay populations in Singapore) backgrounds (Khor et al. 2011; Ramdas et al. 
2011), however this association is absent in Afro-Caribbean patients where other SNP appear 
more significant (Cao et al. 2012). Studies in osteoporosis show comparable variation, with 
the SNP RS17131547 showing a statistically significant association with reduced bone 
mineral density in Afro-Caribbean and White US populations, but being monomorphic in 
Chinese populations (Xiong et al. 2009).  
 
Most existing research of TGFBR3 function has been performed in the context of cancer 
studies where TGFBR3 deletions are thought to have a paradoxical role, being tumour-
promoting if occurring early in disease through presumed impairment of immune suppression 
by TGFβ, but tumour-suppressive if occurring later in disease through probable enhancement 
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of the anti-tumour effect of the local immune system (Gatza, Oh, et al. 2011). In each 
circumstance, loss of TGFBR3 is thought to impair local immune responses through the 
reduction in potency of TGFβ at sites of antigenic challenge.  
 
The functional relevance of RS1805110 has not been studied to date. This polymorphism is a 
non-synonymous SNP (Ser/Phe), which changes the amino acid sequence, predicted to be 
located in the signal sequence region, where it might affect secretion or expression of the 
protein. A protective effect postulated by Chen et al. would suggest either a “gain of function” 
in relation to the anti-inflammatory effect of TGFβ, or a “loss of function” in relation to 
induction of Th17 cells which have been implicated in BD (Na et al. 2013). Future studies 
will be needed to address this. 
 
Our investigation is subject to a number of limitations. Firstly, given the very low frequency 
of the T allele in Caucasian populations, our sample size may have been too small to detect 
statistically significant associations between this SNP and disease groups. Second, since 
patients were recruited from ophthalmology clinics we are unable to comment on any 
association in patients with non-ocular BD. Finally, we have screened for a single 
polymorphism; significant associations may exist with other TGFBR3 SNPs in the Caucasian 
population.	  
 
In conclusion, whilst TGFBR3 RS1805110 has been proven to be associated with BD in a 
Han Chinese population, it is not associated with BD or IIU in Caucasian a population. This 
study highlights the complexity in genetic determinants of BD, and reveals further 
geographical genetic variation in patients with BD.   
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7 FINAL DISCUSSION 
 
7.1 Introduction 
 
We were able to successfully develop a novel experimental model in which all resident T and 
B lymphocytes were betaglycan-deficient. To our knowledge, this is the first example of an in 
vivo system in which to study betaglycan-deficient T and B lymphocytes, and we are the first 
group to investigate the role of betaglycan in peripheral immune responses. We observed 
population of peripheral lymphocyte compartments (Chapter 3) and the development of 
secondary lymphoid tissues in our chimeric animals (Chapter 4), and were able to use our 
chimeras for both in vivo and in vitro assays of TGFβ-dependent T lymphocyte responses 
(Chapter 5). 
 
In addition, we developed a model of antigenic challenge comprising subcutaneous injection 
of 2W1S peptide antigen in conjunction with an adjuvant of Salmonella typhi outer membrane 
porins, in which we were able to induce polarisation of Th1, Treg and Th17 lymphocytes in 
draining lymph nodes, and identify a population of responding 2W1S-specific CD4+ T cells 
(Figure 5.11). To our knowledge, this model has never previously been reported. 
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7.2 Refuting the hypothesis 
 
Our initial hypothesis consisted of three broad statements; through the experiments described 
we have been able to refute each of these. 
 
We hypothesized that betaglycan would be necessary for TGFβ2 signalling to T lymphocytes 
via the cell-surface TGFβ receptor, being an absolute requirement for TGFβ2-mediated 
immune responses. Our in vitro assays demonstrated FoxP3 induction in naïve T lymphocytes 
following exposure to all isoforms of TGFβ in both the presence and absence of betaglycan, 
with no statistically significant difference in the number of FoxP3+ cells induced by TGFβ2 
between betaglycan-deficient and betaglycan-sufficient cell populations at any of the tested 
concentrations of TGFβ (Figures 5.4 to 5.6). We therefore conclude that betaglycan is not an 
absolute requirement for TGFβ2 signalling to T lymphocytes in our assays.  
 
We hypothesized that betaglycan would increase the affinity of both TGFβ1 and TGFβ3 for 
the cell-surface TGFβ receptor on lymphocytes, resulting in impairment of TGFβ1 and 
TGFβ3-mediated T lymphocyte immune responses in the absence of betaglycan. Our in vitro 
assays demonstrated no significant difference in the number of FoxP3+ cells induced by 
TGFβ1 or TGFβ3 when comparing betaglycan-sufficient and betaglycan-deficient cell 
populations (Figures 5.4 to 5.6). We therefore conclude that betaglycan has no influence on 
the relative potency of either TGFβ1 or TGFβ3 for the cell surface receptor on T 
lymphocytes, and does not increase influence the affinity of TGFβ1 or TGFβ3 for the receptor 
in our assays.  
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Finally, we hypothesized that no spontaneous immune dysregulation would be observed in 
vivo under conditions of betaglycan deficiency in environments where TGFβ1 or TGFβ3 
signalling predominates, however disordered Th17 and Treg lymphocyte responses would be 
observed under conditions of antigenic challenge. Observation of naïve chimeras revealed a 
subtle phenotype of increased T lymphocyte activation in betaglycan-deficient chimeras 
(Figure 4.4), with an exaggerated Th1 response, but with no differences in Th17 or Treg 
lymphocyte populations (Figures 4.7 to 4.8). These observations correlated with the results of 
our controlled antigenic challenge experiments, which again showed no alteration of Treg or 
Th17 responses, but demonstrated an exaggerated Th1 response in betaglycan-deficient 
chimeras (Figure 5.12, figures 5.14 to 5.15). We therefore conclude that betaglycan 
deficiency may result in spontaneous (but subclinical) immune dysregulation, with particular 
influence on Th1-mediated immune responses.  
 
7.3 Current understanding of the immunoregulatory role of 
betaglycan 
 
Based on our observations, we conclude that betaglycan is involved in the TGFβ signalling 
process at the T lymphocyte cell surface. We speculate that it mediates TGFβ signalling in T 
lymphocyte homeostasis, contributing to regulation of T lymphocyte activation levels. 
Targeted betaglycan deficiency restricted to T and B lymphocytes appears to cause 
spontaneous CD4+ and CD8+ T lymphocyte activation in naïve mice. Betaglycan is also 
implicated in T lymphocyte polarisation, with targeted deficiency on T and B lymphocytes 
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resulting in increased proportions of Th1 CD4+ T lymphocytes in both naïve and antigen-
experienced mice.  
 
Betaglycan is not implicated in Treg or Th17 polarisation. Targeted betaglycan deficiency 
restricted to T and B lymphocytes results in no gross phenotype of immune mediated disease. 
 
7.3.1 Betaglycan as a regulator of T lymphocyte activation and polarisation 
 
Our data suggests that betaglycan deficiency results in spontaneous CD4+ and CD8+ T 
lymphocyte activation in naïve mice (Figure 4.4). This suggests that betaglycan is involved in 
TGFβ signalling across the cell membrane in T and B lymphocytes, with deletion resulting in 
impairment of the immunosuppressive effect of TGFβ on these cell populations. The exact 
mechanism by which this occurs remains unclear; TGFβ may have a direct influence on 
antigen presentation, since it is known to play an important role in regulation of MHC levels 
(Lee et al. 1997; Panek et al. 1995).  
 
In studies of the TGFβ1 knock-out mouse, increased expression of MHC class I and II has 
been observed on antigen presenting cells in the absence of TGFβ (Geiser et al. 1993). 
Impaired TGFβ signalling may thus cause up-regulation of MHC molecules, resulting in 
abnormal antigen presentation to T lymphocytes and initiation of immune activation in 
apparently naïve animals. This mechanism is however unlikely to explain the variation in 
lymphocyte activation observed in our model, since betaglycan was absent only from T and B 
lymphocytes, whilst all other MHC-expressing cells retained normal levels of betaglycan.  
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Others have suggested that TGFβ may have an indirect role in lymphocyte activation through 
regulation of Treg numbers (Li et al. 2007; Ishigame et al. 2013). Naïve T lymphocytes are 
induced to differentiate to FoxP3+ Treg under the influence of TGFβ (Ming O. Li et al. 2006), 
which subsequently act to suppress local immune responses. Abrogation of TGFβ signalling 
is thus assumed to prevent Treg polarisation, resulting in a shift towards a pro-inflammatory 
environment with disordered activation of local T lymphocytes. Whilst this may contribute to 
the process of T lymphocyte activation in some situations, we observed no significant 
reduction in Treg proportions either in our naïve (Figures 4.7 to 4.8) or antigen-experienced 
animals (Figures 5.12 to 5.15), and furthermore, were unable to demonstrate any role for 
betaglycan in in vitro assays of FoxP3 induction in naïve T lymphocytes (Figures 5.4 to 5.6). 
 
Similar increases in lymphocyte activation have been observed following targeted deletion of 
TGFβRII, although the resulting phenotype was considerably more severe, with over 90% of 
CD4+ and CD8+ T lymphocytes are observed to display a memory phenotype (Gorelik & 
Flavell 2000). This suggests that betaglycan functions in a similar manner to TGFβRII, but 
has less overall influence on TGFβ signalling across the cell surface receptor complex, and is 
consistent with previous observations of betaglycan acting as a co-factor in the signalling 
process rather than being an absolute requirement for TGFβ signal transduction (Cheifetz et 
al. 1990; López-Casillas et al. 1991; Sankar et al. 1995; Stenvers et al. 2003). 
 
In addition to its role in T lymphocyte activation, betaglycan also appears to regulate T 
lymphocyte polarisation, being necessary for regulation of Th1-mediated immune responses 
both at rest (Figures 4.7 to 4.8) and following antigenic challenge (Figures 5.14 to 5.15). 
Excessive Th1 responses have been widely reported in response to the absence of TGFβ 
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signalling. This has largely been considered a secondary effect of reduced Treg differentiation 
in the absence of TGFβ, for example in a murine transfer model, TGFβ from FoxP3+ Treg 
cells was shown to be necessary to suppress Th1 cell differentiation and prevent development 
of experimental colitis (Fantini et al. 2006). Indeed, several studies have demonstrated an 
association between reduced proportions of peripheral Treg lymphocytes and development of 
immune-mediated disease in TGFβ-deficient mice (Ouyang et al. 2010; Gu et al. 2012; 
Takimoto et al. 2010), however these observations do not correlate with our data, since we 
observed no disruption of Treg populations in either our naïve (Figures 4.7 to 4.8) or antigen-
experienced mice (Figures 5.12 to 5.15). 
 
In a mouse model of Th1-mediated type-1 diabetes, Ishigame et al. demonstrated that 
inhibition of TGFβ signalling to CD4+ T lymphocytes through conditional TGFβRII knock-
out resulted in increased Th1 polarisation and development of diabetes, in the presence of 
normal Treg development, maintenance and function (Ishigame et al. 2013). This suggests 
that Treg-independent mechanisms of Th1 polarisation exist under conditions of deficient 
TGFβ signalling, and this may explain the trends in our data. It is thus possible that 
betaglycan deficiency results in direct up-regulation of Th1 polarisation, in a similar, Treg-
independent manner. 
 
Mouse models of targeted TGFβRII deficiency on T lymphocytes result in lethal autoimmune 
disease with marked T lymphocyte activation and inflammatory infiltration of multiple organ 
systems (Gorelik & Flavell 2000; Ming O. Li et al. 2006). In contrast, we observed relatively 
mild T lymphocyte activation, with no evidence of autoimmunity (Figure 4.9) or tissue-
specific inflammatory disease (Figures 4.10 to 4.13) in response to targeted betaglycan 
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deficiency. Betaglycan is ubiquitously expressed by almost all cell types (Pakula et al. 2007), 
and expression of betaglycan by non-T non-B lymphocyte cell populations was unaffected in 
our betaglycan-deficient chimeras (Figure 3.4); it is thus possible that betaglycan-deficient T 
lymphocytes were able to utilise these external sources of betaglycan in TGFβ signal 
transduction. 
 
This may have been achieved in two ways; firstly, it is known that betaglycan can exist in a 
soluble form following cleavage of the receptor at the cell membrane (Velasco-Loyden et al. 
2004). Soluble betaglycan released from resident non-lymphocyte cells in this way may be 
able to interact with the cell-surface TGFβ receptor on local lymphocytes, being able to 
function in a comparable way to membrane-bound betaglycan. Secondly, it has recently been 
shown that IL15 is able to regulate CD4+ T lymphocyte homeostasis via trans-presentation by 
non-lymphocyte cells (Chen et al. 2014); an analogous mechanism may allow TGFβ to be 
trans-presented to the lymphocyte by betaglycan at the cell surface of resident non-
lymphocyte cells. If either of these mechanisms are indeed present in the murine immune 
system, lymphocytes may be able to compensate for betaglycan deficiency at the cell surface, 
and the lymphocytes could not be considered truly betaglycan-deficient in our experimental 
system. In future work this could be addressed with the use of betaglycan blocking antibodies 
administered at the time of antigenic challenge. 
 
Furthermore, the possibility of Smad-independent, and therefore TGFβ-independent FoxP3+ 
induction has been postulated by some authors, who have identified other transcription factors 
such as NFAT, which are able to bind the FoxP3 promoter and induce Treg cells (Tone et al. 
2008; von Boehmer & Nolting 2008). This raises the possibility that in the absence of a fully 
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functioning TGFβ receptor, there may be up-regulation of TGFβ-independent signalling 
pathways and maintenance of immune homeostasis.  
 
Our in vitro assays of TGFβ-dependent T lymphocyte responses were designed to address 
some of these issues. We sorted pooled lymph node and spleen cell suspensions to highly 
purified populations of naïve T lymphocytes, and thus removed all non-lymphocyte cells from 
these assays (Figure 5.1). In the absence of non-T lymphocyte cells, trans-presentation of 
betaglycan was not possible, avoiding this potential source of betaglycan in our knock-out 
cells. It is however possible that our naïve cells may have been ‘contaminated’ with soluble 
betaglycan prior to being sorted; if lymphocytes are indeed able to retain soluble betaglycan at 
the cell surface the effects of our knock-out may again have been masked. 
 
7.3.2 Betaglycan is redundant in Treg and Th17-mediated immune 
responses and is not involved in differential responses to TGFβ 
 
TGFβ is required for in vitro differentiation of both Treg and Th17 from naïve T lymphocytes 
(Yamagiwa et al. 2001; Chen et al. 2003; Ming O. Li et al. 2006; McGeachy & Cua 2008; 
Bettelli et al. 2006). Despite this, we observed no evidence of dysregulated Treg or Th17-
mediated immune responses in our in vivo experiments (Figures 4.7 to 4.8, Figures 5.12 to 
5.15), and furthermore, observed no difference in TGFβ-induced Treg differentiation between 
betaglycan-deficient and betaglycan-sufficient cell populations in our in vitro assays (Figures 
5.4 to 5.6). This was an unexpected observation, having already demonstrated a potential role 
for betaglycan in the regulation of T lymphocyte responses at rest (Chapter 4). 
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As with all in vitro assays, this is a highly artificial scenario, which over-simplifies the true  
biological process; in vivo, TGFβ would first be released in latent form, being activated at its 
target destination (Dallas et al. 2008). We cannot rule out the possibility that betaglycan is in 
fact involved in this activation of TGFβ at the T lymphocyte cell surface. In addition, the 
interaction of recombinant TGFβ with the TGFβ receptor may differ from the interaction with 
native TGFβ, with the role of betaglycan being specific to interaction with the naïve form.  
This could be addressed by the addition of latent, native (human) TGFβ to our assays; 
aqueous humour from un-inflamed eyes would be one possible source, with the additional 
advantage that this is known to be a rich source of TGFβ2 (Denniston et al. 2011). 
It should also be noted that published data suggesting a role for betaglycan in TGFβ2-
dependent cell proliferation is based on experiments using in vitro assays of cell lines (López-
Casillas et al. 1993; Sankar et al. 1995). Whilst cell lines are useful in generating in vitro data, 
they are a highly manipulated and artificial system. It may not be possible to extrapolate such 
data to resident cell populations from in vivo sources. 
 
We must also acknowledge that our in vitro assays do not directly address signalling by TGFβ 
across the cell surface receptor; we are able to draw conclusions concerning the ability of 
TGFβ to induce nuclear transcription factors, but are unable to describe how TGFβ achieves 
this, and cannot comment on the signalling process. Gu et al. investigated TGFβ-dependent 
Treg responses in a transgenic mouse model in which all Treg lacked Smad2 and Smad3 (Gu 
et al. 2012). The resulting animals displayed normal thymic development and peripheral 
maintenance of Treg, suggesting that Smad-independent pathways are important for Treg 
function. Although unlikely, it is possible that the TGFβ-dependent responses observed in our 
assays occurred independently of the TGFβ receptor. Future work is required to measure 
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products of the signalling cascade, such as Smad protein phosphorylation, to confirm that 
receptor signalling is involved in these assays.  
 
It is also possible that betaglycan is not primarily involved in TGFβ signalling, but is involved 
in signal transduction by other ligands, and the previously observed effects of betaglycan 
deficiency on T lymphocyte homeostasis were independent of TGFβ signalling. In addition to 
binding all isoforms of TGFβ, betaglycan is also able to bind a range of other molecules, 
including all members of the TGFβ superfamily including inhibin A, inhibin B and certain 
BMPs (Bilandzic & Stenvers 2011).  It is therefore possible that other non-TGFβ dependent 
pathways are involved in signalling to T lymphocytes in vivo.  
 
This is supported by a recent publication investigating role of betaglycan in foetal thymic 
organ cultures, in which betaglycan was found to be necessary for T lymphocyte maturation, 
primarily through its ability to bind inhibins (Aleman-Muench et al. 2012). Similarly, BMP 
have previously been implicated in T lymphocyte maturation in the thymus (Cejalvo et al. 
2007); it is possible that this effect is also mediated by betaglycan and may be important in 
other resident lymphocyte populations. 
 
Again, our in vitro assays were designed to address this, since we were able to test specific 
isoforms of TGFβ, and in particular were able to assess TGFβ2-dependent responses in the 
complete absence of TGFβ1. Despite this, we remained unable to demonstrate a clear role for 
betaglycan in TGFβ2-dependent T lymphocyte responses (Figures 5.4 to 5.6). 
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Finally, we must acknowledge that we may have chosen an inappropriate assay to assess 
TGFβ signalling via betaglycan, since TGFβ potency is known to vary in different biological 
processes in the same cell. As previously discussed, FHBE cells are naturally deficient in 
betaglycan, and whilst they have been shown to display reduced TGFβ2-mediated growth 
inhibition compared to wild-type cells (Cheifetz et al. 1990), they display similar TGFβ2-
mediated PAI-1 inhibition (ten Dijke et al. 1988). It is thus possible that we may have 
observed a difference in our betaglycan-deficient cell cultures by assessing an alternative end-
point. Given the observation of the potential involvement of betaglycan in Th1 responses, we 
speculate that in vitro assays of Th1 polarisation of naïve T lymphocytes (as discussed in 
Kato & Nariuchi 2000) may reveal differences between betaglycan knock out and wild type 
cells. 
 
7.3.3 Betaglycan as a regulator of tissue-specific immune responses 
 
Overall, we have observed a subtle role for betaglycan in immune responses; whilst we have 
evidence for increases in T lymphocyte activation and Th1 polarisation, this resulted in no 
obvious external phenotype (Chapter 3).  
 
It is perhaps surprising that our naïve betaglycan-deficient chimeras displayed any evidence 
of immune dysregulation, since previously published literature suggests that betaglycan is 
involved in TGFβ2-dependent responses, being necessary for high affinity interactions 
between the ligand and cell-surface receptor complex, but is not required for TGFβ1 or 
TGFβ3 driven processes (López-Casillas et al. 1994; López-Casillas et al. 1993; Sarraj et al. 
2013; Cheifetz et al. 1990). Since the predominant isoform of TGFβ acting in the peripheral 
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murine immune system is TGFβ1 (Rubtsov & Rudensky 2007), any potential influence of 
betaglycan deficiency on TGFβ2 signalling was expected to be masked. We therefore 
speculate that the role of betaglycan may still be more significant in environments where 
TGFβ2 predominates, and thus tissue-specific phenotypes may exist.  
 
Although speculative, there are notable similarities between this observed / predicted action 
of betaglycan and that of another molecule known as Dickkopf-3 (Dkk3). Dkk3 is a secreted 
protein with high expression in immune privileged organs such as the embryo, placenta, brain 
and eye (Niehrs 2006; Nakamura et al. 2007). Animals deficient in Dkk3 show no external 
evidence of immune-mediated disease, and display normal resting T lymphocyte populations 
and normal T lymphocyte activation levels (Meister et al. 2015).  Differences in Dkk3-
deficient mice become apparent on induction of EAE, with increased IFNγ production and T 
lymphocyte activation within the CNS, whilst levels in lymph node and spleen are unaffected. 
Dkk3 has thus been suggested as an important tissue-specific modulator of T lymphocyte 
activity, usually functioning to limit T lymphocyte activation and Th1 polarization. 
 
We speculate that betaglycan-deficient animals may display similar exacerbation of EAE and 
EAU, associated with an exaggeration of the previously observed changes in T lymphocyte 
populations. 
  
7.4 The role of betaglycan in inflammatory disease in humans 
 
The only published association between betaglycan and human inflammatory disease exists 
for BD, specifically in a Han Chinese population (Chen et al. 2012). This is an interesting 
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association, since BD is characterised by severe intra-ocular inflammation (uveitis), which is 
thought to be mediated by CD4+ T lymphocytes under the control of TGFβ. Furthermore, 
TGFβ2 is the predominant intra-ocular isoform (Denniston et al. 2011; Stein-Streilein 2008), 
and despite the lack of supportive evidence in our experiments documented herewith, 
betaglycan has previously been considered particularly important in TGFβ2 signalling 
(Cheifetz et al. 1990; López-Casillas et al. 1991; Sankar et al. 1995). 
 
In uveitis, inflammation is often limited solely to the eye. Despite this, current therapeutic 
strategies in uveitis usually involve systemic immunosuppression with significant unwanted 
side effects in multiple organ systems (Barry et al. 2014). The ideal pharmacological agent in 
uveitis should enable potent suppression of intra-ocular CD4+ T lymphocyte activity, without 
modulation of T lymphocyte activity at other, non-inflamed sites. Whilst TGFβ2 
predominates in the ocular microenvironment (Denniston et al. 2011; Stein-Streilein 2008), 
TGFβ1 is the predominant isoform acting in the peripheral immune system (Rubtsov & 
Rudensky 2007). Modulation of betaglycan by a therapeutic agent may allow targeted 
manipulation TGFβ2 signalling and thus confer the ability to localise the resulting 
immunosuppressive effect to the eye, avoiding unnecessary systemic side effects. 
 
We have observed a variable role for betaglycan in regulating activation and polarisation of 
CD4+ T lymphocytes with increases in lymphocyte activation and Th1 polarisation observed 
in its absence; potentiation of signalling either through up-regulation of betaglycan receptors 
on T lymphocytes or addition of soluble betaglycan may therefore emerge as a useful 
therapeutic strategy in uveitis. 
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Whilst we were unable to demonstrate a statistically significant association between 
betaglycan and BD in a Caucasian population (Barry et al. 2015), we did observe a non-
significant trend towards reduced prevalence of the RS1805110 CC genotype (Table 6.1). It is 
thus possible that a similar association exists in Caucasian patients compared to that observed 
in Han Chinese patients, which may have become statistically significant with a larger sample 
size. Whilst our study is therefore inconclusive, it is supportive of a wider role for betaglycan 
in ocular inflammatory disease. 
 
7.5 Limitations of current investigation and future work 
 
All investigation presented herewith is based on the study of mixed foetal liver chimeric mice; 
whilst this enabled us to generate a novel model of targeted betaglycan deficiency on T and B 
lymphocytes, the relative complexity of the breeding programme (Figure 3.1) resulted in 
unavoidable time constraints in the generation of experimental mice. Furthermore, chimeras 
could only be genotyped after cell transfer, resulting in significant surplus of heterozygote 
mice, with relatively few wild-type and knock-out chimeras. As previously documented, this 
necessitated a more ‘opportunistic’ approach to phenotypic data collection than would be 
ideal, and limited the number of available animals for use in our in vivo and in vitro 
experiments. Future experiments may benefit from the development of models of adoptive 
transfer or conditional betaglycan knock-out mice.  
 
Our investigation was largely restricted to CD4+ T lymphocyte responses with more limited 
assessment of CD8+ responses, and very limited assessment of B lymphocyte and other 
immune cell populations. Given the paucity of literature to inform our investigation, we felt 
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that we were most likely to find a role for betaglycan in known TGFβ-dependent T 
lymphocyte responses, and therefore made this the focus of our investigation. Whilst we 
observed no obvious difference in ratios of T:B lymphocytes (Figure 4.2) or host:donor non-T 
/ non-B lymphocyte populations (Figure 3.4) in our chimeras, we cannot exclude the 
possibility that betaglycan is involved in TGFβ signalling to other cell types, or that 
deficiency on T lymphocyte has indirect effects on other cell populations. In the future, we 
would thus be interested to study proportions of B lymphocyte subsets both in naïve animals 
and in response to controlled antigenic challenge, and also investigate APC subsets in greater 
detail, which may be involved in trans-presentation of betaglycan to the T lymphocyte. 
 
Similarly, histological investigation was restricted to the study of secondary lymphoid organs 
(Figures 4.10 to 4.13), with no assessment of other tissues. Again, we felt that betaglycan 
deficiency was most likely to manifest as disruption of lymphocyte populations and micro-
anatomy in these tissues, and whilst we observed no external evidence of disease in other sites 
(for example diarrhoea to suggest bowel disease, weakness and paralysis to suggest disease of 
the central nervous system), we cannot exclude the possibility of undetected subclinical 
disease in other sites. We would recommend detailed histological examination of brain, eye, 
thymus, liver, kidney and bowel in future work. 
 
As discussed above, betaglycan is unlike other components of the TGFβ receptor complex 
due to the observation that it can also exist in a soluble form. Whilst we are confident that we 
were able to knock-out the cell-surface betaglycan receptor on T and B lymphocytes, it 
remained present on all other cell types. We made no attempt to block the action of soluble 
betaglycan in our in vivo experiments, and it is thus possible that T and B lymphocytes in our 
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betaglycan deficient chimeras were able to compensate for betaglycan deficiency at the cell 
surface by utilising soluble betaglycan from other sources. Whilst our in vitro assays 
addressed this concern to a certain extent, it may be necessary to consider the use of blocking-
antibodies in future experiments. 
 
Considering existing literature, we were surprised to find no evidence of a role for betaglycan 
in TGFβ2 dependent responses in our in vitro assays (Figures 5.4 to 5.6); we suspect this is 
attributable either to the use of activated rather than latent TGFβ in our assays, or to the use of 
TGFβ receptor-independent signalling pathways. We would recommend the use of latent 
TGFβ in future assays, and would also recommend the measurement of Smad 
phosphorylation in these assays to confirm signalling via the TGFβ receptor. We would also 
like to replicate the previously-published growth inhibition assays using cells derived from 
our chimeras. 
 
We were unable to investigate tissue-specific immune responses in our in vivo experiments of 
controlled antigenic challenge. As previously discussed, we suspect betaglycan may act as a 
tissue-specific regulator of T lymphocyte function, being more likely to be important in 
environments where TGFβ2 signalling predominates; our preferred experimental model of 
such tissue-specific responses is EAU, and we would be keen to induce this process in our 
chimeras in the future. 
 
We would also be interested to investigate other polymorphisms in the betaglycan gene across 
a range of ocular inflammatory diseases, and to investigate betaglycan expression in aqueous 
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humour samples of patients with uveitis and controls, to further elucidate whether betaglycan 
is an important mediator of intra-ocular inflammation in humans. 
 
7.6  Conclusion 
 
Our aim was to determine the immunoregulatory role of betaglycan; based on the 
experimental research described within this report, we conclude that betaglycan does indeed 
have a role in immunoregulation, being implicated in activation and polarisation of T 
lymphocytes. Based on our observations, we speculate that betaglycan may act to limit T 
lymphocyte activation and inhibit Th1-mediated immune responses. Betaglycan is not an 
absolute requirement for TGFβ signalling, and appears to have less influence over TGFβ-
mediated signalling processes than the other components of the cell surface receptor. In 
contrast to most existing literature, we have found no clear evidence for a predominant role in 
TGFβ2 signalling, however we suspect this may be due to the endpoints assessed in our 
experiments, and remain open to the possibility that a differential response may become more 
obvious in other assays. 
 
Our understanding of betaglycan remains incomplete, and we acknowledge that we have 
generated far more questions than answers. We have however developed and characterised a 
novel animal model of targeted betaglycan deficiency, which hope provides a strong 
foundation on which to base future work. 
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8 APPENDIX  
 
8.1 Pharmacotherapy for uveitis: current management and 
emerging therapy (published data) 
 
The  introduction to uveitis detailed in section 1.4.7 was written as a review article and 
accepted for publication in Clinical Ophthalmology. 
 
Full citation: 
 
Pharmacotherapy for uveitis: current management and emerging therapy. Barry RJ, Nguyen 
QD, Lee RW, Murray PI, Denniston AK. Clinical Ophthalmology 2014 Sep;22(8):1891-911 
 
The published paper is reproduced over the following pages. 
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8.2 Association analysis of TGFBR3 gene with Behcet’s disease 
and idiopathic intermediate uveitis in a Caucasian population 
(published data) 
 
The investigation detailed in Chapter 6 was written as a scientific paper and accepted for 
publication in the British Journal of Ophthalmology. 
 
Full citation: 
 
Association analysis of TGFBR3 gene with Behcet’s disease and idiopathic intermediate 
uveitis in a Caucasian population. Barry RJ, Alsalem JA, Faassen J, Murray PI, Curnow SJ, 
Wallace GR. British Journal of Ophthalmology 2015 May;99(5):696-9 
 
The published paper is reproduced over the following pages.  
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ABSTRACT
Background Transforming growth factor β (TGFβ) is
an important immunoregulatory cytokine in regulatory
T cell (Treg) and Th17-mediated pathology, including
uveitis due to Behçet’s disease (BD). Of the three
isoforms, TGFβ2 is found at highest levels in the
aqueous humour of uninﬂamed eyes. TGFβ signals
through a cell-surface receptor comprising three subunits
(TGFBR1, 2 and 3). TGFBR3 is considered necessary for
TGFβ2 signal transduction, but not for other isoforms.
A polymorphism in TGFBR3 (rs1805110) has previously
been identiﬁed in Han Chinese patients with BD. We
investigated the frequency of this polymorphism in a
Caucasian population with BD and idiopathic
intermediate uveitis (IIU).
Methods The single-nucleotide polymorphism (SNP)
rs1805110 in TGFBR3 was genotyped in 75 BD
patients, 92 IIU disease controls and 85 disease-free
controls. The association with both diseases was
analysed using Fisher’s exact test.
Results No signiﬁcant difference in rs1805110 allele or
genotype frequency was observed. A low frequency of
the T allele was observed (5.88% control, 9.33% BD,
10.33% IIU) with the TT genotype absent in patients
with BD and IIU (1.18% control, 0% BD and 0% IIU).
Stratiﬁcation analysis according to clinical features of BD
did not associate with the tested SNP.
Conclusions RS1805110 is not associated with BD or
IIU in Caucasian patients. The T allele frequency is
consistent with that presented for Caucasian populations
in the HapMap database (p>0.05). Our results differ
from the previous analysis in Han Chinese patients
(p<0.0001), however, the possibility of having a much
smaller effect due to the low minority frequency cannot
be excluded.
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8.3 International poster presentations 
 
Summaries of experimental data detailed within this thesis were presented as posters at the 
following international conferences: 
 
1. Investigating the response of naïve T cells to the three isoforms of TGFβ. Robert J 
Barry, David R Withers, Philip I Murray, Peter J Lane, S John Curnow. Poster 
presentation at Association for Research in Vision and Ophthalmology (ARVO) 
Annual Scientific Meeting, May 2013, Seattle, Washington, USA. 
 
Summary of pilot data of in vitro assays as presented in chapter 5. 
 
2. Association analysis of TGFBR3 gene with Behcet’s Disease and Idiopathic 
Intermediate Uveitis in a Caucasian population. Robert J Barry, Jawaher A. AlSalem, 
Julia Faassen, S John Curnow, Philip I Murray, Graham R Wallace. Association for 
Research in Vision and Ophthalmology (ARVO) Annual Scientific Meeting, May 
2014, Orlando, Florida, USA. 
 
Summary of investigation and data as presented in chapter 6. 
 
3. Association analysis of TGFBR3 gene with Behcet’s Disease and Idiopathic 
Intermediate Uveitis in a Caucasian population. Robert J Barry, Jawaher A. AlSalem, 
Julia Faassen, S John Curnow, Philip I Murray, Graham R Wallace. Poster 
presentation at International Society for Behcet’s Disease (ISBD) Annual Meeting, 
September 2014, Paris, France. 
 
Summary of investigation and data as presented in chapter 6. 
 
4. The TGFβ co-receptor betaglycan (TGFβRIII) is not implicated in TGFβ-dependent T 
cell responses. Robert J Barry, David R Withers, Philip I Murray, Peter J Lane, S John 
Curnow. Poster presentation at Association for Research in Vision and 
Ophthalmology (ARVO) Annual Scientific Meeting, May 2015, Denver, Colorado, 
USA. 
 
Summary of investigation and data as presented in chapters 3, 4 and 5. 
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